
<html lang="en"     class="pb-page"  data-request-id="735469ac-8fc0-49a7-845a-0ff67cfacfce"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;issue:issue:10.1021/jmcmar.2021.64.issue-9;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.0c01958;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of 4-Arylindolines Containing a Thiazole Moiety as Potential Antitumor Agents Inhibiting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction" /></meta><meta name="dc.Creator" content="Mingze  Qin" /></meta><meta name="dc.Creator" content="Yangyang  Meng" /></meta><meta name="dc.Creator" content="Haoshen  Yang" /></meta><meta name="dc.Creator" content="Lei  Liu" /></meta><meta name="dc.Creator" content="Haotian  Zhang" /></meta><meta name="dc.Creator" content="Simeng  Wang" /></meta><meta name="dc.Creator" content="Chunyang  Liu" /></meta><meta name="dc.Creator" content="Xia  Wu" /></meta><meta name="dc.Creator" content="Di  Wu" /></meta><meta name="dc.Creator" content="Ye  Tian" /></meta><meta name="dc.Creator" content="Yunlei  Hou" /></meta><meta name="dc.Creator" content="Yanfang  Zhao" /></meta><meta name="dc.Creator" content="Yajing  Liu" /></meta><meta name="dc.Creator" content="Congjun  Xu" /></meta><meta name="dc.Creator" content="Lihui  Wang" /></meta><meta name="dc.Description" content="Through specific structural modification of a 4-phenylindoline precursor, new 4-arylindolines containing a thiazole moiety were developed and found to be promising modulators of the programmed cell..." /></meta><meta name="Description" content="Through specific structural modification of a 4-phenylindoline precursor, new 4-arylindolines containing a thiazole moiety were developed and found to be promising modulators of the programmed cell..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 3, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01958" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01958" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01958" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01958" /></link>
        
    
    

<title>Discovery of 4-Arylindolines Containing a Thiazole Moiety as Potential Antitumor Agents Inhibiting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01958" /></meta><meta property="og:title" content="Discovery of 4-Arylindolines Containing a Thiazole Moiety as Potential Antitumor Agents Inhibiting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0018.jpeg" /></meta><meta property="og:description" content="Through specific structural modification of a 4-phenylindoline precursor, new 4-arylindolines containing a thiazole moiety were developed and found to be promising modulators of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) axis. Compound A30 exhibited outstanding biochemical activity, with an IC50 of 11.2 nM in a homogeneous time-resolved fluorescence assay. In the cell-based assay, A30 significantly promoted IFN-γ secretion and rescued T-cell proliferation, which were inhibited by PD-1 activation. Furthermore, A30 showed favorable in vivo antitumor activity in a mouse 4T1 breast carcinoma model. Moreover, in mouse CT26 colon carcinoma models, A30 potently suppressed the growth of CT26/PD-L1 tumor but did not obviously affect the growth of CT26/vector tumor. The results of flow cytometry analysis indicated that A30 inhibited tumor growth by activating the immune microenvironment. We concluded that A30 is a new starting point for further development of PD-1/PD-L1 interaction inhibitors as antitumor agents." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Through specific structural modification of a 4-phenylindoline precursor, new 4-arylindolines containing a thiazole moiety were developed and found to be promising modulators of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) axis. Compound A30 exhibited outstanding biochemical activity, with an IC50 of 11.2 nM in a homogeneous time-resolved fluorescence assay. In the cell-based assay, A30 significantly promoted IFN-γ secretion and rescued T-cell proliferation, which were inhibited by PD-1 activation. Furthermore, A30 showed favorable in vivo antitumor activity in a mouse 4T1 breast carcinoma model. Moreover, in mouse CT26 colon carcinoma models, A30 potently suppressed the growth of CT26/PD-L1 tumor but did not obviously affect the growth of CT26/vector tumor. The results of flow cytometry analysis indicated that A30 inhibited tumor growth by activating the immune microenvironment. We concluded that A30 is a new starting point for further development of PD-1/PD-L1 interaction inhibitors as antitumor agents." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0018.jpeg" /></meta><meta name="twitter:title" content="Discovery of 4-Arylindolines Containing a Thiazole Moiety as Potential Antitumor Agents Inhibiting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01958"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01958">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01958&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01958&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01958&amp;href=/doi/10.1021/acs.jmedchem.0c01958" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 9</span><span class="cit-fg-pageRange">, 5519-5534</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/9" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01938" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01965" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 4-Arylindolines Containing a Thiazole Moiety as Potential Antitumor Agents Inhibiting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Mingze Qin</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mingze Qin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#1a6b73747773747d607f2a2a2b5a2b282c34797577"><span class="__cf_email__" data-cfemail="73021a1d1e1a1d140916434342334241455d101c1e">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mingze++Qin">Mingze Qin</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4634-535X" title="Orcid link">http://orcid.org/0000-0002-4634-535X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yangyang Meng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yangyang Meng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yangyang++Meng">Yangyang Meng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haoshen Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haoshen Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang 110016, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haoshen++Yang">Haoshen Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lei Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lei Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lei++Liu">Lei Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haotian Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haotian Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang 110016, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haotian++Zhang">Haotian Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Simeng Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Simeng Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang 110016, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Simeng++Wang">Simeng Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chunyang Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chunyang Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chunyang++Liu">Chunyang Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xia Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xia Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xia++Wu">Xia Wu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Di Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Di Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Di++Wu">Di Wu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ye Tian</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ye Tian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ye++Tian">Ye Tian</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yunlei Hou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yunlei Hou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yunlei++Hou">Yunlei Hou</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yanfang Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yanfang Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yanfang++Zhao">Yanfang Zhao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yajing Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yajing Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yajing++Liu">Yajing Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Congjun Xu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Congjun Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, PR China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#6d15180e072d000c0401431e141e1843080918430e03"><span class="__cf_email__" data-cfemail="b0c8c5d3daf0ddd1d9dc9ec3c9c3c59ed5d4c59ed3de">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Congjun++Xu">Congjun Xu</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Lihui Wang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lihui Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang 110016, PR China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#533f3b24323d3413202a233b267d3637267d303d"><span class="__cf_email__" data-cfemail="d1bdb9a6b0bfb691a2a8a1b9a4ffb4b5a4ffb2bf">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lihui++Wang">Lihui Wang</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01958&amp;href=/doi/10.1021%2Facs.jmedchem.0c01958" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 9</span><span class="cit-pageRange">, 5519–5534</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 3, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>12 November 2020</li><li><span class="item_label"><b>Published</b> online</span>3 May 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 May 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01958" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01958</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5519%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMingze%2BQin%252C%2BYangyang%2BMeng%252C%2BHaoshen%2BYang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D9%26contentID%3Dacs.jmedchem.0c01958%26title%3DDiscovery%2Bof%2B4-Arylindolines%2BContaining%2Ba%2BThiazole%2BMoiety%2Bas%2BPotential%2BAntitumor%2BAgents%2BInhibiting%2Bthe%2BProgrammed%2BCell%2BDeath-1%252FProgrammed%2BCell%2BDeath-Ligand%2B1%2BInteraction%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5534%26publicationDate%3DMay%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01958"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1220</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01958" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 4-Arylindolines Containing a Thiazole Moiety as Potential Antitumor Agents Inhibiting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Mingze&quot;,&quot;last_name&quot;:&quot;Qin&quot;},{&quot;first_name&quot;:&quot;Yangyang&quot;,&quot;last_name&quot;:&quot;Meng&quot;},{&quot;first_name&quot;:&quot;Haoshen&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Lei&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Haotian&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Simeng&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Chunyang&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Xia&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Di&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Ye&quot;,&quot;last_name&quot;:&quot;Tian&quot;},{&quot;first_name&quot;:&quot;Yunlei&quot;,&quot;last_name&quot;:&quot;Hou&quot;},{&quot;first_name&quot;:&quot;Yanfang&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Yajing&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Congjun&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Lihui&quot;,&quot;last_name&quot;:&quot;Wang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;03&quot;,&quot;issue&quot;:&quot;9&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;5519-5534&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01958&quot;},&quot;abstract&quot;:&quot;Through specific structural modification of a 4-phenylindoline precursor, new 4-arylindolines containing a thiazole moiety were developed and found to be promising modulators of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) axis. Compound A30 exhibited outstanding biochemical activity, with an IC50 of 11.2 nM in a homogeneous time-resolved fluorescence assay. In the cell-based assay, A30 significantly promoted IFN-γ secretion and rescued T-cell proliferation, which were inhibited by PD-1 activation. Furthermore, A30 showed favorable in vivo antitumor activity in a mouse 4T1 breast carcinoma model. Moreover, in mouse CT26 colon carcinoma models, A30 potently suppressed the growth of CT26/PD-L1 tumor but did not obviously affect the growth of CT26/vector tumor. The results of flow cytometry analysis indicated that A30 inhibited tumor growth by activating the immune microenvironment. We concluded that A30 is a new starting point for further development of PD-1/PD-L1 interaction inhibi&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01958&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01958" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01958&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01958" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01958&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01958" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01958&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01958&amp;href=/doi/10.1021/acs.jmedchem.0c01958" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01958" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01958" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01958%26sid%3Dliteratum%253Aachs%26pmid%3D33938739%26genre%3Darticle%26aulast%3DQin%26date%3D2021%26atitle%3DDiscovery%2Bof%2B4-Arylindolines%2BContaining%2Ba%2BThiazole%2BMoiety%2Bas%2BPotential%2BAntitumor%2BAgents%2BInhibiting%2Bthe%2BProgrammed%2BCell%2BDeath-1%252FProgrammed%2BCell%2BDeath-Ligand%2B1%2BInteraction%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D9%26spage%3D5519%26epage%3D5534%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/9" title="Go to Volume 64, Issue 9"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/jmcmar.2021.64.issue-9/20210513/jmcmar.2021.64.issue-9.largecover.jpg" alt="Go to Volume 64, Issue 9"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01958&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Through specific structural modification of a 4-phenylindoline precursor, new 4-arylindolines containing a thiazole moiety were developed and found to be promising modulators of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) axis. Compound <b>A30</b> exhibited outstanding biochemical activity, with an IC<sub>50</sub> of 11.2 nM in a homogeneous time-resolved fluorescence assay. In the cell-based assay, <b>A30</b> significantly promoted IFN-γ secretion and rescued T-cell proliferation, which were inhibited by PD-1 activation. Furthermore, <b>A30</b> showed favorable <i>in vivo</i> antitumor activity in a mouse 4T1 breast carcinoma model. Moreover, in mouse CT26 colon carcinoma models, <b>A30</b> potently suppressed the growth of CT26/PD-L1 tumor but did not obviously affect the growth of CT26/vector tumor. The results of flow cytometry analysis indicated that <b>A30</b> inhibited tumor growth by activating the immune microenvironment. We concluded that <b>A30</b> is a new starting point for further development of PD-1/PD-L1 interaction inhibitors as antitumor agents.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74206" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74206" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The immune checkpoint molecule programmed cell death-1 (PD-1) plays an important role in the physiological regulation of immunity. The binding of PD-1 expressed on the surface of activated T lymphocytes with programmed cell death-ligand 1 (PD-L1) suppresses immune activation to maintain peripheral immune tolerance and protect from autoimmunity during immune attack.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> However, the PD-1/PD-L1 axis is exploited by tumor cells to evade immune surveillance.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> In the tumor microenvironment, the binding of T lymphocyte-released interferon-γ (IFN-γ) to its receptor on the membrane of tumor cells activates interferon regulatory factor 1 (IRF1) via the classical Janus kinase-signal transducer and activator of transcription pathway, inducing the transcription of <i>PD-L1</i> and adaptive expression of PD-L1 by tumor cells.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Thus, inhibiting the PD-1/PD-L1 interaction allows to restore damaged immunity and is considered a promising strategy for cancer immunotherapy.</div><div class="NLM_p">To date, six humanized monoclonal antibodies (mAbs) targeting the PD-1/PD-L1 axis (anti-PD-1: cemiplimab, pembrolizumab, and nivolumab; anti-PD-L1: atezolizumab, durvalumab, and avelumab) have been approved by the U.S. Food and Drug Administration (FDA) to treat different types of cancers, such as melanoma and nonsmall cell lung cancer. Strong antitumor immunity has been created in patients receiving anti-PD-1/PD-L1 mAbs, especially those with high expression of PD-L1 and high tumor mutational burden, highlighting the great potential of cancer immunotherapy targeting the PD-1/PD-L1 axis.<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6−8)</a> In addition, combination regimens containing a PD-1/PD-L1 pathway inhibitor have been extensively investigated, with the aim of generating synergistic antitumor effects.<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9−11)</a> Although mAbs have been successfully developed in recent years, they have intrinsic limitations, such as severe autoimmune adverse effects, insufficient tumor penetration, and the demand for intravenous administration in the treatment. These limitations may be magnified in combination therapies, thereby hindering the design and clinical evaluation of therapeutic regimens. Thus, small-molecule inhibitors are promising therapeutic alternatives for anti-PD-1/PD-L1 immunotherapy.<a onclick="showRef(event, 'ref12 ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15 ref16">(12−16)</a></div><div class="NLM_p">The development of small-molecule inhibitors of the PD-1/PD-L1 interaction has attracted great attention but is still in its early stages. CA-170 is a first-in-class oral bioavailable inhibitor of the PD-1/PD-L1 axis, which entered a phase II clinical trial for cancer intervention. However, the precise mechanism of action (MOA) of CA-170 is unknown, as CA-170 does not directly bind to PD-L1 and does not dissociate the PD-1/PD-L1 complex.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The definition of MOA is helpful to perform structure-based drug design and to identify analogs with improved efficacy.</div><div class="NLM_p">In recent years, researchers from Bristol-Myers Squibb (BMS) identified a series of inhibitors characterized by a biphenyl scaffold. As depicted in the patents corresponding to these inhibitors, several BMS compounds showed promising activity in inhibition of the PD-1/PD-L1 interaction at the biochemical level, making them promising lead compounds for developing inhibitors of the PD-1/PD-L1 pathway (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> The co-crystal structure of the BMS-200/PD-L1 complex has been solved by the Holak group, uncovering that the MOA of these compounds involves the induction of PD-L1 dimerization.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In addition to their biochemical activity, further evaluation at the cellular level has only been reported for a few compounds, including BMS-1001 and BMS-1166.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Recently, the Chen group reported an analog named NP19.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> For the first time, the <i>in vivo</i> antitumor activity of this series of compounds was demonstrated, further supporting their potential use in cancer treatment. Alternatively, the identification of new PD-1/PD-L1 interaction modulators, especially those with a different scaffold, is desirable to discover a suitable candidate for further drug development.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative small-molecule inhibitors of the PD-1/PD-L1 interaction.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01958&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In our previous study, we reported a 4-phenylindoline-containing compound, <b>1</b>, as an inhibitor of the PD-1/PD-L1 interaction.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Remarkably, <b>1</b> exhibited excellent efficacy in restoring T-cell function, which was suppressed by PD-1 activation, and this was significantly superior to that of BMS-1. Therefore, we considered that 4-arylindolines could serve as privileged scaffolds for designing PD-1/PD-L1 pathway inhibitors. However, the potency of <b>1</b> to inhibit the PD-1/PD-L1 interaction at the biochemical level still needs to be enhanced, thus needing a structural optimization campaign to improve the inhibitor activity.</div><div class="NLM_p last">In this study, we disclose our recent work regarding the discovery of 4-arylindolines containing a thiazole moiety as potent inhibitors targeting the PD-1/PD-L1 interaction. Our study culminates in the identification of <b>A30</b>, which exhibited outstanding efficacy at the biochemical level and displayed a potent ability to restore repressed immunity and inhibit tumor growth in mouse 4T1 breast carcinoma and CT26 PD-L1-overexpression colon carcinoma models, representing a good starting point for further drug design.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28581" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28581" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of compounds <b>A1</b>, <b>A2</b>, <b>A5</b>, and <b>A6</b> is shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The amidation of 4-phenylindoline (<b>7a</b>) with the commercially available 5-formylthiophene-2-carboxylic acid provided intermediate <b>8</b>. A NaBH<sub>3</sub>CN-promoted reductive amination reaction was used to convert <b>8</b> to compounds <b>A1</b> and <b>A2</b>.<a onclick="showRef(event, 'ref12 ref23'); return false;" href="javascript:void(0);" class="ref ref12 ref23">(12,23)</a> Parallelly, intermediate <b>9</b> was obtained from <b>7</b> using a synthetic method similar to the preparation of <b>8</b>. The conversion of intermediate <b>9</b> to <b>11</b> was achieved via a two-step reaction comprising Stille coupling with tributyl(vinyl)stannane and olefin oxidization by NaIO<sub>4</sub> in the presence of K<sub>2</sub>OsO<sub>4</sub>·2H<sub>2</sub>O.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> Finally, the desired compounds, <b>A5</b> and <b>A6</b>, were synthesized from <b>11</b> under conditions similar to those described for preparing <b>A1</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compound<b>s A1</b>, <b>A2</b>, <b>A5</b>, and <b>A6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01958&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 5-formylthiophene-2-carboxylic acid or 2-bromothiazole-5-carboxylic acid, HATU, DIPEA, DMF, rt., 3 h, 62–73%; (b) appropriate amine, AcOH, NaBH<sub>3</sub>CN, DCM/MeOH (1/1), rt., 9–16 h, 9–22%; (c) tributyl(vinyl)stannane, Pd(PPh<sub>3</sub>)<sub>4</sub>, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O (3/1), 100 °C, 2 h, 53%; (d) K<sub>2</sub>OsO<sub>4</sub>·2H<sub>2</sub>O, NaIO<sub>4</sub>, 1,4-dioxane/H<sub>2</sub>O (5/1), rt., 2 h, 86%.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> depicts the synthetic route of compounds <b>A7–15</b> and <b>A34–36</b>. Ethyl 2-amino-2-thioxoacetate (<b>12</b>) was cyclized with 2-bromomalonaldehyde to yield thiazole <b>13</b>. The key intermediate <b>15</b> was conveniently produced by reacting <b>13</b> with ethane-1,2-diol followed by a LiOH-mediated hydrolysis reaction.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Subsequently, the amidation reaction of <b>15</b> with 4-bromoindoline gave rise to <b>16</b>, which was converted to aldehyde <b>17</b> in the presence of <i>p</i>-toluenesulfonic acid. Sequential reactions including NaBH<sub>3</sub>CN-mediated reductive amination and Suzuki–Miyaura coupling were applied to convert <b>17</b> to the desired compounds, <b>A7–15</b>. Compounds <b>A34–36</b>, bearing a benzoxazole moiety at the terminal, were prepared by reacting intermediate <b>17</b> with 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[<i>d</i>]oxazole before the setup of a reductive amination reaction with appropriate amines.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>A7</b>–<b>15</b> and <b>A34</b>–<b>36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01958&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2-bromomalonaldehyde, DME, rt., 10 h, 51%; (b) ethane-1,2-diol, TsOH·H<sub>2</sub>O, toluene, 110 °C, 5 h, 76%; (c) LiOH, THF/H<sub>2</sub>O (4/1), rt., 2 h, 45%; (d) 4-bromoindoline, HATU, DIPEA, DMF, rt., 3 h, 77%; (e) TsOH·H<sub>2</sub>O, acetone/H<sub>2</sub>O (3/2), 70 °C, 4 h, 81%; (f) 2-aminoethan-1-ol, AcOH, NaBH<sub>3</sub>CN, DCM/MeOH (1/1), rt., 12 h, 35%; (g) aryl borate, PdCl<sub>2</sub>(dppf), Cs<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O (3/1), 70–100 °C, 4–12 h, 5–16%; (h) appropriate amine, AcOH, NaBH<sub>3</sub>CN, DCM/MeOH (1/1), rt., 13–16 h, 6–23%, or <span class="smallcaps smallerCapital">l</span>-proline, NaBH(OAc)<sub>3</sub>, DCM, reflux, 2 h, 16%.</p></p></figure><div class="NLM_p">The preparation of compounds <b>A3</b>, <b>A4</b>, and <b>A16–33</b> is outlined in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. The aldehydes <b>21a</b> and <b>21b</b> were generated from <b>7a</b> or <b>7b</b> under conditions similar to those applied for the conversion of <b>15</b> to <b>17</b>. Through NaBH<sub>3</sub>CN- or NaBH(OAc)<sub>3</sub>-mediated reductive amination reactions, the target compounds <b>A3</b>, <b>A4</b>, and <b>A16–33</b> were readily prepared.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>A3</b>, <b>A4</b>, and <b>A16</b>–<b>33</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01958&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>15</b>, HATU, DIPEA, DMF, rt., 3–4 h, 76–82%; (b) TsOH·H<sub>2</sub>O, acetone/H<sub>2</sub>O (3/2), 70 °C, 3–5 h, 63–79%; (c) appropriate amine, AcOH, NaBH<sub>3</sub>CN, DCM/MeOH (1/1), rt., 8–16 h, 6–23%, or appropriate amine, NaBH(OAc)<sub>3</sub>, DCM, reflux, 2–6 h, 7–26%.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44732" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44732" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Discovery of the Thiazole-Containing Compounds <b>A3</b> and <b>A4</b></h3><div class="NLM_p">Structural optimizations on <b>1</b> were performed to identify compounds with superior activity in inhibition of the PD-1/PD-L1 interaction. In our previous study, the modification of the central phenyl ring of <b>1</b> failed to improve inhibitor activity.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> We speculated that the six-membered aromatic ring in this region might be replaced, and thus, we tried to increase the activity of inhibitors by introducing a five-membered heterocyclic fragment. First, compounds <b>A1–6</b> containing a thiophene or thiazole moiety were prepared as proof-of-concept compounds, and their ability to inhibit the PD-1/PD-L1 interaction was evaluated by a well-established homogeneous time-resolved fluorescence (HTRF) assay. In addition, they were assessed for unspecific toxicity to Jurkat cells using a cell counting kit-8 (CCK-8) assay. In this study, <b>1</b> exhibited reproducible potency in inhibition of the PD-1/PD-L1 interaction (IC<sub>50</sub>, 151.5 nM), with negligible effects on the growth of Jurkat cells (IC<sub>50</sub>, 38.6 μM). Additionally, BMS-1 displayed potent inhibitory activity against the PD-1/PD-L1 interaction (IC<sub>50</sub>, 76.2 nM) and weak toxicity to Jurkat cells (IC<sub>50</sub>, 18.4 μM).</div><div class="NLM_p">The biochemical data in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> indicated that the central aryl moiety played an important role in inhibitor activity against the PD-1/PD-L1 interaction. Compound <b>A1</b>, bearing a thiophene group, displayed increased activity compared to <b>1</b>, demonstrating an IC<sub>50</sub> of 59.7 nM. The replacement of the thiophene moiety with thiazole gave rise to <b>A3</b>, which exhibited excellent potency, with an IC<sub>50</sub> of 9.3 nM. Notably, changing the position of the nitrogen atom resulted in a significant decline in activity, as shown for <b>A5</b>, which demonstrated an IC<sub>50</sub> of 233.1 nM. In addition to compound <b>A3</b>, which contained an aminoethanol tail group, compound <b>A4</b>, carrying a <i>N</i>-(2-aminoethyl)acetamide fragment, exhibited strong potency as well, suggesting that the devised thiazole moiety was well fitted for this region of the inhibitor.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Inhibitory Activities of Compounds <b>A1</b>–<b>6</b> against the PD-1/PD-L1 Interaction and Toxicities to Jurkat Cells</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0012.gif" alt="" id="gr11" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0013.gif" alt="" id="gr12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">The data are generated from two independent experiments.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">The data are generated from three independent experiments.</p></div></div><div></div></div><div class="NLM_p">As reported by the Holak group, a conformational change of <sub>A</sub>Tyr56 in PD-L1 was observed when BMS-200, bearing a 2,3-dihydro-1,4-benzodioxinyl group at the terminal, bound to the PD-L1 dimer.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> This study highlighted the flexibility of this inhibitor binding site, making it possible to improve inhibitor potency by modifying the terminal aryl fragment. Accordingly, compounds <b>A7–15</b> were prepared and evaluated for their biochemical activity and unspecific toxicity.</div><div class="NLM_p">As depicted in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, substantial variations in activity were observed for these newly synthesized compounds, regarding their potency to inhibit the PD-1/PD-L1 interaction. Among them, compound <b>A8</b>, with a 2,3-dihydro-1,4-benzodioxinyl fragment, displayed comparable activity to <b>A3</b>, demonstrating an IC<sub>50</sub> of 12.9 nM. Compounds <b>A10</b> (IC<sub>50</sub>, 73.1 nM) with benzo[<i>d</i>]oxazol-5-yl and <b>A15</b> (IC<sub>50</sub>, 35.6 nM) with 1-methyl-1<i>H</i>-indazol-4-yl also exhibited a high level of activity, although they were less active than <b>A3</b>. Swapping the position of the heteroatoms in <b>A10</b> generated <b>A9</b>, which exhibited a 5.65-fold decrease in efficacy. Similarly, replacing the benzo[<i>d</i>]oxazol-5-yl of <b>A10</b> with a benzo[<i>d</i>]thiazol-5-yl moiety (<b>A11</b>) resulted in a 6.39-fold decline in inhibitor activity. Compound <b>A14</b>, bearing a 1<i>H</i>-indol-4-yl moiety, exhibited moderate activity, demonstrating an IC<sub>50</sub> of 142.4 nM. Finally, when introducing a pyridin-4-yl (<b>A7</b>), 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl (<b>A12</b>), or quinoxalin-6-yl (<b>A13</b>) fragment, a sharp reduction in the inhibition of the PD-1/PD-L1 interaction was observed.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Inhibitory Activities of Compounds <b>A7</b>–<b>15</b> against the PD-1/PD-L1 Interaction and Toxicities to Jurkat Cells</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0014.gif" alt="" id="gr13" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0015.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">The data are generated from two independent experiments.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">The data are generated from three independent experiments.</p></div></div><div></div></div><div class="NLM_p">Furthermore, compounds <b>A8</b>, <b>A10</b>, and <b>A15</b> were evaluated for their unspecific toxicity to Jurkat T cells. Both <b>A8</b> and <b>A10</b> showed negligible effects on the growth of Jurkat T cells, indicating that they did not directly suppress cancer cell growth <i>in vitro</i>. In contrast, <b>A15</b> was more cytotoxic, demonstrating an IC<sub>50</sub> of 9.5 μM.</div><div class="NLM_p">Considering the above results, we chose <b>A3</b>, <b>A8</b>, and <b>A10</b> as precursors and explored in detail the effects of the hydrophilic tail groups of inhibitors by synthesizing compounds <b>A16–36</b>.</div><div class="NLM_p">As shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, most of these compounds, bearing diverse hydrophilic tails except for <b>A24</b> and <b>A34</b>, exhibited promising inhibitory activity against the PD-1/PD-L1 interaction, suggesting that this part of the inhibitor exhibited a relatively shallow structure–activity relationship (SAR). Among them, <b>A16–19</b>, <b>A21</b>, <b>A23</b>, <b>A25</b>, <b>A27</b>, <b>A28</b>, <b>A30</b>, and <b>A31</b> displayed more pronounced activity, with IC<sub>50</sub> values below 30 nM.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Inhibitory Activities of Compounds <b>A16</b>–<b>36</b> against the PD-1/PD-L1 Interaction and Toxicities to Jurkat Cells</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0016.gif" alt="" id="gr15" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0017.gif" alt="" id="gr16" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">The data are generated from two independent experiments.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">The data are generated from three independent experiments.</p></div></div><div></div></div><div class="NLM_p">Compound <b>A19</b> (IC<sub>50</sub>, 8.1 nM), possessing an <span class="smallcaps smallerCapital">l</span>-proline moiety, was extremely active, but its replacement with a <span class="smallcaps smallerCapital">d</span>-proline moiety in compound <b>A24</b> triggered a sharp decline in potency (IC<sub>50</sub>, >200 nM). These results suggested that the suitable orientation of the carboxyl group is critical for high activity, possibly owing to the formation of a hydrogen bond between the carboxyl group and an amino acid residue of PD-L1. Compound <b>A20</b>, with a pipecolinic acid group, exhibited significantly reduced biochemical activity compared to that of <b>A19</b>, with an IC<sub>50</sub> of 76.5 nM. Similar to <b>A3</b>, both compounds <b>A17</b> and <b>A18</b>, having a hydroxyl group at the terminal, exhibited promising efficacy in inhibiting the PD-1/PD-L1 interaction, with IC<sub>50</sub> values of 27.6 and 13.5 nM, respectively. Interestingly, the methylation of the hydroxyl group of <b>A3</b> gave rise to <b>A16</b>, which showed only a slight decrease in biochemical activity (IC<sub>50</sub>, 20.2 nM). Furthermore, compound <b>A21</b> (IC<sub>50</sub>, 14.7 nM), generated by introducing a tetrahydro-2<i>H</i>-pyran-4-yl group, displayed activity comparable to <b>A3</b>. These results indicated that a hydrogen-bond donor might not be necessary for this series of compounds. Considering the potent activity of <b>A4</b>, <b>A23</b> was prepared by replacing the acetamide fragment of <b>A4</b> with a methanesulfonamide moiety, and a slight improvement in activity was observed for <b>A23</b> (IC<sub>50</sub>, 23.4 nM). However, the reversal of the sulfamide moiety resulted in a 3.66-fold decrease (<b>A22</b>) in biochemical activity.</div><div class="NLM_p">Similar SARs could also be observed in compounds <b>A25–33</b>, possessing a 2,3-dihydro-1,4-benzodioxinyl moiety. However, compounds <b>A34–36</b>, bearing a benzo[<i>d</i>]oxazol-5-yl moiety, were not active enough; therefore, they were not considered for further investigation.</div><div class="NLM_p last">Among these compounds, <b>A17</b>, <b>A18</b>, and <b>A23</b> showed apparent toxic effects on the proliferation of Jurkat cells, demonstrating IC<sub>50</sub> values of 0.9, 1.2, and 5.9 μM, respectively, while the other compounds were much less cytotoxic.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Evaluation of Immunoregulatory Activity Based On IFN-γ Secretion</h3><div class="NLM_p">Considering their promising biochemical activity and weak toxicity, selected compounds (<b>A3</b>, <b>A8</b>, <b>A16</b>, <b>A18</b>, <b>A19</b>, <b>A21</b>, <b>A23</b>, <b>A25</b>, <b>A27</b>, <b>A28</b>, <b>A30</b>, and <b>A31</b>) were evaluated for their immune regulation properties in a T cell-tumor co-culture model with continuous PD-1 activation. Compound <b>1</b>, which has been shown to display strong immunoregulatory activity, was used as a positive control. Hep3B cells were engineered to stably express human PD-L1 and then co-cultured with primary CD3<sup>+</sup> T cells isolated from peripheral blood mononuclear cells (PBMCs). Indicated concentrations (50 nM and 1 μM) of the tested compounds were added, and the IFN-γ levels were measured after 72 h of co-culture to reflect their ability to restore repressed immune function. As shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, most of the synthesized compounds, including <b>1</b>, significantly promoted IFN-γ production at the tested concentrations. In particular, several compounds, including <b>A8</b>, <b>A16</b>, <b>A18</b>, <b>A19</b>, <b>A21</b>, <b>A23</b>, <b>A27</b>, <b>A30</b>, and <b>A31</b>, exhibited potent efficacy at the 50 nM concentration, promoting IFN-γ secretion by 77.0–324.3%. In this experimental model, <b>A30</b> exhibited the most promising immunoregulatory activity. Upon treatment with 50 nM and 1 μM <b>A30</b>, IFN-γ secretion was increased by 173.4 and 283.8%, respectively, an increase much more remarkable than that induced by <b>1</b> (67.6 and 194.6%, respectively). As shown, compound <b>A18</b> remarkably promoted IFN-γ production at a concentration of 50 nM; however, a sharply decreased IFN-γ level was observed upon treatment with 1 μM <b>A18</b>. As determined by CCK-8 assay, <b>A18</b> exhibited obvious toxicity to Jurkat T cells; thus, we speculated that the negative effect of <b>A18</b> on immunity might be partially ascribed to its toxic effects on primary T cells. It should also be noted that, although the selected compounds were approximately 10-fold more active than <b>1</b> at the biochemical level, only some of them showed significantly increased activity in restoring T-cell function. It might be difficult to transform a ∼10-fold increase in biochemical activity into an obvious improvement in cellular activity in a complex cellular environment.</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Effects of selected compounds on IFN-γ secretion in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3<sup>+</sup> T cells. The data are presented as mean ± SEM, *<i>p</i> < 0.05 and **<i>p</i> < 0.01 vs control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01958&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Evaluation of Immunoregulatory Activity Based On T-Cell Proliferation</h3><div class="NLM_p">Given the remarkable activation of <b>A30</b> on T-cell function, we then evaluated its effects on T-cell proliferation to further investigate its immunoregulatory activity. For this, 96-well plates were coated with anti-CD3ε antibody and recombinant PD-L1 protein mixed with <b>A30</b> or <b>1</b>. T cells isolated from mouse spleen and labeled by CFSE were seeded into precoated plates and incubated for 72 h. Flow cytometry was then performed to determine T-cell proliferation using anti-PD-L1 mAb (EC<sub>50</sub>, 0.71 μg/mL) as the positive control (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B, both <b>A30</b> and <b>1</b> dose-dependently rescued T-cell proliferation, which was repressed by PD-1 activation. In particular, <b>A30</b> (EC<sub>50</sub>, 0.41 μM) exhibited significantly more potent activity than <b>1</b> (EC<sub>50</sub>, 2.01 μM), confirming the promising immunoregulatory activity of <b>A30</b><i>in vitro</i>.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effects of (A) anti-PD-L1 mAb and (B) <b>A30</b> and <b>1</b> on T-cell proliferation repressed by PD-1 activation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01958&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> <i>In Vivo</i> Antitumor Activity of <b>A30</b> in a 4T1 Tumor-Bearing Mouse Model</h3><div class="NLM_p">Considering the promising activity of <b>A30</b> at both biochemical and cellular levels, this compound was evaluated for its antitumor activity in a mouse 4T1 breast carcinoma model. 4T1 cells were injected subcutaneously into the back of female BALB/c mice. When implanted tumors reached approximately 100–150 mm<sup>3</sup> in volume, the mice were treated intravenously with saline and <b>A30</b> (6 and 12 mg/kg) five times every 2 days. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A, <b>A30</b> significantly suppressed 4T1 tumor growth; the tumor growth inhibition (TGI) values were 33.7 and 42.6% for mice treated with 6 and 12 mg/kg <b>A30</b>, respectively. Moreover, after treatment, the average tumor weights of the two <b>A30</b>-treated groups were 1.2 and 1.01 g, respectively (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01958/suppl_file/jm0c01958_si_003.pdf" class="ext-link">Figure S1B</a>), which were lower than that of the vehicle-treated control (1.53 g). <b>A30</b> was well tolerated at both tested concentrations, and no significant body weight loss was observed during the treatment period, indicating a favorable safety profile (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B).</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <i>In vivo</i> antitumor activity of <b>A30</b> in a mouse 4T1 breast carcinoma model. (A) Growth curve of implanted tumors during the treatment period. (B) Changes in the body weight of mice during the treatment period. The data are shown as mean ± SD, **<i>p</i> < 0.01 and ***<i>p</i> < 0.001 vs control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01958&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> <i>In Vivo</i> Antitumor Activity of <b>A30</b> in a CT26 PD-L1-Overexpression Tumor-Bearing Mouse Model</h3><div class="NLM_p">To further confirm that the antitumor efficacy of <b>A30</b> is correlated with the regulation of the PD-1/PD-L1 pathway, we engineered CT26 colon cancer cells to generate CT26 PD-L1-overexpression cells. <b>A30</b> did not significantly affect the viability of CT26/vector or CT26/PD-L1 cells <i>in vitro</i>, as evaluated by the CCK-8 assay (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01958/suppl_file/jm0c01958_si_003.pdf" class="ext-link">Figure S2</a>). BALB/c mice were subcutaneously implanted with CT26/PD-L1 or CT26/vector cells to establish mouse models with different levels of PD-L1 expression. PD-L1 expression levels in both cell lines and tumor tissues were confirmed by flow cytometry (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01958/suppl_file/jm0c01958_si_003.pdf" class="ext-link">Figure S3A</a>). When tumor volume reached approximately 50–100 mm<sup>3</sup>, the mice were randomized into four groups and treated intraperitoneally with control buffer and <b>A30</b> (6 mg/kg) once a day for 16 days. As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A, CT26/PD-L1 cells had an enhanced tumorigenicity compared to parent CT26/vector cells. Importantly, <b>A30</b> exhibited remarkable inhibition of CT26/PD-L1 tumor growth (TGI = 42.0%), while the inhibitory effects on the growth of CT26/vector tumor (TGI = 13.8%) were weak. The potent ability of <b>A30</b> to inhibit CT26/PD-L1 tumor growth was also reflected by the remarkable decrease in tumor weight following treatment (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01958/suppl_file/jm0c01958_si_003.pdf" class="ext-link">Figure S3C</a>). The above data indicated that the antitumor activity of <b>A30</b> is associated with the disruption of the PD-1/PD-L1 pathway rather than an off-target effect. In addition, <b>A30</b> did not cause a significant loss in body weight or difference in the weight of viscera in mice of all treatment groups, suggesting that it was well tolerated (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01958/suppl_file/jm0c01958_si_001.pdb" class="ext-link">Figure S3D</a>).</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <i>In vivo</i> antitumor activity of <b>A30</b> in CT26/PD-L1 and CT26/vector models. (A) Growth curve of implanted tumors during the treatment period. (B) Changes in the body weight of mice during the treatment period. The data are shown as mean ± SD, ***<i>p</i> < 0.001 CT26/PD-L1 control group vs CT26/vector control and CT26/PD-L1 <b>A30</b>-treated groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01958&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> <b>A30</b> Suppressed CT26/PD-L1 Tumor Growth by Activating the Immune Microenvironment in Mice</h3><div class="NLM_p">To investigate the potential immune regulation exhibited by <b>A30</b>, tumor single-cell suspension and spleen lymphocytes were obtained from the CT26/PD-L1 tumor-bearing mouse model and were analyzed via flow cytometry.</div><div class="NLM_p">As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A, the proportion of tumor-infiltrating lymphocytes (TILs) in tumor tissues was increased by <b>A30</b>. The percentage of infiltrated CD8<sup>+</sup> T cells in CD3<sup>+</sup> T cells was remarkably elevated in the <b>A30</b>-treated group (54.4%) compared with that in the control group (24%) (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). In addition, the ability of CD3<sup>+</sup> T cells to produce cytokines was measured. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C,D, the proportions of both IFN-γ<sup>+</sup> and IL-2<sup>+</sup> CD3<sup>+</sup> T cells were significantly increased after <b>A30</b> treatment. These results indicated that <b>A30</b> could activate the tumor immune microenvironment.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effects of <b>A30</b> on infiltration and function of TILs in CT26/PD-L1 mice. (A) Proportion of TILs. (B) Proportion of CD8<sup>+</sup> T cells in CD3<sup>+</sup> T cells. (C) Proportion of IFN-γ<sup>+</sup> CD3<sup>+</sup> T cells. (D) Proportion of IL-2<sup>+</sup> CD3<sup>+</sup> T cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01958&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In the analysis of mice spleen tissues, we found the similar phenomenon of immune activation induced by <b>A30</b>, including the increased proportion and function of CD3<sup>+</sup> T cells (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01958/suppl_file/jm0c01958_si_003.pdf" class="ext-link">Figure S4</a>). In addition, we analyzed the spleens of healthy mice for comparison. The results suggested that <b>A30</b> restored repressed immune function toward the healthy level.</div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Docking Analysis of <b>A30</b> with Dimeric PD-L1</h3><div class="NLM_p">We explored the putative binding mode of <b>A30</b> in inhibitor binding sites formed by PD-L1 dimers using the BMS-200/PD-L1 complex as a template (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). The 2,3-dihydro-1,4-benzodioxinyl and indoline moieties of <b>A30</b> established multiple hydrophobic interactions with dimeric PD-L1, such as π–σ interactions with Ala121 of each monomer and π–alkyl interactions with Met115 of each monomer. Moreover, the aminotetrahydro-2<i>H</i>-pyran moiety interacted with the side chains of Asp122 and Asn63 via two hydrogen bonds, contributing to ligand binding. The thiazole group created a π–π stacking interaction with Tyr56 and a π–anion interaction with Asp122. This binding mode illustrated that <b>A30</b> fitted well within the inhibitor binding pocket formed by dimeric PD-L1.</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Molecular docking analysis of <b>A30</b> with dimeric PD-L1 protein. (B) Superposition of <b>A30</b> and BMS-200 in the binding site formed by dimeric PD-L1. The crystal structure of the PD-L1 dimer was taken from the RCSB Protein Data Bank (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5N2F">5N2F</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01958&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56413" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56413" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cancer immunotherapy using anti-PD-1/PD-L1 mAbs has achieved impressive clinical success; however, the development of small-molecule inhibitors requires further attention. The search for potent small-molecule inhibitors is desirable because they may have more favorable tumor penetration and toxic properties, which could potentially provide a strategy to partially overcome the inherent shortcomings of mAbs. To date, only CA-170 (a peptidomimetic) has entered phase II clinical trials as a treatment for solid tumors. Therefore, the discovery of novel non-peptide small-molecule inhibitors with validated immunoregulatory activity is needed to facilitate the development of cancer immunotherapy targeting the PD-1/PD-L1 interaction.</div><div class="NLM_p">Here, we disclosed the structural optimization of 4-arylindolines, which resulted in the identification of compounds bearing a thiazole moiety as potent inhibitors of the PD-1/PD-L1 interaction. Several compounds, namely, <b>A3</b>, <b>A8</b>, <b>A16–19</b>, <b>A21</b>, <b>A23</b>, <b>A25</b>, <b>A27</b>, <b>A28</b>, <b>A30</b>, and <b>A31</b>, exhibited outstanding activity against the PD-1/PD-L1 interaction at the biochemical level, demonstrating IC<sub>50</sub> values ranging from 8.1 to 27.6 nM, and thus an activity higher than <b>1</b> and BMS-1. At the cellular level, most of the tested compounds significantly restored damaged T-cell function caused by abnormal PD-1 activation. In particular, compound <b>A30</b> showed the most promising activity, as it promoted IFN-γ production in a dose-dependent manner, maximally increasing IFN-γ secretion by 283.8% at a concentration of 1 μM. The promising immunoregulatory activity of <b>A30</b> was further confirmed by its activity in rescuing T-cell proliferation, which was repressed by PD-1 activation. In addition, no significant toxicity was observed for <b>A30</b> in the cell-based experiments. In a 4T1 tumor-bearing mouse model, <b>A30</b> demonstrated significant <i>in vivo</i> antitumor potency with a favorable safety profile, supporting its potential use in cancer immunotherapy. Furthermore, <b>A30</b> displayed more potent efficacy in a mouse CT26/PD-L1 tumor model compared to that in a CT26/vector tumor model, indicating that the mechanism of action of <b>A30</b> is associated with modulation of the PD-1/PD-L1 pathway rather than an off-target effect. The results of flow cytometry analysis demonstrated that <b>A30</b> activated the immune microenvironment, as reflected by the increased proportion and function of lymphocytes in both the tumor and spleen tissues.</div><div class="NLM_p">In this study, the SARs of the newly synthesized 4-arylindolines were explored. Improved inhibitor activity against the PD-1/PD-L1 interaction could be achieved by optimizing the central aryl fragment, as most compounds bearing a thiazole moiety exhibited significantly increased activity compared to <b>1</b>. Compounds <b>A1</b> and <b>A2</b>, with a thiophene group, also displayed potent activity, further indicating the tolerance of specific five-membered aryl moieties for this part of the inhibitor. On the other hand, the phenyl and 2,3-dihydro-1,4-benzodioxinyl groups were well tolerated as the terminal moiety of the compounds. More detailed investigations on the substitution patterns of the phenyl ring are warranted. These SAR results pave the way for future optimization of inhibitors, and comprehensive studies are underway in our laboratory.</div><div class="NLM_p">When receiving anti-PD-1/PD-L1 mAb therapy, a number of patients suffered from serious side effects, which led to the discontinuation of treatment. Thus, unspecific toxicity is a major issue to be considered while developing PD-1/PD-L1 interaction inhibitors. In our study, the toxic effects of inhibitors were assessed by CCK-8 assay using Jurkat T cells. While most compounds showed weak toxicity, <b>A17</b> and <b>A18</b> were much more toxic, demonstrating IC<sub>50</sub> values of 0.9 and 1.2 μM, respectively. At the biochemical level, <b>A18</b> exhibited strong inhibitory activity against the PD-1/PD-L1 interaction; however, its ability to restore immune function was counteracted, at least partially, by unspecific toxicity to T cells. Identification of compounds with a favorable safety profile is necessary to avoid undesired toxicity.</div><div class="NLM_p last">In conclusion, our study uncovered <b>A30</b> as a new-generation inhibitor of the PD-1/PD-L1 interaction. The identification of <b>A30</b> and its analogs will facilitate the future development of small-molecule modulators for cancer immunotherapy.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82048" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82048" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> General Methods</h3><div class="NLM_p">Reagents and solvents were obtained commercially and used without further purification. Melting points of the final compounds were determined on a B̈chi Melting Point B-540 apparatus (B̈chi Labortechnik, Flawil, Switzerland). A Bruker AV-400 spectrometer was used to record the <sup>1</sup>H and <sup>13</sup>C NMR spectra of the synthesized compounds, with TMS as an internal standard. The low resolution ESI-MS was recorded on an Agilent 1100 LC–MS spectrometer, and high-resolution mass spectrometry was performed on an Agilent Accurate-Mass Q-TOF 6530 in ESI mode. The purity of the final compounds was determined by HPLC on an Agilent 1260 machine loading a C18 reversed-phase column (4.6 mm × 250 mm, 5 μm). The mobile phases include phase A (100% methanol) and phase B (NaH<sub>2</sub>PO<sub>4</sub> and H<sub>3</sub>PO<sub>4</sub> buffer solution, pH = 2.5), which were used in a gradient elution program (0 min, phase A: 5%, phase B: 95%; 25 min, phase A: 95%, phase B: 5%) with a flow rate of 1.0 mL/min. UV detection was performed at 220 and 310 nm. All final compounds were confirmed to be >95% pure.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 5-(4-Phenylindoline-1-carbonyl)thiophene-2-carbaldehyde (<b>8</b>)</h4><div class="NLM_p">Intermediate <b>7a</b> (0.2 g, 1.03 mmol), HATU (0.59 g, 1.55 mmol), and DIPEA (0.66 g, 5.13 mmol) was added to a solution of 5-formylthiophene-2-carboxylic acid (0.18 g, 1.15 mmol) in DMF (5 mL). The reaction mixture was stirred at room temperature for 3 h. When TLC showed the completion of the reaction, the solution was poured into water. The precipitate was filtered off to give a residue, which was triturated with ether to give intermediate <b>8</b> (0.25 g, yield 73.2%). Yellow solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.02 (s, 1H), 8.07 (d, <i>J</i> = 4.0 Hz, 2H), 7.87 (d, <i>J</i> = 3.9 Hz, 1H), 7.51–7.47 (m, 4H), 7.42–7.38 (m, 1H), 7.35 (t, <i>J</i> = 7.9 Hz, 1H), 7.16 (d, <i>J</i> = 7.6 Hz, 1H), 4.38 (t, <i>J</i> = 8.1 Hz, 2H), 3.24 (t, <i>J</i> = 8.1 Hz, 2H). ESI-MS <i>m</i>/<i>z</i>: 334.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Intermediate <b>9</b> was synthesized using the same method as that for <b>8</b> by reacting <b>7a</b> with 2-bromothiazole-5-carboxylic acid.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> (2-Bromothiazol-5-yl)(4-phenylindolin-1-yl)methanone (<b>9</b>)</h4><div class="NLM_p last">Yellow solid (yield 62%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (s, 1H), 8.08 (s, 1H), 7.51–7.45 (m, 4H), 7.42–7.37 (m, 1H), 7.35 (t, <i>J</i> = 7.9 Hz, 1H), 7.15 (d, <i>J</i> = 7.6 Hz, 1H), 4.41 (t, <i>J</i> = 8.1 Hz, 2H), 3.26 (t, <i>J</i> = 8.1 Hz, 2H). ESI-MS <i>m</i>/<i>z</i>: 385.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> (4-Phenylindolin-1-yl)(2-vinylthiazol-5-yl)methanone (<b>10</b>)</h4><div class="NLM_p last">To a mixture of intermediate <b>9</b> (0.5 g, 1.3 mmol), tributyl(vinyl)stannane (0.45 g, 1.41 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (0.15 g, 0.13 mmol) in a mixture of 1,4-dioxane (3 mL) and water (1 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (1.06 g, 3.25 mmol). The mixture was stirred at 100 °C for 2 h under a N<sub>2</sub> atmosphere. When TLC showed the completion of the reaction, the reaction mixture was cooled to room temperature and filtered. The filtrate was diluted with water and extracted with DCM. The organic layer was washed with brine and concentrated to give a residue, which was purified by column chromatography (MeOH/DCM, 1/200 to 1/100) to give intermediate <b>10</b> (0.23 g, yield 53.3%). Brown solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.37 (s, 1H), 8.09 (s, 1H), 7.48 (m, 4H), 7.41 (m, 1H), 7.34 (t, <i>J</i> = 7.8 Hz, 1H), 7.14 (d, <i>J</i> = 7.4 Hz, 1H), 7.01 (dd, <i>J</i> = 17.5, 10.9 Hz, 1H), 6.23 (d, <i>J</i> = 17.5 Hz, 1H), 5.73 (d, <i>J</i> = 11.0 Hz, 1H), 4.42 (s, 2H), 3.25 (t, <i>J</i> = 8.1 Hz, 2H). ESI-MS <i>m</i>/<i>z</i>: 333.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 5-(4-Phenylindoline-1-carbonyl)thiazole-2-carbaldehyde (<b>11</b>)</h4><div class="NLM_p last">To a solution of intermediate <b>10</b> (0.2 g, 0.6 mmol) in a mixture of 1,4-dioxane (5 mL) and water (1 mL) was added K<sub>2</sub>OsO<sub>4</sub>·2H<sub>2</sub>O (0.044 g, 0.12 mmol). Stirring was continued for 10 min at room temperature. Subsequently, NaIO<sub>4</sub> (0.51 g, 2.4 mmol) was added, the mixture was stirred at room temperature for another 2 h. After that time, the reaction mixture was poured into water. The precipitate was filtered off to yield intermediate <b>11</b> (0.17 g, yield 85.6%). Gray solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.99 (s, 1H), 8.73 (s, 1H), 7.52–7.46 (m, 5H), 7.43–7.33 (m, 2H), 7.18 (d, <i>J</i> = 7.5 Hz, 1H), 4.40 (t, <i>J</i> = 7.9 Hz, 2H), 3.26 (t, <i>J</i> = 8.1 Hz, 2H). ESI-MS <i>m</i>/<i>z</i>: 335.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Ethyl 5-Formylthiazole-2-carboxylate (<b>13</b>)</h4><div class="NLM_p last">A mixture of ethyl 2-amino-2-thioxoacetate (10 g, 75.18 mmol) and 2-bromomalonaldehyde (11.28 g, 75.24 mmol) in 1,2-dimethoxyethane (30 mL) was stirred at room temperature for 10 h. After that time, the reaction mixture was diluted with water and extracted with DCM. The organic layer was washed with aqueous NaHCO<sub>3</sub> and brine and then concentrated to generate intermediate <b>13</b> (7.14 g, yield 51.3%). Yellow solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.15 (s, 1H), 8.87 (s, 1H), 4.42 (q, <i>J</i> = 7.1 Hz, 2H), 1.35 (t, <i>J</i> = 7.1 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 186.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Ethyl 5-(1,3-Dioxolan-2-yl)thiazole-2-carboxylate (<b>14</b>)</h4><div class="NLM_p last">A mixture of intermediate <b>13</b> (8 g, 43.24 mmol) and ethane-1,2-diol (9.39 g, 151.34 mmol) was dissolved in toluene (80 mL) followed by the addition of TsOH·H<sub>2</sub>O (0.66 g, 3.47 mmol). The reaction mixture was stirred at 110 °C for 5 h and was monitored by TLC. The reaction mixture was washed with aqueous NaHCO<sub>3</sub> and brine, and the organic layer was evaporated to give intermediate <b>14</b> (7.5 g, yield 75.8%). Yellow oil. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.17 (s, 1H), 6.24 (s, 1H), 4.38 (q, <i>J</i> = 7.1 Hz, 2H), 4.05 (dt, <i>J</i> = 13.0, 8.6 Hz, 2H), 4.00 (dt, <i>J</i> = 9.1, 8.6 Hz, 2H), 1.33 (t, <i>J</i> = 7.1 Hz, 3H). ESI-MS <i>m</i>/<i>z</i>: 230.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 5-(1,3-Dioxolan-2-yl)thiazole-2-carboxylic Acid (<b>15</b>)</h4><div class="NLM_p">Intermediate <b>14</b> (6 g, 26.2 mmol) was dissolved in a mixture of THF (12 mL) and H<sub>2</sub>O (3 mL). LiOH (1.26 g, 52.61 mmol) was added, and the reaction mixture was stirred at room temperature for 2 h. After that time, the mixture was concentrated and diluted with H<sub>2</sub>O. The solution was acidized using HCl (1 N, aqueous) until the pH was 5–6 and then was extracted with butyl alcohol. The organic layer was concentrated to provide intermediate <b>15</b> (2.36 g, yield 44.8%). Yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.73 (s, 1H), 6.03 (s, 1H), 4.04–4.00 (m, 2H), 3.94–3.90 (m, 2H). ESI-MS <i>m</i>/<i>z</i>: 202.0 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Intermediate <b>16</b> was synthesized using the same method as that for<b>8</b> by reacting 4-bromoindoline with <b>15</b>.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (5-(1,3-Dioxolan-2-yl)thiazol-2-yl)(4-bromoindolin-1-yl)methanone (<b>16</b>)</h4><div class="NLM_p last">Brown solid (yield 77%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.23–8.14 (m, 2H), 7.34 (m, 1H), 7.22 (m, 1H), 6.23 (s, 1H), 4.73 (t, <i>J</i> = 8.1 Hz, 2H), 4.13–3.95 (m, 4H), 3.19 (t, <i>J</i> = 8.3 Hz, 2H). ESI-MS <i>m</i>/<i>z</i>: 381. [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 2-(4-Bromoindoline-1-carbonyl)thiazole-5-carbaldehyde (<b>17</b>)</h4><div class="NLM_p last">TsOH·H<sub>2</sub>O (2 g, 10.51 mmol) was added to a solution of intermediate <b>16</b> (2 g, 5.26 mmol) in a mixture of acetone (9 mL) and H<sub>2</sub>O (6 mL). The suspension was allowed to stir at 70 °C for 4 h. After that time, the reaction mixture was cooled to room temperature and poured into water. The precipitate was filtered off to give a residue, which was triturated with ether to provide intermediate <b>17</b> (1.43 g, yield 80.9%). Yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.15 (s, 1H), 8.88 (s, 1H), 8.20 (d, <i>J</i> = 7.8 Hz, 1H), 7.37 (d, <i>J</i> = 7.9 Hz, 1H), 7.25 (t, <i>J</i> = 8.1 Hz, 1H), 4.77 (s, 2H), 3.21 (t, <i>J</i> = 8.2 Hz, 2H). ESI-MS <i>m</i>/<i>z</i>: 337.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (4-Bromoindolin-1-yl)(5-(((2-hydroxyethyl)amino)methyl)thiazol-2-yl)methanone (<b>18</b>)</h4><div class="NLM_p last">To a solution of intermediate <b>17</b> (1.2 g, 3.57 mmol) and 2-aminoethan-1-ol (1.09 g, 17.85 mmol) in a mixture of DCM (5 mL) and MeOH (5 mL) were added two drops of acetic acid. After stirring at room temperature for 3 h, NaBH<sub>3</sub>CN (1.13 g, 17.98 mmol) was added to the solution. Stirring was continued for 9 h at room temperature until TLC indicated the completion of the reaction. The solvent was concentrated and diluted with DCM. The organic layer was washed with brine and evaporated to give a residue, which was triturated with ether to generate intermediate <b>18</b> (2.39 g, yield 35.2%). Yellow solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.18 (d, <i>J</i> = 5.0 Hz, 1H), 7.92 (s, 1H), 7.32 (d, <i>J</i> = 8.0 Hz, 1H), 7.21 (t, <i>J</i> = 8.1 Hz, 1H), 4.73 (t, <i>J</i> = 8.2 Hz, 2H), 4.51 (t, <i>J</i> = 5.4 Hz, 1H), 4.00 (s, 2H), 3.46 (q, <i>J</i> = 5.7 Hz, 2H), 3.18 (t, <i>J</i> = 8.4 Hz, 2H), 2.60 (t, <i>J</i> = 5.7 Hz, 2H). ESI-MS <i>m</i>/<i>z</i>: 382.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 2-(4-(Benzo[<i>d</i>]oxazol-5-yl)indoline-1-carbonyl)thiazole-5-carbaldehyde (<b>19</b>)</h4><div class="NLM_p">To a solution of intermediate <b>17</b> (0.5 g, 1.49 mmol) and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[<i>d</i>]oxazole (0.4 g, 1.63 mmol) in a mixture of 1,4-dioxane (3 mL) and water (1 mL) were added PdCl<sub>2</sub>(dppf) (0.11 g, 0.15 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (0.88 g, 2.7 mmol). The reaction mixture was stirred at 80 °C for 6 h under a N<sub>2</sub> atmosphere. When TLC showed the completion of the reaction, the reaction mixture was cooled to room temperature and filtered off. The filtrate was diluted with water and extracted with DCM. The organic layer was washed with brine and evaporated to give a residue, which was purified by column chromatography (ethyl acetate/petroleum ether, 1/50 to 1/5) to give intermediate <b>19</b> (0.12 g, yield 21.5%). White solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.15 (s, 1H), 8.87 (s, 1H), 8.82 (s, 1H), 8.27 (d, <i>J</i> = 7.9 Hz, 1H), 7.93 (s, 1H), 7.88 (d, <i>J</i> = 8.6 Hz, 1H), 7.57 (d, <i>J</i> = 8.3 Hz, 1H), 7.41 (t, <i>J</i> = 7.7 Hz, 1H), 7.26 (d, <i>J</i> = 7.4 Hz, 1H), 4.71 (t, <i>J</i> = 7.9 Hz, 2H), 3.32–3.29 (m, 2H). ESI-MS <i>m</i>/<i>z</i>: 376.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Intermediates <b>20a</b> and <b>20b</b> were synthesized using the same method as that for <b>8</b> by reacting <b>15</b> with <b>7a</b> and <b>7b</b>, respectively.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (5-(1,3-Dioxolan-2-yl)thiazol-2-yl)(4-phenylindolin-1-yl)methanone (<b>20a</b>)</h4><div class="NLM_p last">Light yellow solid (yield 82%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.23 (d, <i>J</i> = 7.6 Hz, 1H), 8.14 (s, 1H), 7.48 (q, <i>J</i> = 7.4 Hz, 4H), 7.38 (m, 2H), 7.17 (d, <i>J</i> = 7.6 Hz, 1H), 6.23 (s, 1H), 4.67 (t, <i>J</i> = 7.7 Hz, 2H), 4.13–4.05 (m, 2H), 4.04–3.98 (m, 2H), 3.26 (t, <i>J</i> = 8.0 Hz, 2H). ESI-MS <i>m</i>/<i>z</i>: 379.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (5-(1,3-Dioxolan-2-yl)thiazol-2-yl)(4-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)indolin-1-yl)methanone (<b>20b</b>)</h4><div class="NLM_p">Light yellow solid (yield 76%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.18 (d, <i>J</i> = 8.1 Hz, 1H), 8.15 (s, 1H), 7.32 (t, <i>J</i> = 7.9 Hz, 1H), 7.12 (d, <i>J</i> = 7.7 Hz, 1H), 6.98 (s, 1H), 6.95 (s, 2H), 6.23 (s, 1H), 4.66 (t, <i>J</i> = 8.0 Hz, 2H), 4.28 (s, 4H), 4.09–4.06 (m, 2H), 4.02–3.98 (m, 2H), 3.25 (t, <i>J</i> = 8.2 Hz, 2H). ESI-MS <i>m</i>/<i>z</i>: 437.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Intermediates <b>21a</b> and <b>22b</b> were synthesized from <b>20a</b> and <b>20b</b>, respectively, using the same method as that for <b>17</b>.</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 2-(4-Phenylindoline-1-carbonyl)thiazole-5-carbaldehyde (<b>21a</b>)</h4><div class="NLM_p last">Light yellow solid (yield 79%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.15 (s, 1H), 8.87 (s, 1H), 8.25 (d, <i>J</i> = 8.0 Hz, 1H), 7.54–7.46 (m, 4H), 7.40 (dd, <i>J</i> = 12.9, 7.2 Hz, 2H), 7.21 (d, <i>J</i> = 7.5 Hz, 1H), 4.70 (t, <i>J</i> = 8.1 Hz, 2H), 3.29 (t, <i>J</i> = 8.1 Hz, 2H). ESI-MS <i>m</i>/<i>z</i>: 335.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 2-(4-(2,3-Dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)indoline-1-carbonyl)thiazole-5-carbaldehyde (<b>21b</b>)</h4><div class="NLM_p last">Light yellow solid (yield 63%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.15 (s, 1H), 8.86 (s, 1H), 8.19 (t, <i>J</i> = 7.1 Hz, 1H), 7.40–7.30 (m, 1H), 7.13 (m, 1H), 6.98 (d, <i>J</i> = 3.4 Hz, 1H), 6.95 (d, <i>J</i> = 2.1 Hz, 2H), 4.72–4.63 (m, 2H), 4.29 (s, 4H), 3.32–3.22 (m, 2H). ESI-MS <i>m</i>/<i>z</i>: 393.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (5-(((2-Hydroxyethyl)amino)methyl)thiophen-2-yl)(4-phenylindolin-1-yl)methanone (<b>A1</b>)</h4><div class="NLM_p">To a solution of intermediate <b>8</b> (100 mg, 0.3 mmol) in a mixture of DCM (2 mL) and methanol (2 mL) was added 2-aminoethan-1-ol (91.64 mg, 1.5 mmol) followed by the addition two drops of acetic acid. After stirring at room temperature for 5 h, NaBH<sub>3</sub>CN (94.26 mg, 1.5 mmol) was added. The reaction mixture was stirred at room temperature for another 10 h. When TLC indicated the completion of the reaction, the solvent was evaporated and diluted with DCM. The organic layer was washed with brine and concentrated to give a residue, which was purified by column chromatography (MeOH/DCM, 1/200 to 1/15) to yield compound <b>A1</b> (17.71 mg, yield 15.6%). Light yellow solid. mp 85.2–87.7 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.05 (d, <i>J</i> = 7.7 Hz, 1H), 7.60 (d, <i>J</i> = 3.6 Hz, 1H), 7.53–7.45 (m, 4H), 7.43–7.37 (m, 1H), 7.32 (t, <i>J</i> = 7.8 Hz, 1H), 7.11 (d, <i>J</i> = 7.5 Hz, 1H), 7.05 (d, <i>J</i> = 3.3 Hz, 1H), 4.54 (t, <i>J</i> = 5.4 Hz, 1H), 4.40 (t, <i>J</i> = 8.1 Hz, 2H), 3.95 (s, 2H), 3.49 (q, <i>J</i> = 5.3 Hz, 2H), 3.24 (t, <i>J</i> = 8.0 Hz, 2H), 2.64 (t, <i>J</i> = 5.7 Hz, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.14, 143.97, 140.04, 138.39, 137.92, 130.60, 130.40, 128.95 (2C), 128.50 (2C), 128.07, 127.75, 125.62, 124.54, 116.40, 60.41, 51.14, 50.86, 47.88, 28.57. HRMS (ESI) for C<sub>22</sub>H<sub>22</sub>N<sub>2</sub>O<sub>2</sub>S [M + H]<sup>+</sup>: calcd, 379.1475; found, 379.1480. Purity, 97.2%.</div><div class="NLM_p last">Compounds <b>A2–6</b> were synthesized using the same method as that for <b>A1</b> by reacting <b>8</b>, <b>11</b>, and <b>21a</b> with appropriate amines.</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>N</i>-(2-(((5-(4-Phenylindoline-1-carbonyl)thiophen-2-yl)methyl)amino)ethyl)acetamide (<b>A2</b>)</h4><div class="NLM_p last">Light yellow solid (17.62 mg, yield 14%). mp 84.1–86.3 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.04 (d, <i>J</i> = 7.8 Hz, 1H), 7.80 (s, 1H), 7.59 (d, <i>J</i> = 3.7 Hz, 1H), 7.51–7.45 (m, 4H), 7.41–7.36 (m, 1H), 7.32 (t, <i>J</i> = 7.8 Hz, 1H), 7.10 (d, <i>J</i> = 7.6 Hz, 1H), 7.03 (d, <i>J</i> = 3.5 Hz, 1H), 4.39 (t, <i>J</i> = 8.1 Hz, 2H), 3.91 (s, 2H), 3.23 (t, <i>J</i> = 8.0 Hz, 2H), 3.13 (q, <i>J</i> = 6.2 Hz, 2H), 2.59 (t, <i>J</i> = 6.4 Hz, 2H), 1.79 (s, 3H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.51, 161.16, 151.58, 143.98, 140.04, 138.38, 137.75, 130.59, 130.38, 128.95 (2C), 128.49 (2C), 128.06, 127.75, 125.33, 124.52, 116.40, 50.86, 48.35, 47.84, 38.94, 28.57, 23.04. HRMS (ESI) for C<sub>24</sub>H<sub>25</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>: calcd, 420.1740; found, 420.1743. Purity, 98.1%.</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (5-(((2-Hydroxyethyl)amino)methyl)thiazol-2-yl)(4-phenylindolin-1-yl)methanone (<b>A3</b>)</h4><div class="NLM_p last">Light yellow solid (11.35 mg, yield 10%). mp 142.1–143.6 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.23 (d, <i>J</i> = 8.7 Hz, 1H), 7.91 (s, 1H), 7.52–7.46 (m, 4H), 7.41–7.38 (m, 1H), 7.36 (t, <i>J</i> = 7.8 Hz, 1H), 7.16 (d, <i>J</i> = 7.6 Hz, 1H), 4.68 (t, <i>J</i> = 8.5 Hz, 2H), 4.51 (t, <i>J</i> = 5.3 Hz, 1H), 4.00 (s, 2H), 3.47 (q, <i>J</i> = 5.7 Hz, 2H), 3.26 (t, <i>J</i> = 8.2 Hz, 2H), 2.61 (t, <i>J</i> = 5.7 Hz, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 162.67, 158.55, 143.73, 141.61, 139.98, 138.52, 130.90, 128.97 (2C), 128.53 (2C), 128.19, 127.80, 125.24, 116.58, 60.52, 51.12, 50.78, 45.23, 28.48. HRMS (ESI) for C<sub>21</sub>H<sub>21</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>: calcd, 380.1427; found, 380.1432. Purity, 98.9%.</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>N</i>-(2-(((2-(4-Phenylindoline-1-carbonyl)thiazol-5-yl)methyl)amino)ethyl)acetamide (<b>A4</b>)</h4><div class="NLM_p last">Light yellow solid (10.94 mg, yield 9%). mp 141.9–144.0 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.23 (s, 1H), 7.91 (s, 1H), 7.80 (s, 1H), 7.53–7.45 (m, 4H), 7.40 (t, <i>J</i> = 6.9 Hz, 1H), 7.36 (t, <i>J</i> = 7.7 Hz, 1H), 7.16 (d, <i>J</i> = 7.6 Hz, 1H), 4.68 (t, <i>J</i> = 7.6 Hz, 2H), 3.98 (s, 2H), 3.26 (t, <i>J</i> = 8.1 Hz, 2H), 3.13 (q, <i>J</i> = 5.8 Hz, 2H), 2.58 (t, <i>J</i> = 6.3 Hz, 2H), 1.79 (s, 3H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.50, 164.34, 158.55, 146.71, 143.73, 141.45, 139.98, 138.51, 130.89, 128.96 (2C), 128.53 (2C), 128.19, 127.79, 125.23, 116.58, 50.78, 48.27, 45.09, 38.95, 28.48, 23.04. HRMS (ESI) for C<sub>23</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub>S [M + H]<sup>+</sup>: calcd, 421.1693; found, 421.1690. Purity, 96.3%.</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (2-(((2-Hydroxyethyl)amino)methyl)thiazol-5-yl)(4-phenylindolin-1-yl)methanone (<b>A5</b>)</h4><div class="NLM_p last">White solid (10.1 mg, yield 9%). mp 123.4–126.0 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.26 (s, 1H), 8.07 (s, 1H), 7.51–7.46 (m, 4H), 7.41–7.38 (m, 1H), 7.33 (t, <i>J</i> = 7.9 Hz, 1H), 7.13 (d, <i>J</i> = 7.5 Hz, 1H), 4.56 (t, <i>J</i> = 5.3 Hz, 1H), 4.38 (t, <i>J</i> = 8.2 Hz, 2H), 4.04 (s, 2H), 3.50 (q, <i>J</i> = 5.5 Hz, 2H), 3.24 (t, <i>J</i> = 8.1 Hz, 2H), 2.69 (t, <i>J</i> = 5.7 Hz, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 178.83, 159.99, 144.76, 143.60, 139.95, 138.47, 134.59, 130.54, 128.97 (2C), 128.50 (2C), 128.15, 127.79, 124.87, 116.30, 60.78, 51.76, 50.89, 50.65, 28.42. HRMS (ESI) for C<sub>21</sub>H<sub>21</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>: calcd, 380.1427; found, 380.1429. Purity, 97.6%.</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>N</i>-(2-(((5-(4-Phenylindoline-1-carbonyl)thiazol-2-yl)methyl)amino)ethyl)acetamide (<b>A6</b>)</h4><div class="NLM_p">Yellow solid (27.67 mg, yield 22%). mp 96.2–98.0 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.26 (s, 1H), 8.07 (s, 1H), 7.83 (t, <i>J</i> = 4.6 Hz, 1H), 7.51–7.45 (m, 4H), 7.42–7.37 (m, 1H), 7.33 (t, <i>J</i> = 7.8 Hz, 1H), 7.13 (d, <i>J</i> = 7.6 Hz, 1H), 4.39 (t, <i>J</i> = 8.2 Hz, 2H), 4.01 (s, 2H), 3.24 (t, <i>J</i> = 8.1 Hz, 2H), 3.16 (q, <i>J</i> = 6.2 Hz, 2H), 2.66 (t, <i>J</i> = 6.4 Hz, 2H), 1.80 (s, 3H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 178.62, 169.57, 159.96, 144.73, 143.60, 139.95, 138.46, 134.68, 130.52, 128.96 (2C), 128.49 (2C), 128.15, 127.78, 124.87, 116.31, 50.65, 50.61, 48.83, 39.04, 28.41, 23.05. HRMS (ESI) for C<sub>23</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub>S [M + H]<sup>+</sup>: calcd, 421.1693; found, 421.1688. Purity, 98.1%.</div><div class="NLM_p last">Compounds <b>A7–15</b> were synthesized from <b>18</b> through the Suzuki–Miyaura coupling reaction using the same method as that for the conversion of <b>17</b> to <b>19</b>.</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (5-(((2-Hydroxyethyl)amino)methyl)thiazol-2-yl)(4-(pyridin-4-yl)indolin-1-yl)methanone (<b>A7</b>)</h4><div class="NLM_p last">Light yellow solid (10.97 mg, yield 11%). mp 157.3–158.3 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.67 (d, <i>J</i> = 5.5 Hz, 2H), 8.30 (d, <i>J</i> = 6.3 Hz, 1H), 7.91 (s, 1H), 7.54 (d, <i>J</i> = 5.6 Hz, 2H), 7.41 (t, <i>J</i> = 7.8 Hz, 1H), 7.24 (d, <i>J</i> = 7.6 Hz, 1H), 4.69 (t, <i>J</i> = 7.8 Hz, 2H), 4.52 (t, <i>J</i> = 4.9 Hz, 1H), 4.00 (s, 2H), 3.47 (q, <i>J</i> = 5.3 Hz, 2H), 3.30 (t, <i>J</i> = 8.2 Hz, 2H), 2.61 (t, <i>J</i> = 5.7 Hz, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.13, 158.64, 150.29 (2C), 147.28, 146.96, 144.02, 141.42, 135.71, 131.25, 128.50, 124.94, 123.39 (2C), 117.73, 60.67, 51.22, 50.79, 45.36, 28.30. HRMS (ESI) for C<sub>20</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>S [M + H]<sup>+</sup>: calcd, 381.1380; found, 381.1383. Purity, 97.3%.</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (4-(2,3-Dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)indolin-1-yl)(5-(((2-hydroxyethyl)amino)methyl)thiazol-2-yl)methanone (<b>A8</b>)</h4><div class="NLM_p last">White solid (8.03 mg, yield 7%). mp 135.5–138.3 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.18 (d, <i>J</i> = 5.8 Hz, 1H), 7.90 (s, 1H), 7.31 (t, <i>J</i> = 7.8 Hz, 1H), 7.10 (d, <i>J</i> = 7.6 Hz, 1H), 6.98 (s, 1H), 6.94 (s, 2H), 4.66 (t, <i>J</i> = 6.6 Hz, 2H), 4.52 (t, <i>J</i> = 5.0 Hz, 1H), 4.28 (s, 4H), 4.00 (s, 2H), 3.47 (q, <i>J</i> = 5.2 Hz, 2H), 3.24 (t, <i>J</i> = 8.0 Hz, 2H), 2.61 (t, <i>J</i> = 5.0 Hz, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.31, 158.52, 146.85, 143.65, 143.31, 141.37, 138.00, 133.15, 130.72, 128.08, 125.04, 121.51, 117.52, 117.07, 116.24, 64.51, 64.48, 60.68, 51.22, 50.78, 45.37, 28.55. HRMS (ESI) for C<sub>23</sub>H<sub>23</sub>N<sub>3</sub>O<sub>4</sub>S [M + H]<sup>+</sup>: calcd, 438.1482; found, 438.1489. Purity, 98.9%.</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (4-(Benzo[<i>d</i>]oxazol-6-yl)indolin-1-yl)(5-(((2-hydroxyethyl)amino)methyl)thiazol-2-yl)methanone (<b>A9</b>)</h4><div class="NLM_p last">Light yellow solid (5.51 mg, yield 5%). mp 131.9–134.0 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.81 (s, 1H), 8.26 (d, <i>J</i> = 6.5 Hz, 1H), 7.91 (d, <i>J</i> = 6.4 Hz, 2H), 7.89 (d, <i>J</i> = 8.2 Hz, 1H), 7.53 (d, <i>J</i> = 8.2 Hz, 1H), 7.38 (t, <i>J</i> = 7.8 Hz, 1H), 7.23 (d, <i>J</i> = 7.6 Hz, 1H), 4.68 (t, <i>J</i> = 7.6 Hz, 2H), 4.53 (t, <i>J</i> = 5.6 Hz, 1H), 4.00 (s, 2H), 3.48 (q, <i>J</i> = 5.4 Hz, 2H), 3.30 (t, <i>J</i> = 8.2 Hz, 2H), 2.62 (t, <i>J</i> = 5.8 Hz, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.83, 158.19, 154.77, 149.60, 146.52, 143.39, 140.98, 138.97, 137.64, 137.40, 130.79, 127.83, 125.21, 125.16, 119.96, 116.37, 110.83, 60.28, 50.83, 50.38, 44.97, 28.03. HRMS (ESI) for C<sub>22</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub>S [M + H]<sup>+</sup>: calcd, 421.1329; found, 421.1333. Purity, 96.7%.</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (4-(Benzo[<i>d</i>]oxazol-5-yl)indolin-1-yl)(5-(((2-hydroxyethyl)amino)methyl)thiazol-2-yl)methanone (<b>A10</b>)</h4><div class="NLM_p last">Light yellow solid (13.23 mg, yield 12%). mp 127.5–130.4 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.82 (s, 1H), 8.25 (d, <i>J</i> = 7.9 Hz, 1H), 7.91 (s, 2H), 7.87 (d, <i>J</i> = 8.4 Hz, 1H), 7.56 (dd, <i>J</i> = 8.4, 1.5 Hz, 1H), 7.38 (t, <i>J</i> = 7.8 Hz, 1H), 7.22 (d, <i>J</i> = 7.4 Hz, 1H), 4.69 (t, <i>J</i> = 7.2 Hz, 2H), 4.52 (t, <i>J</i> = 5.3 Hz, 1H), 4.00 (s, 2H), 3.47 (q, <i>J</i> = 5.6 Hz, 2H), 3.29 (t, <i>J</i> = 8.2 Hz, 2H), 2.61 (t, <i>J</i> = 5.7 Hz, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.24, 158.59, 155.28, 149.14, 146.93, 143.75, 141.39, 140.42, 138.23, 136.88, 131.18, 128.22, 126.52, 125.64, 120.01, 116.63, 111.56, 60.69, 51.23, 50.80, 45.37, 28.44. HRMS (ESI) for C<sub>22</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub>S [M + H]<sup>+</sup>: calcd, 421.1329; found, 421.1334. Purity, 98.2%.</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (4-(Benzo[<i>d</i>]thiazol-5-yl)indolin-1-yl)(5-(((2-hydroxyethyl)amino)methyl)thiazol-2-yl)methanone (<b>A11</b>)</h4><div class="NLM_p last">Light yellow solid (17.17 mg, yield 15%). mp 162.8–164.3 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.47 (s, 1H), 8.27 (d, <i>J</i> = 8.2 Hz, 2H), 8.19 (s, 1H), 7.91 (s, 1H), 7.63 (d, <i>J</i> = 8.1 Hz, 1H), 7.40 (t, <i>J</i> = 7.7 Hz, 1H), 7.26 (d, <i>J</i> = 7.5 Hz, 1H), 4.70 (t, <i>J</i> = 8.0 Hz, 2H), 4.54 (t, <i>J</i> = 5.3 Hz, 1H), 4.01 (s, 2H), 3.48 (q, <i>J</i> = 5.2 Hz, 2H), 3.31 (d, <i>J</i> = 8.2 Hz, 2H), 2.62 (t, <i>J</i> = 5.6 Hz, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.87, 158.19, 156.99, 153.37, 146.42, 143.42, 141.02, 137.86, 137.62, 132.71, 130.81, 127.88, 125.84, 125.17, 122.61, 122.28, 116.35, 60.26, 50.81, 50.42, 44.95, 28.07. HRMS (ESI) for C<sub>22</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>S<sub>2</sub> [M + H]<sup>+</sup>: calcd, 437.1100; found, 437.1105. Purity, 96.8%.</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (4-(1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridin-5-yl)indolin-1-yl)(5-(((2-hydroxyethyl)amino)methyl)thiazol-2-yl)methanone (<b>A12</b>)</h4><div class="NLM_p last">Yellow solid (11.01 mg, yield 10%). mp 149.3–151.1 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.77 (s, 1H), 8.33 (d, <i>J</i> = 2.2 Hz, 1H), 8.23 (d, <i>J</i> = 8.1 Hz, 1H), 8.07 (d, <i>J</i> = 2.1 Hz, 1H), 7.91 (s, 1H), 7.54–7.53 (m, 1H), 7.37 (t, <i>J</i> = 7.9 Hz, 1H), 7.21 (d, <i>J</i> = 7.5 Hz, 1H), 6.51 (dd, <i>J</i> = 3.4, 1.8 Hz, 1H), 4.69 (t, <i>J</i> = 8.1 Hz, 2H), 4.54 (t, <i>J</i> = 5.3 Hz, 1H), 4.01 (s, 2H), 3.48 (q, <i>J</i> = 5.2 Hz, 2H), 3.30 (t, <i>J</i> = 8.3 Hz, 2H), 2.62 (t, <i>J</i> = 5.8 Hz, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.33, 158.54, 148.11, 146.75, 143.73, 142.67, 141.41, 137.07, 131.28, 128.16, 127.80, 127.68, 127.33, 125.71, 119.70, 116.30, 100.46, 60.66, 51.22, 50.77, 45.35, 28.50. HRMS (ESI) for C<sub>22</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, calcd: 420.1489, found:420.1485. Purity, 98.6%.</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (5-(((2-Hydroxyethyl)amino)methyl)thiazol-2-yl)(4-(quinoxalin-6-yl)indolin-1-yl)methanone (<b>A13</b>)</h4><div class="NLM_p last">Yellow solid (9.05 mg, yield 8%). mp 136.4–140.3 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.01–8.99 (m, 2H), 8.31 (d, <i>J</i> = 8.1 Hz, 1H), 8.20 (d, <i>J</i> = 8.6 Hz, 1H), 8.19 (d, <i>J</i> = 2.0 Hz, 1H), 8.04 (dd, <i>J</i> = 8.6, 2.1 Hz, 1H), 7.92 (s, 1H), 7.44 (t, <i>J</i> = 7.9 Hz, 1H), 7.35 (d, <i>J</i> = 7.3 Hz, 1H), 4.71 (t, <i>J</i> = 8.2 Hz, 2H), 4.53 (t, <i>J</i> = 5.3 Hz, 1H), 4.01 (s, 2H), 3.48 (q, <i>J</i> = 5.5 Hz, 2H), 3.37 (t, <i>J</i> = 8.2 Hz, 2H), 2.62 (t, <i>J</i> = 5.8 Hz, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 162.66, 158.66, 147.01, 146.65, 146.30, 143.99, 142.54, 141.81, 141.71, 141.41, 137.10, 131.48, 131.19, 129.76, 128.48, 128.34, 125.56, 117.30, 60.70, 51.23, 50.86, 45.38, 28.47. HRMS (ESI) for C<sub>23</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup>: calcd, 432.1489; found, 432.1493. Purity, 97.5%.</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (4-(1<i>H</i>-Indol-4-yl)indolin-1-yl)(5-(((2-hydroxyethyl)amino)methyl)thiazol-2-yl)methanone (<b>A14</b>)</h4><div class="NLM_p last">Light yellow solid (17.6 mg, yield 16%). mp 197.4–198.1 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.26 (s, 1H), 8.24 (d, <i>J</i> = 6.6 Hz, 1H), 7.89 (s, 1H), 7.43 (d, <i>J</i> = 8.0 Hz, 1H), 7.39–7.35 (m, 2H), 7.21 (d, <i>J</i> = 7.5 Hz, 1H), 7.17 (t, <i>J</i> = 7.6 Hz, 1H), 7.00 (d, <i>J</i> = 7.0 Hz, 1H), 6.25 (s, 1H), 4.66 (t, <i>J</i> = 7.3 Hz, 2H), 4.52 (t, <i>J</i> = 5.1 Hz, 1H), 4.00 (s, 2H), 3.47 (q, <i>J</i> = 5.7 Hz, 2H), 3.10 (t, <i>J</i> = 8.0 Hz, 2H), 2.61 (t, <i>J</i> = 5.5 Hz, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.51, 158.66, 146.77, 143.75, 141.53, 138.52, 136.59, 131.90, 131.58, 127.75, 126.48, 126.24, 126.03, 121.40, 119.41, 116.35, 111.41, 100.88, 60.75, 51.29, 50.80, 45.43, 28.57. HRMS (ESI) for C<sub>23</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub>S [M + H]<sup>+</sup>: calcd, 419.1536; found, 419.1533. Purity, 99.1%.</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (5-(((2-Hydroxyethyl)amino)methyl)thiazol-2-yl)(4-(1-methyl-1<i>H</i>-indazol-4-yl)indolin-1-yl)methanone (<b>A15</b>)</h4><div class="NLM_p">Light yellow solid (7.96 mg, yield 7%). mp 250.9–252.5 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.30 (d, <i>J</i> = 7.0 Hz, 1H), 7.91 (s, 1H), 7.89 (s, 1H), 7.68 (d, <i>J</i> = 8.4 Hz, 1H), 7.50 (t, <i>J</i> = 7.7 Hz, 1H), 7.42 (t, <i>J</i> = 7.7 Hz, 1H), 7.25 (d, <i>J</i> = 7.5 Hz, 1H), 7.17 (d, <i>J</i> = 6.9 Hz, 1H), 4.68 (t, <i>J</i> = 7.6 Hz, 2H), 4.55 (s, 1H), 4.10 (s, 3H), 4.01 (s, 2H), 3.51–3.46 (m, 2H), 3.14 (t, <i>J</i> = 8.1 Hz, 2H), 2.62 (t, <i>J</i> = 5.6 Hz, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.29, 158.61, 146.80, 143.93, 141.43, 140.26, 136.58, 132.93, 132.06, 131.50, 128.03, 126.40, 125.78, 122.49, 120.70, 116.92, 109.45, 60.66, 51.22, 50.74, 45.35, 35.92, 28.42. HRMS (ESI) for C<sub>23</sub>H<sub>23</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup>: calcd, 434.1645; found, 434.1648. Purity, 98.0%.</div><div class="NLM_p last">Compounds <b>A16–18</b> were synthesized using the same method as that for <b>A1</b> by reacting <b>21a</b> with appropriate amines.</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (5-(((2-Methoxyethyl)amino)methyl)thiazol-2-yl)(4-phenylindolin-1-yl)methanone (<b>A16</b>)</h4><div class="NLM_p last">Light yellow solid (17.65 mg, yield 15%). mp 64.1–66.9 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.23 (d, <i>J</i> = 6.5 Hz, 1H), 7.90 (s, 1H), 7.51–7.46 (m, 4H), 7.42–7.37 (m, 1H), 7.35 (t, <i>J</i> = 7.8 Hz, 1H), 7.15 (d, <i>J</i> = 7.6 Hz, 1H), 4.67 (t, <i>J</i> = 7.5 Hz, 2H), 4.00 (s, 2H), 3.41 (t, <i>J</i> = 5.5 Hz, 2H), 3.27–3.23 (m, 5H), 2.70 (t, <i>J</i> = 5.5 Hz, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.38, 158.54, 146.52, 143.72, 141.52, 139.98, 138.51, 130.88, 128.95 (2C), 128.52 (2C), 128.18, 127.79, 125.22, 116.58, 71.89, 58.39, 50.77, 48.03, 45.31, 28.47. HRMS (ESI) for C<sub>22</sub>H<sub>23</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>: calcd, 394.1584; found, 394.1582. Purity, 97.2%.</div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (5-((3-Hydroxyazetidin-1-yl)methyl)thiazol-2-yl)(4-phenylindolin-1-yl)methanone (<b>A17</b>)</h4><div class="NLM_p last">White solid (7.02 mg, yield 6%). mp 155.8–157.2 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.22 (d, <i>J</i> = 7.3 Hz, 1H), 7.90 (s, 1H), 7.51–7.46 (m, 4H), 7.39 (t, <i>J</i> = 6.7 Hz, 1H), 7.35 (t, <i>J</i> = 7.8 Hz, 1H), 7.16 (d, <i>J</i> = 7.6 Hz, 1H), 5.38 (d, <i>J</i> = 6.4 Hz, 1H), 4.67 (t, <i>J</i> = 7.8 Hz, 2H), 4.25–4.18 (m, 1H), 3.83 (s, 2H), 3.55 (td, <i>J</i> = 6.0, 2.1 Hz, 2H), 3.25 (t, <i>J</i> = 8.2 Hz, 2H), 2.83 (td, <i>J</i> = 6.1, 2.1 Hz, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.98, 158.40, 143.70, 141.96, 139.97, 138.52, 130.92, 128.97 (2C), 128.53 (2C), 128.20, 127.80, 125.27, 116.59, 64.09, 60.92, 54.79, 50.77, 28.48. HRMS (ESI) for C<sub>22</sub>H<sub>21</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>: calcd, 392.1427; found, 392.1428. Purity, 96.8%.</div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (5-((((1<i>r</i>,4<i>r</i>)-4-Hydroxycyclohexyl)amino)methyl)thiazol-2-yl)(4-phenylindolin-1-yl)methanone (<b>A18</b>)</h4><div class="NLM_p last">Light yellow solid (16.86 mg, yield 13%). mp 194.2–195.1 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.22 (d, <i>J</i> = 7.9 Hz, 1H), 7.89 (s, 1H), 7.51–7.46 (m, 4H), 7.42–7.39 (m, 1H), 7.36 (t, <i>J</i> = 8.1 Hz, 1H), 7.16 (d, <i>J</i> = 7.7 Hz, 1H), 4.67 (t, <i>J</i> = 8.2 Hz, 2H), 4.46 (d, <i>J</i> = 4.4 Hz, 1H), 3.98 (s, 2H), 3.37 (dd, <i>J</i> = 9.9, 4.2 Hz, 1H), 3.25 (t, <i>J</i> = 8.2 Hz, 2H), 2.39–2.32 (m, 1H), 1.88–1.76 (m, 4H), 1.16–1.00 (m, 4H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.05, 158.58, 147.89, 143.75, 140.92, 139.99, 138.49, 130.84, 128.94 (2C), 128.52 (2C), 128.16, 127.77, 125.18, 116.57, 69.11, 55.43, 50.77, 42.92, 34.22, 31.09, 28.48. HRMS (ESI) for C<sub>25</sub>H<sub>27</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>: calcd, 434.1897; found, 434.1894. Purity, 97.2%.</div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> ((2-(4-Phenylindoline-1-carbonyl)thiazol-5-yl)methyl)-<span class="smallcaps smallerCapital">l</span>-proline (<b>A19</b>)</h4><div class="NLM_p">A mixture of intermediate <b>21a</b> (100 mg, 0.3 mmol), <span class="smallcaps smallerCapital">l</span>-proline (40 mg, 0.35 mmol), and NaBH(OAc)<sub>3</sub> (190.8 mg, 0.9 mmol) in DCM (3 mL) was stirred under reflux for 3 h until TLC showed the completion of the reaction. The reaction mixture was washed with water. The organic layer was concentrated to give a residue, which was purified by column chromatography (MeOH/DCM, 1/100 to 1/15) to yield compound <b>A19</b> (15.95 mg, yield 12.3%). White solid. mp 171.6–172.7 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>, with the addition of a drop of D<sub>2</sub>O) δ 8.22 (d, <i>J</i> = 8.2 Hz, 1H), 7.98 (s, 1H), 7.53–7.46 (m, 4H), 7.42–7.39 (m, 1H), 7.37 (t, <i>J</i> = 8.0 Hz, 1H), 7.17 (d, <i>J</i> = 7.7 Hz, 1H), 4.66 (t, <i>J</i> = 8.2 Hz, 2H), 4.32 (d, <i>J</i> = 14.3 Hz, 1H), 4.15 (d, <i>J</i> = 14.3 Hz, 1H), 3.44 (t, <i>J</i> = 7.3 Hz, 1H), 3.25 (t, <i>J</i> = 8.2 Hz, 2H), 3.17 (t, <i>J</i> = 11.3 Hz, 1H), 2.73–2.64 (m, 1H), 2.20–2.11 (m, 1H), 1.94–1.72 (m, 3H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.29, 165.89, 158.33, 143.84, 143.50, 140.46, 139.82, 138.52, 130.88, 129.00 (2C), 128.47 (2C), 128.25, 127.84, 125.41, 116.62, 65.49, 53.35, 50.75, 49.13, 29.14, 28.40, 23.18. HRMS (ESI) for C<sub>24</sub>H<sub>23</sub>N<sub>3</sub>O<sub>3</sub>S [M + H]<sup>+</sup>: calcd, 434.1533; found, 434.1535. Purity, 98.7%.</div><div class="NLM_p last">Compound <b>A20</b> was synthesized using the same method as that for <b>A19</b> by reacting <b>21a</b> with (<i>S</i>)-piperidine-2-carboxylic acid.</div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (<i>S</i>)-1-((2-(4-Phenylindoline-1-carbonyl)thiazol-5-yl)methyl)piperidine-2-carboxylic Acid (<b>A20</b>)</h4><div class="NLM_p">White solid (13.38 mg, yield 10%). mp 176.3–178.9 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>, with the addition of a drop of D<sub>2</sub>O) δ 8.22 (d, <i>J</i> = 8.1 Hz, 1H), 7.91 (s, 1H), 7.52–7.48 (m, 4H), 7.43–7.39 (m, 1H), 7.38 (t, <i>J</i> = 8.1 Hz, 1H), 7.17 (d, <i>J</i> = 7.6 Hz, 1H), 4.67 (t, <i>J</i> = 8.1 Hz, 2H), 4.12 (d, <i>J</i> = 14.7 Hz, 1H), 3.98 (d, <i>J</i> = 14.7 Hz, 1H), 3.25 (t, <i>J</i> = 8.2 Hz, 2H), 3.23–3.20 (m, 1H), 2.98–2.92 (m, 1H), 2.42–2.36 (m, 1H), 1.85–1.71 (m, 2H), 1.55–1.36 (m, 4H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.06, 158.53, 144.46, 143.71, 142.27, 139.97, 138.51, 130.91, 128.96 (2C), 128.53 (2C), 128.20, 127.80, 125.25, 116.59, 62.91, 51.64, 50.78, 49.15, 29.31, 28.49, 25.42, 22.13. HRMS (ESI) for C<sub>25</sub>H<sub>25</sub>N<sub>3</sub>O<sub>3</sub>S [M + H]<sup>+</sup>: calcd, 448.1689; found, 448.1687. Purity, 98.8%.</div><div class="NLM_p last">Compounds <b>A21–23</b> were synthesized using the same method as that for <b>A1</b> by reacting <b>21a</b> with appropriate amines.</div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (4-Phenylindolin-1-yl)(5-(((tetrahydro-2<i>H</i>-pyran-4-yl)amino)methyl)thiazol-2-yl)methanone (<b>A21</b>)</h4><div class="NLM_p last">Light yellow solid (26.35 mg, yield 21%). mp 164.0–167.6 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.23 (d, <i>J</i> = 7.2 Hz, 1H), 7.91 (s, 1H), 7.52–7.46 (m, 4H), 7.42–7.39 (m, 1H), 7.36 (t, <i>J</i> = 8.0 Hz, 1H), 7.16 (d, <i>J</i> = 7.4 Hz, 1H), 4.67 (t, <i>J</i> = 8.2 Hz, 2H), 4.02 (s, 2H), 3.83 (dt, <i>J</i> = 11.2, 3.3 Hz, 2H), 3.30–3.23 (m, 4H), 2.68–2.58 (m, 1H), 1.78 (d, <i>J</i> = 13.4 Hz, 2H), 1.34–1.24 (m, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.17, 158.58, 143.74, 141.15, 139.99, 138.51, 130.88, 128.96 (2C), 128.53 (2C), 128.19, 127.79, 125.21, 116.57, 66.20, 52.85, 50.78, 42.09, 33.41, 28.48. HRMS (ESI) for C<sub>24</sub>H<sub>25</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>: calcd, 420.1740; found, 420.1743. Purity, 97.2%.</div></div><div id="sec5_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 2-(((2-(4-Phenylindoline-1-carbonyl)thiazol-5-yl)methyl)amino)ethane-1-sulfonamide (<b>A22</b>)</h4><div class="NLM_p last">Light yellow solid (15.88 mg, yield 12%). mp 132.9–135.1 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.23 (d, <i>J</i> = 6.9 Hz, 1H), 7.92 (s, 1H), 7.51–7.46 (m, 4H), 7.41–7.38 (m, 1H), 7.36 (t, <i>J</i> = 7.9 Hz, 1H), 7.16 (d, <i>J</i> = 7.6 Hz, 1H), 6.85 (s, 2H), 4.68 (t, <i>J</i> = 8.2 Hz, 2H), 4.01 (s, 2H), 3.25 (t, <i>J</i> = 8.2 Hz, 2H), 3.17 (t, <i>J</i> = 7.1 Hz, 2H), 2.94 (t, <i>J</i> = 7.1 Hz, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.52, 158.50, 146.13, 143.72, 141.66, 139.97, 138.51, 130.88, 128.96 (2C), 128.52 (2C), 128.18, 127.79, 125.24, 116.59, 54.61, 50.77, 44.87, 43.43, 28.48. HRMS (ESI) for C<sub>21</sub>H<sub>22</sub>N<sub>4</sub>O<sub>3</sub>S<sub>2</sub> [M + H]<sup>+</sup>: calcd, 443.1206; found, 443.1210. Purity, 97.3%.</div></div><div id="sec5_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> <i>N</i>-(2-(((2-(4-Phenylindoline-1-carbonyl)thiazol-5-yl)methyl)amino)ethyl)methanesulfonamide (<b>A23</b>)</h4><div class="NLM_p">Yellow solid (17.75 mg, yield 13%). mp 141.8–145.8 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.23 (d, <i>J</i> = 7.3 Hz, 1H), 7.92 (s, 1H), 7.50–7.47 (m, 4H), 7.41–7.38 (m, 1H), 7.36 (t, <i>J</i> = 7.9 Hz, 1H), 7.16 (d, <i>J</i> = 7.6 Hz, 1H), 6.98 (t, <i>J</i> = 5.7 Hz, 1H), 4.68 (t, <i>J</i> = 8.0 Hz, 2H), 4.00 (s, 2H), 3.26 (t, <i>J</i> = 8.2 Hz, 2H), 3.05 (q, <i>J</i> = 6.2 Hz, 2H), 2.91 (s, 3H), 2.66 (t, <i>J</i> = 6.5 Hz, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.42, 158.53, 146.38, 143.72, 141.58, 139.98, 138.52, 130.90, 128.96 (2C), 128.53 (2C), 128.19, 127.80, 125.24, 116.59, 50.78, 48.52, 44.98, 42.69, 28.48. HRMS (ESI) for C<sub>22</sub>H<sub>24</sub>N<sub>4</sub>O<sub>3</sub>S<sub>2</sub> [M + H]<sup>+</sup>: calcd, 457.1363; found, 457.1370. Purity, 96.1%.</div><div class="NLM_p last">Compounds <b>A24</b> were synthesized using the same method as that for <b>A19</b> by reacting <b>21a</b> with <span class="smallcaps smallerCapital">d</span>-proline.</div></div><div id="sec5_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> ((2-(4-Phenylindoline-1-carbonyl)thiazol-5-yl)methyl)-<span class="smallcaps smallerCapital">d</span>-proline (<b>A24</b>)</h4><div class="NLM_p">White solid (11.67 mg, yield 9%). mp 91.2–93.4 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>, with the addition of a drop of D<sub>2</sub>O) δ 8.22 (d, <i>J</i> = 8.1 Hz, 1H), 7.91 (s, 1H), 7.50–7.45 (m, 4H), 7.41–7.38 (m, 1H), 7.35 (t, <i>J</i> = 7.8 Hz, 1H), 7.15 (d, <i>J</i> = 7.7 Hz, 1H), 4.66 (t, <i>J</i> = 8.4 Hz, 2H), 4.23 (d, <i>J</i> = 14.3 Hz, 1H), 3.98 (d, <i>J</i> = 14.4 Hz, 1H), 3.34–3.17 (m, 4H), 3.01 (s, 1H), 2.12–2.03 (m, 1H), 1.90–1.72 (m, 3H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 175.01, 165.18, 158.40, 143.69, 143.40, 142.45, 139.96, 138.48, 130.86, 128.94 (2C), 128.51 (2C), 128.17, 127.77, 125.23, 116.59, 64.75, 52.64, 50.75, 49.16, 29.15, 28.47, 23.12. HRMS (ESI) for C<sub>24</sub>H<sub>23</sub>N<sub>3</sub>O<sub>3</sub>S [M + H]<sup>+</sup>: calcd, 434.1533; found, 434.1531. Purity, 98.7%.</div><div class="NLM_p last">Compounds <b>A25–27</b> were synthesized using the same method as that for <b>A1</b> by reacting <b>21b</b> with appropriate amines.</div></div><div id="sec5_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (4-(2,3-Dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)indolin-1-yl)(5-(((2-methoxyethyl)amino)methyl)thiazol-2-yl)methanone (<b>A25</b>)</h4><div class="NLM_p last">Yellow oil (19.88 mg, yield 16%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.18 (d, <i>J</i> = 7.2 Hz, 1H), 7.88 (s, 1H), 7.29 (t, <i>J</i> = 7.8 Hz, 1H), 7.09 (d, <i>J</i> = 7.6 Hz, 1H), 6.97 (s, 1H), 6.93 (s, 2H), 4.64 (t, <i>J</i> = 7.8 Hz, 2H), 4.28 (s, 4H), 3.99 (s, 2H), 3.41 (t, <i>J</i> = 5.5 Hz, 2H), 3.25 (s, 3H), 3.22 (t, <i>J</i> = 8.2 Hz, 2H), 2.70 (t, <i>J</i> = 5.5 Hz, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.38, 158.45, 146.64, 143.63, 143.28, 141.37, 137.95, 133.15, 130.62, 128.02, 124.98, 121.47, 117.47, 117.05, 116.23, 71.97, 64.50, 64.47, 58.37, 50.74, 48.08, 45.38, 28.54. HRMS (ESI) for C<sub>24</sub>H<sub>25</sub>N<sub>3</sub>O<sub>4</sub>S [M + H]<sup>+</sup>: calcd, 452.1639; found, 452.1641. Purity, 95.6%.</div></div><div id="sec5_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> (4-(2,3-Dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)indolin-1-yl)(5-((3-hydroxyazetidin-1-yl)methyl)thiazol-2-yl)methanone (<b>A26</b>)</h4><div class="NLM_p last">Light yellow solid (25.2 mg, yield 22%). mp 183.1–184.0 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.18 (d, <i>J</i> = 6.9 Hz, 1H), 7.90 (s, 1H), 7.31 (t, <i>J</i> = 7.7 Hz, 1H), 7.10 (d, <i>J</i> = 7.6 Hz, 1H), 6.98 (s, 1H), 6.94 (s, 2H), 5.37 (d, <i>J</i> = 6.3 Hz, 1H), 4.66 (t, <i>J</i> = 7.3 Hz, 2H), 4.28 (s, 4H), 4.24–4.18 (m, 1H), 3.83 (s, 2H), 3.54 (t, <i>J</i> = 6.3 Hz, 2H), 3.24 (t, <i>J</i> = 8.0 Hz, 2H), 2.83 (t, <i>J</i> = 6.4 Hz, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.96, 158.33, 143.64, 143.30, 141.81, 137.97, 133.13, 130.69, 128.06, 125.05, 121.49, 117.50, 117.06, 116.25, 64.51, 64.48, 64.12, 60.96, 54.90, 50.75, 28.54. HRMS (ESI) for C<sub>24</sub>H<sub>23</sub>N<sub>3</sub>O<sub>4</sub>S [M + H]<sup>+</sup>: calcd, 450.1482; found, 450.1485. Purity, 99.2%.</div></div><div id="sec5_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> (4-(2,3-Dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)indolin-1-yl)(5-((((1r,4r)-4-hydroxycyclohexyl)amino)methyl)thiazol-2-yl)methanone (<b>A27</b>)</h4><div class="NLM_p">Yellow solid (28.81 mg, yield 23%). mp 170.2–172.6 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.18 (d, <i>J</i> = 8.0 Hz, 1H), 7.88 (s, 1H), 7.31 (t, <i>J</i> = 7.9 Hz, 1H), 7.10 (d, <i>J</i> = 7.6 Hz, 1H), 6.98 (s, 1H), 6.94 (s, 2H), 4.65 (t, <i>J</i> = 8.1 Hz, 2H), 4.46 (d, <i>J</i> = 4.4 Hz, 1H), 4.28 (s, 4H), 3.98 (s, 2H), 3.24 (t, <i>J</i> = 8.2 Hz, 2H), 2.39–2.31 (m, 1H), 1.85 (d, <i>J</i> = 11.5 Hz, 2H), 1.79 (d, <i>J</i> = 10.9 Hz, 2H), 1.15–1.01 (m, 4H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.09, 158.52, 147.79, 143.64, 143.29, 140.91, 137.96, 133.15, 130.65, 128.04, 124.99, 121.49, 117.49, 117.06, 116.23, 69.10, 64.51, 64.48, 55.44, 50.76, 42.91, 34.21, 31.08, 28.55. HRMS (ESI) for C<sub>27</sub>H<sub>29</sub>N<sub>3</sub>O<sub>4</sub>S [M + H]<sup>+</sup>: calcd, 492.1952; found, 492.1949. Purity, 97.9%.</div><div class="NLM_p last">Compounds <b>A28</b> and <b>A29</b> were synthesized using the same method as that for <b>A19</b> by reacting <b>21b</b> with appropriate amines.</div></div><div id="sec5_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> ((2-(4-(2,3-Dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)indoline-1-carbonyl)thiazol-5-yl)methyl)-<span class="smallcaps smallerCapital">l</span>-proline (<b>A28</b>)</h4><div class="NLM_p last">White solid (8.77 mg, yield 7%). mp 144.7–146.5 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.18 (d, <i>J</i> = 8.1 Hz, 1H), 7.91 (s, 1H), 7.31 (t, <i>J</i> = 7.9 Hz, 1H), 7.10 (d, <i>J</i> = 7.6 Hz, 1H), 6.98 (s, 1H), 6.94 (s, 2H), 4.66 (t, <i>J</i> = 8.3 Hz, 2H), 4.28 (s, 4H), 4.19 (d, <i>J</i> = 14.5 Hz, 1H), 3.96 (d, <i>J</i> = 14.5 Hz, 1H), 3.29 (dd, <i>J</i> = 8.5, 6.0 Hz, 1H), 3.24 (t, <i>J</i> = 8.2 Hz, 3H), 2.98 (q, <i>J</i> = 6.5 Hz, 1H), 2.11–2.03 (m, 1H), 1.89–1.82 (m, 1H), 1.78–1.72 (m, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 174.70, 165.25, 158.36, 143.64, 143.30, 142.43, 137.98, 133.13, 130.71, 128.07, 125.07, 121.50, 117.50, 117.06, 116.26, 64.51, 64.48, 60.13, 52.71, 50.76, 49.21, 29.15, 28.55, 23.15. HRMS (ESI) for C<sub>26</sub>H<sub>25</sub>N<sub>3</sub>O<sub>5</sub>S [M + H]<sup>+</sup>: calcd, 492.1588; found, 492.1590. Purity, 99.3%.</div></div><div id="sec5_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> (<i>S</i>)-1-((2-(4-(2,3-Dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)indoline-1-carbonyl)thiazol-5-yl)methyl)piperidine-2-carboxylic Acid (<b>A29</b>)</h4><div class="NLM_p">White solid (33.5 mg, yield 26%). mp 170.4–173.3 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.18 (d, <i>J</i> = 6.1 Hz, 1H), 7.88 (s, 1H), 7.31 (t, <i>J</i> = 7.9 Hz, 1H), 7.10 (d, <i>J</i> = 7.7 Hz, 1H), 6.98 (s, 1H), 6.94 (s, 2H), 4.66 (t, <i>J</i> = 7.0 Hz, 2H), 4.28 (s, 4H), 4.04 (d, <i>J</i> = 14.8 Hz, 1H), 3.89 (d, <i>J</i> = 14.9 Hz, 1H), 3.24 (t, <i>J</i> = 7.6 Hz, 3H), 2.92–2.87 (m, 1H), 2.35–2.29 (m, 1H), 1.76 (q, <i>J</i> = 6.0 Hz, 2H), 1.51–1.37 (m, 4H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.99, 158.45, 143.63, 143.28, 142.30, 137.95, 133.13, 130.66, 128.04, 125.01, 121.48, 117.48, 117.05, 116.23, 64.51, 64.47, 51.60, 50.75, 49.45, 29.49, 28.53, 25.57, 22.43. HRMS (ESI) for C<sub>27</sub>H<sub>27</sub>N<sub>3</sub>O<sub>5</sub>S [M + H]<sup>+</sup>: calcd, 506.1744; found, 506.1737. Purity, 98.5%.</div><div class="NLM_p last">Compounds <b>A30–35</b> were synthesized using the same method as that for <b>A1</b> by reacting <b>21b</b> and <b>19</b> with appropriate amines.</div></div><div id="sec5_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> (4-(2,3-Dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)indolin-1-yl)(5-(((tetrahydro-2H-pyran-4-yl)amino)methyl)thiazol-2-yl)methanone (<b>A30</b>)</h4><div class="NLM_p last">White solid (23.12 mg, yield 19%). mp 188.6–191.0 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.18 (d, <i>J</i> = 8.1 Hz, 1H), 7.90 (s, 1H), 7.31 (t, <i>J</i> = 7.8 Hz, 1H), 7.10 (d, <i>J</i> = 7.6 Hz, 1H), 6.98 (s, 1H), 6.94 (s, 2H), 4.66 (t, <i>J</i> = 8.2 Hz, 2H), 4.28 (s, 4H), 4.02 (s, 2H), 3.82 (dt, <i>J</i> = 11.3, 3.0 Hz, 2H), 3.29–3.22 (m, 4H), 2.66–2.60 (m, 1H), 1.78 (d, <i>J</i> = 11.3 Hz, 2H), 1.29–1.25 (m, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.18, 158.51, 147.47, 143.64, 143.30, 141.08, 137.97, 133.15, 130.67, 128.06, 125.01, 121.50, 117.50, 117.06, 116.24, 66.20, 64.51, 64.48, 52.87, 50.77, 42.12, 33.44, 28.55. HRMS (ESI) for C<sub>26</sub>H<sub>27</sub>N<sub>3</sub>O<sub>4</sub>S [M + H]<sup>+</sup>: calcd, 478.1795; found, 478.1797. Purity, 98.8%.</div></div><div id="sec5_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> <i>N</i>-(2-(((2-(4-(2,3-Dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)indoline-1-carbonyl)thiazol-5-yl)methyl)amino)ethyl)acetamide (<b>A31</b>)</h4><div class="NLM_p last">Light yellow solid (24.39 mg, yield 20%). mp 187.6–188.4 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.18 (d, <i>J</i> = 5.9 Hz, 1H), 7.90 (s, 1H), 7.80 (s, 1H), 7.31 (t, <i>J</i> = 6.6 Hz, 1H), 7.10 (d, <i>J</i> = 7.0 Hz, 1H), 6.98 (s, 1H), 6.94 (s, 2H), 4.66 (t, <i>J</i> = 7.2 Hz, 2H), 4.28 (s, 4H), 3.98 (s, 2H), 3.24 (t, <i>J</i> = 7.2 Hz, 2H), 3.13 (d, <i>J</i> = 5.0 Hz, 2H), 2.58 (t, <i>J</i> = 6.0 Hz, 2H), 1.79 (s, 3H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.52, 164.37, 158.48, 146.63, 143.64, 143.29, 141.43, 137.97, 133.14, 130.67, 128.05, 125.02, 121.49, 117.50, 117.06, 116.24, 64.51, 64.48, 50.76, 48.27, 45.09, 38.95, 28.54, 23.03. HRMS (ESI) for C<sub>25</sub>H<sub>26</sub>N<sub>4</sub>O<sub>4</sub>S [M + H]<sup>+</sup>: calcd, 479.1748; found, 479.1755. Purity, 96.9%.</div></div><div id="sec5_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 2-(((2-(4-(2,3-Dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)indoline-1-carbonyl)thiazol-5-yl)methyl)amino)ethane-1-sulfonamide (<b>A32</b>)</h4><div class="NLM_p last">White solid (12.76 mg, yield 10%). mp 206.3–209.1 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.18 (d, <i>J</i> = 7.3 Hz, 1H), 7.93 (s, 1H), 7.31 (t, <i>J</i> = 7.8 Hz, 1H), 7.10 (d, <i>J</i> = 7.6 Hz, 1H), 6.98 (s, 1H), 6.94 (s, 2H), 6.85 (s, 2H), 4.66 (t, <i>J</i> = 7.7 Hz, 2H), 4.28 (s, 4H), 4.01 (s, 2H), 3.24 (t, <i>J</i> = 8.1 Hz, 2H), 3.16 (t, <i>J</i> = 7.1 Hz, 2H), 2.93 (t, <i>J</i> = 7.1 Hz, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.15, 158.04, 145.69, 143.24, 142.90, 141.24, 137.58, 132.73, 130.30, 127.67, 124.65, 121.10, 117.11, 116.66, 115.85, 64.10, 64.07, 54.20, 50.37, 44.46, 43.02, 28.14. HRMS (ESI) for C<sub>23</sub>H<sub>24</sub>N<sub>4</sub>O<sub>5</sub>S<sub>2</sub> [M + H]<sup>+</sup>: calcd, 501.1261; found, 501.1259. Purity, 98.9%.</div></div><div id="sec5_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> <i>N</i>-(2-(((2-(4-(2,3-Dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)indoline-1-carbonyl)thiazol-5-yl)methyl)amino)ethyl)methanesulfonamide (<b>A33</b>)</h4><div class="NLM_p last">Light yellow solid (20.98 mg, yield 16%). mp 138.7–140.0 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.18 (d, <i>J</i> = 6.3 Hz, 1H), 7.91 (s, 1H), 7.31 (t, <i>J</i> = 7.6 Hz, 1H), 7.10 (d, <i>J</i> = 7.5 Hz, 1H), 6.98 (s, 1H), 6.94 (s, 2H), 4.66 (t, <i>J</i> = 7.9 Hz, 2H), 4.28 (s, 4H), 3.99 (s, 2H), 3.24 (t, <i>J</i> = 7.9 Hz, 2H), 3.05 (q, <i>J</i> = 6.2 Hz, 2H), 2.91 (s, 3H), 2.66 (t, <i>J</i> = 6.2 Hz, 2H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.53, 158.59, 146.52, 143.75, 143.41, 141.64, 138.10, 133.25, 130.82, 128.19, 125.16, 121.62, 117.62, 117.17, 116.36, 64.61, 64.58, 50.88, 48.63, 45.10, 42.81, 28.64. HRMS (ESI) for C<sub>24</sub>H<sub>26</sub>N<sub>4</sub>O<sub>5</sub>S<sub>2</sub> [M + H]<sup>+</sup>: calcd, 515.1417; found, 515.1420. Purity, 96.2%.</div></div><div id="sec5_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> <i>N</i>-(2-(((2-(4-(Benzo[<i>d</i>]oxazol-5-yl)indoline-1-carbonyl)thiazol-5-yl)methyl)amino)ethyl)acetamide (<b>A34</b>)</h4><div class="NLM_p last">White solid (28.28 mg, yield 23%). mp 180.6–182.3 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.82 (s, 1H), 8.25 (d, <i>J</i> = 7.1 Hz, 1H), 7.91 (s, 2H), 7.87 (d, <i>J</i> = 8.4 Hz, 1H), 7.80 (s, 1H), 7.56 (d, <i>J</i> = 8.4 Hz, 1H), 7.38 (t, <i>J</i> = 7.8 Hz, 1H), 7.22 (d, <i>J</i> = 7.6 Hz, 1H), 4.69 (t, <i>J</i> = 7.2 Hz, 2H), 3.98 (s, 2H), 3.29 (t, <i>J</i> = 7.2 Hz, 2H), 3.13 (q, <i>J</i> = 6.0 Hz, 2H), 2.58 (t, <i>J</i> = 6.3 Hz, 2H), 1.80 (s, 3H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.60, 164.38, 158.57, 155.27, 149.14, 143.73, 141.62, 140.41, 138.23, 136.88, 131.18, 128.23, 126.52, 125.66, 120.00, 116.64, 111.56, 50.80, 48.20, 45.00, 38.86, 28.43, 23.02. HRMS (ESI) for C<sub>24</sub>H<sub>23</sub>N<sub>5</sub>O<sub>3</sub>S [M + H]<sup>+</sup>: calcd, 462.1594; found, 462.1596. Purity, 99.0%.</div></div><div id="sec5_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> (4-(Benzo[<i>d</i>]oxazol-5-yl)indolin-1-yl)(5-((((1<i>r</i>,4<i>r</i>)-4-hydroxycyclohexyl)amino)methyl)thiazol-2-yl)methanone (<b>A35</b>)</h4><div class="NLM_p">Light yellow solid (7.59 mg, yield 6%). mp 64.4–66.9 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.82 (s, 1H), 8.25 (d, <i>J</i> = 7.2 Hz, 1H), 7.91 (d, <i>J</i> = 12.6 Hz, 2H), 7.87 (d, <i>J</i> = 8.4 Hz, 1H), 7.56 (d, <i>J</i> = 8.4 Hz, 1H), 7.38 (t, <i>J</i> = 7.8 Hz, 1H), 7.21 (d, <i>J</i> = 7.7 Hz, 1H), 4.68 (t, <i>J</i> = 7.8 Hz, 2H), 4.47 (d, <i>J</i> = 4.4 Hz, 1H), 4.00 (s, 2H), 3.28 (t, <i>J</i> = 7.8 Hz, 2H), 2.40–2.33 (m, 1H), 1.85 (d, <i>J</i> = 13.3 Hz, 2H), 1.79 (d, <i>J</i> = 11.1 Hz, 2H), 1.16–1.02 (m, 4H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.03, 158.65, 155.25, 149.13, 147.63, 143.73, 140.38, 138.21, 136.89, 131.15, 128.25, 126.56, 125.66, 119.97, 116.64, 111.57, 69.12, 55.35, 50.79, 42.80, 34.13, 30.98, 28.41. HRMS (ESI) for C<sub>26</sub>H<sub>26</sub>N<sub>4</sub>O<sub>3</sub>S [M + H]<sup>+</sup>: calcd, 475.1798; found, 475.1806. Purity, 98.0%.</div><div class="NLM_p last">Compound <b>A36</b> was synthesized using the same method as that for <b>A19</b> by reacting <b>19</b> with <span class="smallcaps smallerCapital">l</span>-proline.</div></div><div id="sec5_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> ((2-(4-(Benzo[<i>d</i>]oxazol-5-yl)indoline-1-carbonyl)thiazol-5-yl)methyl)-<span class="smallcaps smallerCapital">l</span>-proline(<b>A36</b>)</h4><div class="NLM_p last">White solid (20.23 mg, yield 16%). mp 136.0–138.4 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>, with the addition of a drop of D<sub>2</sub>O) δ 8.79 (s, 1H), 8.24 (s, 1H), 7.91 (d, <i>J</i> = 17.3 Hz, 2H), 7.86 (d, <i>J</i> = 8.5 Hz, 1H), 7.55 (d, <i>J</i> = 6.8 Hz, 1H), 7.37 (t, <i>J</i> = 8.1 Hz, 1H), 7.21 (d, <i>J</i> = 7.6 Hz, 1H), 4.67 (t, <i>J</i> = 8.1 Hz, 2H), 4.23 (d, <i>J</i> = 14.3 Hz, 1H), 4.00 (d, <i>J</i> = 14.5 Hz, 1H), 3.35–3.23 (m, 4H), 3.02 (s, 1H), 2.12–2.04 (m, 1H), 1.91–1.70 (m, 3H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 174.39, 164.75, 158.04, 154.87, 148.73, 143.30, 142.03, 140.01, 137.81, 136.45, 130.77, 127.81, 126.10, 125.27, 119.60, 116.25, 111.13, 54.89, 52.29, 50.38, 48.80, 28.74, 28.03, 22.72. HRMS (ESI) for C<sub>25</sub>H<sub>22</sub>N<sub>4</sub>O<sub>4</sub>S [M + H]<sup>+</sup>: calcd, 475.1435; found, 475.1433. Purity, 96.1%.</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> <i>In Vitro</i> PD-1/PD-L1 Binding Assay</h3><div class="NLM_p last">The biochemical activity of the final compounds was evaluated using the PD-1/PD-L1 binding assay kit (Cisbio, cat. no. 64ICP01PEG). The experiments were conducted according to manufacturer’s instructions.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Cytotoxicity Assay</h3><div class="NLM_p last">Jurkat cells with a density of 4 × 10<sup>4</sup>/mL in RMPI-1640 with 10% FBS were seeded into a 96-well plate. The tested compounds with indicated concentrations (50, 16.67, 5.56, 1.85, 0.62, 0.21, and 0.069 μM) were added and incubated for 72 h. CCK-8 solution (Dojindo, Japan) was added to each well and incubated with the cells at 37 °C for 3 h. The absorbance was monitored on a microplate reader (Molecular Device, USA) at 450 nm. Inhibition rate = (1 – OD (compound treatment group)/OD (con)) × 100%. The IC<sub>50</sub> values were determined using GraphPad Prism 6 software.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Determination of IFN-γ Release</h3><div class="NLM_p last">CD3<sup>+</sup> T cells were isolated from fresh PBMCs using an EasySep Human T Cell Isolation Kit (negative selection, STEMCELL Technologies). Hep3B cells stably expressing OS-8 (anti-CD3 single chain variable fragment) and human PD-L1 (hPD-L1) were harvested, treated with 10 μg/mL mitomycin C at 37 °C for 1.5 h, and then washed with PBS. Hep3B/OS-8/hPD-L1 and T cells (2.5 × 10<sup>4</sup> in 50 μL of complete media and 5 × 10<sup>4</sup> in 100 μL of complete media, respectively) were added to the 96-well plates followed by the addition of test compounds in 50 μL of complete media and co-culture at 37 °C for 3 days. After that time, the supernatants (150 μL) were harvested to determine IFN-γ levels by ELISA.<a onclick="showRef(event, 'ref12 ref22'); return false;" href="javascript:void(0);" class="ref ref12 ref22">(12,22)</a></div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Determination of T-Cell Proliferation</h3><div class="NLM_p last">The 96-well plates were coated with 5 μg/mL anti-CD3ε antibody (Biolegend 100,340) at 4 °C overnight. After washing with PBS, the wells were coated with 6 μg/mL recombinant PD-L1 protein (Biolegend 758206), which was mixed with the tested compounds at 4 °C overnight. Anti-PD-L1 mAb (Biolegend 124,318) was used as a positive control to verify the accuracy of the experimental model. T cells were isolated from mouse spleen using the EasySep Mouse T Cell Isolation Kit (STEMCELL #19851) and then stained using the CellTrace CFSE Cell Proliferation Kit (Invitrogen C34570). Coated wells were washed with PBS, and 200 μL of CFSE labeled T cells (1 × 10<sup>6</sup> cells/mL) was added into the wells and incubated at 37 °C for 72 h. T-cell proliferation was measured by flow cytometry and calculated as follows: relative proliferation rate = (experiment group – PD-L1 group)/(CD3 group – PD-L1 group) × 100%. The plates in the experiment group were coated with anti-CD3ε antibody, recombinant PD-L1 protein, and the test compounds (<b>A30</b>, <b>1</b>, and anti-PD-L1 mAb); PD-L1 group (model control), with anti-CD3ε antibody and recombinant PD-L1 protein; and CD3 group (blank control), with anti-CD3ε antibody. The EC<sub>50</sub> values were determined using GraphPad Prism 6 software.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> <i>In Vivo</i> Study in Mouse 4T1 Models</h3><div class="NLM_p last">The experimental procedures and protocols were approved by the Committee on the Ethics of Animal Experiments of Sun Yat-sen University. Female BALB/c mice (6–8 weeks old) were purchased from the Laboratory Animal Center of Sun Yat-sen University. The animals were fed in a specific pathogen-free facility and used in accordance with institutional guidelines. 4T1 cell suspension (100 μL; 2 × 10<sup>7</sup> cells/mL) was injected subcutaneously into the back of female BALB/c mice. When implanted tumors reached a volume of 100–150 mm<sup>3</sup>, the mice were randomly divided into three groups (five mice per group) and treated with saline and <b>A30</b> (6 mg/kg and 12 mg/kg) five times every 2 days by intravenous administration. Tumor volumes and body weights were measured every 2 days during treatment. All tumor-bearing mice were sacrificed after 21 days of treatment, and the tumor tissues were carefully excised and weighed. The tumor volume (TV) was calculated as follows: TV = [length (mm) × width<sup>2</sup> (mm<sup>2</sup>)]/2. The relative tumor volume (RTV) was calculated as follows: RTV = <i>V</i><sub>t</sub>/<i>V</i><sub>0</sub>. Tumor volume was shown on indicated days as the median tumor volume ± SD indicated for groups of mice. Tumor growth inhibition value (TGI) was calculated at the end of treatment. TGI = (1 – RTV (treated)/RTV (control)) × 100%.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> <i>In Vivo</i> Study in Mouse CT26 PD-L1-Overexpression Models</h3><div class="NLM_p last">The experimental procedures and protocols were approved by the Committee on the Ethics of Animal Experiments of Shenyang Pharmaceutical University. Male BALB/c mice (6–8 weeks old) were purchased from Liaoning Changsheng Biotechnology Co., Ltd. CT26/PD-L1 or CT26/vector cell suspension (100 μL; 1 × 10<sup>7</sup> cells/mL) was injected subcutaneously into the right flank of the mice. When implanted tumors reached approximately 50–100 mm<sup>3</sup> in volume, the mice were randomly divided into four groups (five mice per group) and treated intraperitoneally with control buffer (PBS with 5% DMSO and 10% Tween-80) and <b>A30</b> (6 mg/kg, dissolved in control buffer) once a day for 16 days. Tumor volumes and body weights were monitored every 2 days. Mice were sacrificed when the treatment was completed, and the tumor tissues and organs were carefully excised and weighed. The tumor volume and TGI were calculated using the abovementioned methods, and viscera index was calculated using the following formula: viscera index = (organ weight/body weight) × 100.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Tumor Single-Cell Suspension Preparation</h3><div class="NLM_p last">Tumor tissues were obtained from mice under aseptic conditions. Tumor tissues were cut into small pieces without connective tissues and necrotic tissues. For 0.5–1 g of tumor tissues, tumor digestion medium was prepared by combining the following: 500 μL of 10× Collagenase/ Hyaluronidase solution (STEMCELL #07912), 750 μL of DNase I solution (1 mg/mL Absin abs47047435), and 3.75 mL of RPMI-1640 medium (Gibco C11875500BT). Tumor tissues were digested in tumor digestion medium at 37 °C for 25–30 min with gentle shaking. The digested tumor cell suspension was filtered through a 70 μm filter and then washed by PBS with 2% FBS.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Spleen Lymphocyte Separation</h3><div class="NLM_p last">Spleens were obtained from mice under aseptic conditions and then grinded in 4–5 mL of mouse Lymphocyte Separation Medium (DaKeWei 7211011) using a syringe plunger. Spleen suspension was filtered through a 70 μm filter and then was transferred into a 15 mL centrifuge tube. After layering 1 mL of RPMI-1640, the spleen suspension was centrifuged for 30 min without break. The white layer between RPMI-1640 and mouse Lymphocyte Separation Medium was collected and washed by PBS with 2% FBS two times.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Flow Cytometry</h3><div class="NLM_p last">For surface marker detection, tumor single-cell suspension and spleen lymphocytes were incubated at 4 °C for 30 min in PBS with 0.1% Fixable Viability Dye (eBioscience 65-0863-14). Cells were washed and incubated in staining buffer (PBS with 1% FBS) with surface marker antibody (Biolegend CD3-APC 100235, CD3-PE 100205, CD4-FITC 100405, CD8-APC 100711, CD8-PE 100707, CD45-APC 103112, PD-L1-PE 124307). Cells were washed and resuspended in staining buffer for flow cytometry measurements. For cytokine detection, tumor single-cell suspension and spleen lymphocytes were incubated in RPMI-1640 with 10% FBS and 0.2% Cell Stimulation Cocktail (plus protein transport inhibitors) (eBioscience 00-4975-93) at 37 °C for 12 h. Cells were stained with Fixable Viability Dye and surface marker antibody as described above and then were fixed and permeabilized by a BD Cytofix/Cytoperm Fixation/Permeabilization Kit (BD 554714). Cells were incubated at 4 °C for 30 min in 1× BD Perm/Wash buffer with cytokine antibody (eBioscience IFN-γ-APC 17-7311-81, BD IL-2-APC 562041) and then washed in 1× BD Perm/Wash buffer two times. Cells were resuspended in staining buffer for flow cytometry measurements. Flow cytometry was performed on an ACEA NovoCyte, and the data was analyzed using NovoExpress.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> Statistical Analysis</h3><div class="NLM_p last">Data was analyzed using GraphPad Prism 6. Data was provided as mean ± SD unless otherwise indicated. The statistical significance (<i>p</i> < 0.05) was calculated by one-way analysis of variance (ANOVA) and unpaired two-tailed Student’s <i>t</i>-test.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Molecular Docking</h3><div class="NLM_p last">Molecular graphic manipulations and visualizations were performed using Discovery Studio Visualizer 4.0. The docking program was conducted using AutoDock 4.2. The co-crystal structure of BMS-200/PD-L1 complex was obtained from the Protein Data Bank (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5N2F">5N2F</a>). The original ligand and water molecules were removed before docking analysis. Kollman charges and hydrogen atoms were added to protein atoms. The other relevant parameters used in docking studies were set to default values. The docking experiment was performed for 200 times, generating 200 conformations. The model possessing the highest stabilization energy was selected for further studies.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i83"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01958" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05786" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05786" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01958?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01958</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">5N2F-<b>A30</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01958/suppl_file/jm0c01958_si_001.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01958/suppl_file/jm0c01958_si_001.pdb" class="ext-link">CSV</a>)</p></li><li><p class="inline">Figures generated from <i>in vitro</i> studies of <b>A30</b> for effects on CT26 cell viability and <i>in vivo</i> activity in mouse 4T1 and CT26 tumor models; flow cytometry analysis of spleen lymphocytes after <b>A30</b> treatment; and <sup>1</sup>H NMR, <sup>13</sup>C NMR, and HPLC spectra and HRMS of the final compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01958/suppl_file/jm0c01958_si_001.pdb" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01958/suppl_file/jm0c01958_si_001.pdb">jm0c01958_si_001.pdb (162.21 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01958/suppl_file/jm0c01958_si_002.csv">jm0c01958_si_002.csv (3.2 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01958/suppl_file/jm0c01958_si_003.pdf">jm0c01958_si_003.pdf (4.78 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01958" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22513" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22513" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mingze Qin</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drug Design and Discovery, Ministry
of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4634-535X" title="Orcid link">http://orcid.org/0000-0002-4634-535X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#17667e797a7e79706d72272726572625213974787a"><span class="__cf_email__" data-cfemail="4f3e262122262128352a7f7f7e0f7e7d79612c2022">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Congjun Xu</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmaceutical Sciences, Sun Yat-sen
University, Guangzhou 510006, PR China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e8909d8b82a885898184c69b919b9dc68d8c9dc68b86"><span class="__cf_email__" data-cfemail="39414c5a537954585055174a404a4c175c5d4c175a57">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lihui Wang</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology, Shenyang Pharmaceutical
University, Shenyang 110016, PR China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#9ef2f6e9fff0f9deede7eef6ebb0fbfaebb0fdf0"><span class="__cf_email__" data-cfemail="aec2c6d9cfc0c9eeddd7dec6db80cbcadb80cdc0">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yangyang Meng</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drug Design and Discovery, Ministry
of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haoshen Yang</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology, Shenyang Pharmaceutical
University, Shenyang 110016, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lei Liu</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drug Design and Discovery, Ministry
of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haotian Zhang</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology, Shenyang Pharmaceutical
University, Shenyang 110016, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simeng Wang</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology, Shenyang Pharmaceutical
University, Shenyang 110016, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chunyang Liu</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drug Design and Discovery, Ministry
of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xia Wu</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drug Design and Discovery, Ministry
of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Di Wu</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drug Design and Discovery, Ministry
of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ye Tian</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drug Design and Discovery, Ministry
of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yunlei Hou</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drug Design and Discovery, Ministry
of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yanfang Zhao</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drug Design and Discovery, Ministry
of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yajing Liu</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drug Design and Discovery, Ministry
of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i84">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52748" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52748" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors appreciate the financial supports from the Educational Career Development Support Plan for Young and Middle-aged Teachers in Shenyang Pharmaceutical University (ZQN2019008), the Liaoning Revitalization Talents Program (XLYC1808037), and the Natural Science Foundation of Liaoning Province (20180550522).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">ABBREVIATIONS</td></tr><tr><td class="NLM_term">BMS</td><td class="NLM_def"><p class="first last">Bristol-Myers Squibb</p></td></tr><tr><td class="NLM_term">CCK-8</td><td class="NLM_def"><p class="first last">cell counting kit-8</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">2-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N′</i>,<i>N′</i>-tetramethyluronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HTRF</td><td class="NLM_def"><p class="first last">homogeneous time-resolved fluorescence</p></td></tr><tr><td class="NLM_term">IFN-γ</td><td class="NLM_def"><p class="first last">interferon-γ</p></td></tr><tr><td class="NLM_term">IRF1</td><td class="NLM_def"><p class="first last">interferon regulatory factor 1</p></td></tr><tr><td class="NLM_term">mAb</td><td class="NLM_def"><p class="first last">monoclonal antibody</p></td></tr><tr><td class="NLM_term">MOA</td><td class="NLM_def"><p class="first last">mechanism of action</p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">peripheral blood mononuclear cell</p></td></tr><tr><td class="NLM_term">PD-1</td><td class="NLM_def"><p class="first last">programmed cell death-1</p></td></tr><tr><td class="NLM_term">PdCl<sub>2</sub>(dppf)</td><td class="NLM_def"><p class="first last">[1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)</p></td></tr><tr><td class="NLM_term">PD-L1</td><td class="NLM_def"><p class="first last">programmed cell death-ligand 1</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TILs</td><td class="NLM_def"><p class="first last">tumor-infiltrating lymphocytes</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i86">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88532" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88532" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 26 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Constantinidou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alifieris, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trafalis, D. T.</span></span> <span> </span><span class="NLM_article-title">Targeting programmed cell death-1 (PD-1) and ligand (PD-L1): a new era in cancer active immunotherapy</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>194</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">106</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2018.09.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1016%2Fj.pharmthera.2018.09.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=30268773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVGisbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2019&pages=84-106&author=A.+Constantinidouauthor=C.+Alifierisauthor=D.+T.+Trafalis&title=Targeting+programmed+cell+death-1+%28PD-1%29+and+ligand+%28PD-L1%29%3A+a+new+era+in+cancer+active+immunotherapy&doi=10.1016%2Fj.pharmthera.2018.09.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy</span></div><div class="casAuthors">Constantinidou, Anastasia; Alifieris, Constantinos; Trafalis, Dimitrios T.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">84-106</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Improved understanding of the immune system and its role in cancer development and progression has led to impressive advances in the field of cancer immunotherapy over the last decade.  While the field is rapidly evolving and the list of drugs receiving regulatory approval for the treatment of various cancers is fast growing, the group of PD1- PDL-1 inhibitors is establishing a leading role amongst immunomodulatory agents.  PD1- PDL-1 inhibitors act against pathways involved in adaptive immune suppression resulting in immune checkpoint blockade.  Within the last four years two PD-1 and three PD-L1 inhibitors have been utilized in clin. practice against a variety of malignancies.  Focus was initially placed on targeting cancers considered immunogenic such as melanoma, renal and lung cancers but subsequently the application expanded to include amongst others Hodgkin Lymphoma, urothelial as well as head and neck cancer.  This article provides a comprehensive review of the early and late phase trials that led to the regulatory approval of all five PD1- PDL-1 inhibitors in the corresponding cancer types.  It presents available data on the combinations of PD1- PDL-1 inhibitors with other therapies (immunotherapy, targeted therapy and chemotherapy), the toxicity profile of the PD1- PDL-1 inhibitors and ongoing trials testing the efficacy of these agents in cancer types beyond those that have been addressed already.  Finally, current and future challenges in the application of PD-1 and PD-L1 inhibitors are discussed with emphasis on the role of predictive biomarkers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNoSdhwOBHPbVg90H21EOLACvtfcHk0ljqm_IfKaJy_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVGisbvL&md5=6f9a8f63f7cc9eb59d9454fb6942ae8d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2018.09.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2018.09.008%26sid%3Dliteratum%253Aachs%26aulast%3DConstantinidou%26aufirst%3DA.%26aulast%3DAlifieris%26aufirst%3DC.%26aulast%3DTrafalis%26aufirst%3DD.%2BT.%26atitle%3DTargeting%2520programmed%2520cell%2520death-1%2520%2528PD-1%2529%2520and%2520ligand%2520%2528PD-L1%2529%253A%2520a%2520new%2520era%2520in%2520cancer%2520active%2520immunotherapy%26jtitle%3DPharmacol.%2520Ther.%26date%3D2019%26volume%3D194%26spage%3D84%26epage%3D106%26doi%3D10.1016%2Fj.pharmthera.2018.09.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourque, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitz, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malenkovich, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouser, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreno, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span> <span> </span><span class="NLM_article-title">Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">1027</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1084/jem.192.7.1027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1084%2Fjem.192.7.1027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=11015443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntFSlt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2000&pages=1027-1034&author=G.+J.+Freemanauthor=A.+J.+Longauthor=Y.+Iwaiauthor=K.+Bourqueauthor=T.+Chernovaauthor=H.+Nishimuraauthor=L.+J.+Fitzauthor=N.+Malenkovichauthor=T.+Okazakiauthor=M.+C.+Byrneauthor=H.+F.+Hortonauthor=L.+Fouserauthor=L.+Carterauthor=V.+Lingauthor=M.+R.+Bowmanauthor=B.+M.+Carrenoauthor=M.+Collinsauthor=C.+R.+Woodauthor=T.+Honjo&title=Engagement+of+the+PD-1+immunoinhibitory+receptor+by+a+novel+B7+family+member+leads+to+negative+regulation+of+lymphocyte+activation&doi=10.1084%2Fjem.192.7.1027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation</span></div><div class="casAuthors">Freeman, Gordon J.; Long, Andrew J.; Iwai, Yoshiko; Bourque, Karen; Chernova, Tatyana; Nishimura, Hiroyuki; Fitz, Lori J.; Malenkovich, Nelly; Okazaki, Taku; Byrne, Michael C.; Horton, Heidi F.; Fouser, Lynette; Carter, Laura; Ling, Vincent; Bowman, Michael R.; Carreno, Beatriz M.; Collins, Mary; Wood, Clive R.; Honjo, Tasuku</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1027-1034</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">PD-1 is an immunoinhibitory receptor expressed by activated T cells, B cells, and myeloid cells.  Mice deficient in PD-1 exhibit a breakdown of peripheral tolerance and demonstrate multiple autoimmune features.  The authors report here that the ligand of PD-1 (PD-L1) is a member of the B7 gene family.  Engagement of PD-1 by PD-L1 leads to the inhibition of T cell receptor-mediated lymphocyte proliferation and cytokine secretion.  In addn., PD-1 signaling can inhibit at least suboptimal levels of CD28-mediated costimulation.  PD-L1 is expressed by antigen-presenting cells, including human peripheral blood monocytes stimulated with interferon γ, and activated human and murine dendritic cells.  In addn., PD-L1 is expressed in nonlymphoid tissues such as heart and lung.  The relative levels of inhibitory PD-L1 and costimulatory B7-1/B7-2 signals on antigen-presenting cells may det. the extent of T cell activation and consequently the threshold between tolerance and autoimmunity.  PD-L1 expression on nonlymphoid tissues and its potential interaction with PD-1 may subsequently det. the extent of immune responses at sites of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZIeEjiecqBbVg90H21EOLACvtfcHk0lh8OuzPppB-zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntFSlt7o%253D&md5=bc1499033282cd9dbfa396a4e2697f6e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1084%2Fjem.192.7.1027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.192.7.1027%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DLong%26aufirst%3DA.%2BJ.%26aulast%3DIwai%26aufirst%3DY.%26aulast%3DBourque%26aufirst%3DK.%26aulast%3DChernova%26aufirst%3DT.%26aulast%3DNishimura%26aufirst%3DH.%26aulast%3DFitz%26aufirst%3DL.%2BJ.%26aulast%3DMalenkovich%26aufirst%3DN.%26aulast%3DOkazaki%26aufirst%3DT.%26aulast%3DByrne%26aufirst%3DM.%2BC.%26aulast%3DHorton%26aufirst%3DH.%2BF.%26aulast%3DFouser%26aufirst%3DL.%26aulast%3DCarter%26aufirst%3DL.%26aulast%3DLing%26aufirst%3DV.%26aulast%3DBowman%26aufirst%3DM.%2BR.%26aulast%3DCarreno%26aufirst%3DB.%2BM.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DC.%2BR.%26aulast%3DHonjo%26aufirst%3DT.%26atitle%3DEngagement%2520of%2520the%2520PD-1%2520immunoinhibitory%2520receptor%2520by%2520a%2520novel%2520B7%2520family%2520member%2520leads%2520to%2520negative%2520regulation%2520of%2520lymphocyte%2520activation%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2000%26volume%3D192%26spage%3D1027%26epage%3D1034%26doi%3D10.1084%2Fjem.192.7.1027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butte, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keir, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phamduy, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span> <span> </span><span class="NLM_article-title">Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2007.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1016%2Fj.immuni.2007.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=17629517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosFeqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=111-122&author=M.+J.+Butteauthor=M.+E.+Keirauthor=T.+B.+Phamduyauthor=A.+H.+Sharpeauthor=G.+J.+Freeman&title=Programmed+death-1+ligand+1+interacts+specifically+with+the+B7-1+costimulatory+molecule+to+inhibit+T+cell+responses&doi=10.1016%2Fj.immuni.2007.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Programmed Death-1 Ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses</span></div><div class="casAuthors">Butte, Manish J.; Keir, Mary E.; Phamduy, Theresa B.; Sharpe, Arlene H.; Freeman, Gordon J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-122</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Pathways in the B7:CD28 family of costimulatory mols. regulate T cell activation and tolerance.  B7-dependent responses in Cd28-/- Ctla4-/- T cells together with reports of stimulatory and inhibitory functions for Programmed Death-1 Ligand 1 or 2 mols. (PD-L1 or PD-L2) have suggested addnl. receptors for these B7 family members.  The authors show that B7-1 and PD-L1 interacted with affinity intermediate to that of B7-1:CD28 and B7-1:CTLA-4.  The PD-L1:B7-1 interface overlapped with the B7-1:CTLA-4 and PD-L1:PD-1 (Programmed Death-1) interfaces.  T cell activation and cytokine prodn. were inhibited by the interaction of B7-1 with PD-L1.  The responses of PD-1-deficient vs. PD-1,B7-1 double-deficient T cells to PD-L1 and of CD28,CTLA-4 double-deficient vs. CD28,CTLA-4,PD-L1 triple-deficient T cells to B7-1 demonstrated that PD-L1 and B7-1 interact specifically to inhibit T cell activation.  The authors' findings point to a substantial bidirectional inhibitory interaction between B7-1 and PD-L1 and add an addnl. dimension to immunoregulatory functions of the B7:CD28 family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMR5dpv_Vr5LVg90H21EOLACvtfcHk0lgfAkV43a3jsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosFeqtrk%253D&md5=8fabef0e1244a1d356378867d92a248e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2007.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2007.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DButte%26aufirst%3DM.%2BJ.%26aulast%3DKeir%26aufirst%3DM.%2BE.%26aulast%3DPhamduy%26aufirst%3DT.%2BB.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26atitle%3DProgrammed%2520death-1%2520ligand%25201%2520interacts%2520specifically%2520with%2520the%2520B7-1%2520costimulatory%2520molecule%2520to%2520inhibit%2520T%2520cell%2520responses%26jtitle%3DImmunity%26date%3D2007%26volume%3D27%26spage%3D111%26epage%3D122%26doi%3D10.1016%2Fj.immuni.2007.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dermani, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samadi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahmani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlan, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najafi, R.</span></span> <span> </span><span class="NLM_article-title">PD-1/PD-L1 immune checkpoint: potential target for cancer therapy</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_fpage">1313</span>– <span class="NLM_lpage">1325</span>, <span class="refDoi"> DOI: 10.1002/jcp.27172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1002%2Fjcp.27172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=30191996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1KjsL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=1313-1325&author=F.+K.+Dermaniauthor=P.+Samadiauthor=G.+Rahmaniauthor=A.+K.+Kohlanauthor=R.+Najafi&title=PD-1%2FPD-L1+immune+checkpoint%3A+potential+target+for+cancer+therapy&doi=10.1002%2Fjcp.27172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy</span></div><div class="casAuthors">Dermani, Fatemeh K.; Samadi, Pouria; Rahmani, Golebagh; Kohlan, Alisa K.; Najafi, Rezvan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1313-1325</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Recent studies show that cancer cells are sometimes able to evade the host immunity in the tumor microenvironment.  Cancer cells can express high levels of immune inhibitory signaling proteins.  One of the most crit. checkpoint pathways in this system is a tumor-induced immune suppression (immune checkpoint) mediated by the programmed cell death protein 1 (PD-1) and its ligand, programmed death ligand 1 (PD-L1).  PD-1 is highly expressed by activated T cells, B cells, dendritic cells, and natural killer cells, whereas PD-L1 is expressed on several types of tumor cells.  Many studies have shown that blocking the interaction between PD-1 and PD-L1 enhances the T-cell response and mediates antitumor activity.  In this review, we highlight a brief overview of the mol. and biochem. events that are regulated by the PD-1 and PD-L1 interaction in various cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBszcahhx8VLVg90H21EOLACvtfcHk0lgfAkV43a3jsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1KjsL7F&md5=b8b9b458baa4e36d8a163ae4cd2845be</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fjcp.27172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.27172%26sid%3Dliteratum%253Aachs%26aulast%3DDermani%26aufirst%3DF.%2BK.%26aulast%3DSamadi%26aufirst%3DP.%26aulast%3DRahmani%26aufirst%3DG.%26aulast%3DKohlan%26aufirst%3DA.%2BK.%26aulast%3DNajafi%26aufirst%3DR.%26atitle%3DPD-1%252FPD-L1%2520immune%2520checkpoint%253A%2520potential%2520target%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2019%26spage%3D1313%26epage%3D1325%26doi%3D10.1002%2Fjcp.27172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span> <span> </span><span class="NLM_article-title">PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: new development and challenges</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>405</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2017.06.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1016%2Fj.canlet.2017.06.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=28688973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFCgsL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=405&publication_year=2017&pages=29-37&author=X.+Mengauthor=Y.+Liuauthor=J.+Zhangauthor=F.+Tengauthor=L.+Xingauthor=J.+Yu&title=PD-1%2FPD-L1+checkpoint+blockades+in+non-small+cell+lung+cancer%3A+new+development+and+challenges&doi=10.1016%2Fj.canlet.2017.06.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges</span></div><div class="casAuthors">Meng, Xiangjiao; Liu, Yanli; Zhang, Jianjun; Teng, Feifei; Xing, Ligang; Yu, Jinming</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">405</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29-37</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">PD-1/PD-L1 checkpoint blockades have dramatically changed the landscape for second-line treatment of non-small cell lung cancer (NSCLC).  Based on the promising results of Keynote-024 presented so far, pembrolizumab has been approved as first-line treatment for advanced PD-L1 pos. NSCLC patients.  However, overall response rate (ORR) is limited to PD-1/PD-L1 checkpoint blockades when used as single agent.  Combining with chemotherapy, anti-CTLA-4 antibodies, targeted therapy, radiotherapy or other treatment options is perceived as an appealing method aimed at achieving higher efficacy.  There are many clin. trials on going or finished assessing the efficacy and safety of the PD-1/PD-L1 blockades alone or combining with other approaches in first-line or second-line treatments.  A lot of challenges need to be overcome before PD-1/PD-L1 checkpoint blockades are widely used in the patients with NSCLC including the identification of optimal combination, treatment-related adverse effects, the high cost and lack of effective predictive markers.  In this review, we focus on outlining current clin. trials and challenges for future research of PD-1/PD-L1 pathway checkpoint blockades in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCJltkyVf6jbVg90H21EOLACvtfcHk0lioJsLhJWmHhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFCgsL7L&md5=a41e659833915b7d6fc6b715cfe84a57</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2017.06.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2017.06.033%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DTeng%26aufirst%3DF.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DJ.%26atitle%3DPD-1%252FPD-L1%2520checkpoint%2520blockades%2520in%2520non-small%2520cell%2520lung%2520cancer%253A%2520new%2520development%2520and%2520challenges%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D405%26spage%3D29%26epage%3D37%26doi%3D10.1016%2Fj.canlet.2017.06.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalbasi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">Tumour-intrinsic resistance to immune checkpoint blockade</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1038/s41577-019-0218-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1038%2Fs41577-019-0218-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=31570880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVOqurfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=25-39&author=A.+Kalbasiauthor=A.+Ribas&title=Tumour-intrinsic+resistance+to+immune+checkpoint+blockade&doi=10.1038%2Fs41577-019-0218-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tumour-intrinsic resistance to immune checkpoint blockade</span></div><div class="casAuthors">Kalbasi, Anusha; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-39</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  'Immune checkpoint blockade' for cancer describes the use of therapeutic antibodies that disrupt neg. immune regulatory checkpoints and unleash pre-existing antitumor immune responses.  Antibodies targeting the checkpoint mols. cytotoxic T lymphocyte antigen 4 (CTLA4), programmed cell death 1 (PD1) and PD1 ligand 1 (PD-L1) have had early success in the clinic, which has led to approval by the US Food and Drug Administration of multiple agents in several cancer types.  Yet, clinicians still have very limited tools to discriminate a priori patients who will and will not respond to treatment.  This has fuelled a wave of research into the mol. mechanisms of tumor-intrinsic resistance to immune checkpoint blockade, leading to the rediscovery of biol. processes crit. to antitumor immunity, namely interferon signalling and antigen presentation.  Other efforts have shed light on the immunol. implications of canonical cancer signalling pathways, such as WNT-β-catenin signalling, cell cycle regulatory signalling, mitogen-activated protein kinase signalling and pathways activated by loss of the tumor suppressor phosphoinositide phosphatase PTEN.  Here we review each of these mol. mechanisms of resistance and explore ongoing approaches to overcome resistance to immune checkpoint blockade and expand the spectrum of patients who can benefit from immune checkpoint blockade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0rmwAAmvFGbVg90H21EOLACvtfcHk0lioJsLhJWmHhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVOqurfM&md5=9ba5285a05c554b90760620c367547ef</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fs41577-019-0218-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41577-019-0218-4%26sid%3Dliteratum%253Aachs%26aulast%3DKalbasi%26aufirst%3DA.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DTumour-intrinsic%2520resistance%2520to%2520immune%2520checkpoint%2520blockade%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2020%26volume%3D20%26spage%3D25%26epage%3D39%26doi%3D10.1038%2Fs41577-019-0218-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazhenova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frampton, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzrock, R.</span></span> <span> </span><span class="NLM_article-title">Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2598</span>– <span class="NLM_lpage">2608</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-0386</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1158%2F1535-7163.MCT-17-0386" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=28835386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGisrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=2598-2608&author=A.+M.+Goodmanauthor=S.+Katoauthor=L.+Bazhenovaauthor=S.+P.+Patelauthor=G.+M.+Framptonauthor=V.+Millerauthor=P.+J.+Stephensauthor=G.+A.+Danielsauthor=R.+Kurzrock&title=Tumor+mutational+burden+as+an+independent+predictor+of+response+to+immunotherapy+in+diverse+cancers&doi=10.1158%2F1535-7163.MCT-17-0386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers</span></div><div class="casAuthors">Goodman, Aaron M.; Kato, Shumei; Bazhenova, Lyudmila; Patel, Sandip P.; Frampton, Garrett M.; Miller, Vincent; Stephens, Philip J.; Daniels, Gregory A.; Kurzrock, Razelle</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2598-2608</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Immunotherapy induces durable responses in a subset of patients with cancer.  High tumor mutational burden (TMB) may be a response biomarker for PD-1/PD-L1 blockade in tumors such as melanoma and non-small cell lung cancer (NSCLC).  Our aim was to examine the relationship between TMB and outcome in diverse cancers treated with various immunotherapies.  We reviewed data on 1,638 patients who had undergone comprehensive genomic profiling and had TMB assessment.  Immunotherapy-treated patients (N = 151) were analyzed for response rate (RR), progression-free survival (PFS), and overall survival (OS).  Higher TMB was independently assocd. with better outcome parameters (multivariable anal.).  The RR for patients with high (≥20 mutations/mb) vs. low to intermediate TMB was 22/38 (58%) vs. 23/113 (20%; P = 0.0001); median PFS, 12.8 mo vs. 3.3 mo (P ≤ 0.0001); median OS, not reached vs. 16.3 mo (P = 0.0036).  Results were similar when anti-PD-1/PD-L1 monotherapy was analyzed (N = 102 patients), with a linear correlation between higher TMB and favorable outcome parameters; the median TMB for responders vs. nonresponders treated with anti-PD-1/PD-L1 monotherapy was 18.0 vs. 5.0 mutations/mb (P < 0.0001).  Interestingly, anti-CTLA4/anti-PD-1/PD-L1 combinations vs. anti-PD-1/PD-L1 monotherapy was selected as a factor independent of TMB for predicting better RR (77% vs. 21%; P = 0.004) and PFS (P = 0.024).  Higher TMB predicts favorable outcome to PD-1/PD-L1 blockade across diverse tumors.  Benefit from dual checkpoint blockade did not show a similarly strong dependence on TMB.  Mol Cancer Ther; 16(11); 2598-608. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUwjFKpJPbjrVg90H21EOLACvtfcHk0lgc9lS-NlVIEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGisrvL&md5=47c40d69a862cc0077452e32fbc5ef53</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0386%26sid%3Dliteratum%253Aachs%26aulast%3DGoodman%26aufirst%3DA.%2BM.%26aulast%3DKato%26aufirst%3DS.%26aulast%3DBazhenova%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DS.%2BP.%26aulast%3DFrampton%26aufirst%3DG.%2BM.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DDaniels%26aufirst%3DG.%2BA.%26aulast%3DKurzrock%26aufirst%3DR.%26atitle%3DTumor%2520mutational%2520burden%2520as%2520an%2520independent%2520predictor%2520of%2520response%2520to%2520immunotherapy%2520in%2520diverse%2520cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D2598%26epage%3D2608%26doi%3D10.1158%2F1535-7163.MCT-17-0386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hodges, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatalica, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huse, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Groot, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overwijk, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spetzler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimberger, A. B.</span></span> <span> </span><span class="NLM_article-title">Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy</span>. <i>Neuro-Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1047</span>– <span class="NLM_lpage">1057</span>, <span class="refDoi"> DOI: 10.1093/neuonc/nox026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1093%2Fneuonc%2Fnox026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=28371827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFOmt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=1047-1057&author=T.+R.+Hodgesauthor=M.+Ottauthor=J.+Xiuauthor=Z.+Gatalicaauthor=J.+Swensenauthor=S.+Zhouauthor=J.+T.+Huseauthor=J.+De+Grootauthor=S.+Liauthor=W.+W.+Overwijkauthor=D.+Spetzlerauthor=A.+B.+Heimberger&title=Mutational+burden%2C+immune+checkpoint+expression%2C+and+mismatch+repair+in+glioma%3A+implications+for+immune+checkpoint+immunotherapy&doi=10.1093%2Fneuonc%2Fnox026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy</span></div><div class="casAuthors">Hodges, Tiffany R.; Ott, Martina; Xiu, Joanne; Gatalica, Zoran; Swensen, Jeff; Zhou, Shouhao; Huse, Jason T.; de Groot, John; Li, Shulin; Overwijk, Willem W.; Spetzler, David; Heimberger, Amy B.</div><div class="citationInfo"><span class="NLM_cas:title">Neuro-Oncology (Cary, NC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1047-1057</span>CODEN:
                <span class="NLM_cas:coden">NEURJR</span>;
        ISSN:<span class="NLM_cas:issn">1523-5866</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background.  Despite a multiplicity of clin. trials testing immune checkpoint inhibitors, the frequency of expression of potential predictive biomarkers is unknown in glioma.  Methods.  In this study, we profiled the frequency of shared biomarker phenotypes.  To clarify the relationships among tumor mutational load (TML), mismatch repair (MMR), and immune checkpoint expression, we profiled patients with glioma (n = 327), including glioblastoma (GBM) (n = 198), whose samples had been submitted for anal. from 2009 to 2016.  The calcn. algorithm for TML included nonsynonymous mutation counts per tumor, with germline mutations filtered out.  Immunohistochem. anal. and next-generation sequencing were used to det. tumor-infiltrating lymphocyte expression pos. for programmed cell death protein 1 (PD-1), PD ligand 1 (PD-L1) expression on tumor cells, MMR (MLH1, MSH2, MSH6, and PMS2) protein expression and mutations, and DNA polymerase epsilon (POLE) mutations.  Results.  High TML was only found in 3.5% of GBM patients (7 of 198) and was assocd. with the absence of protein expression of mutL homolog 1 (MLH1) (P = .0345), mutS homolog 2 (MSH2) (P = .0099), MSH6 (P = .0022), and postmeiotic segregation increased 2 (PMS2) (P = .0345) and the presence of DNA MMR mutations.  High and moderate TML GBMs did not have an enriched influx of CD8 + T cells, PD-1 + T cells, or tumor-expressed PD-L1.  IDH1 mutant gliomas were not enriched for high TML, PD-1 + T cells, or PD-L1 expression.  Conclusions.  To clarify the relationships among TML, MMR, and immune checkpoint expression, we profiled the frequency of shared biomarker phenotypes.  On the basis of a variety of potential biomarkers of response to immune checkpoints, only small subsets of glioma patients are likely to benefit from monotherapy immune checkpoint inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptvDAw21Yh-rVg90H21EOLACvtfcHk0lgc9lS-NlVIEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFOmt7zI&md5=abcfbec32be314e5404ffd76cd0b305f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnox026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnox026%26sid%3Dliteratum%253Aachs%26aulast%3DHodges%26aufirst%3DT.%2BR.%26aulast%3DOtt%26aufirst%3DM.%26aulast%3DXiu%26aufirst%3DJ.%26aulast%3DGatalica%26aufirst%3DZ.%26aulast%3DSwensen%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DHuse%26aufirst%3DJ.%2BT.%26aulast%3DDe%2BGroot%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DOverwijk%26aufirst%3DW.%2BW.%26aulast%3DSpetzler%26aufirst%3DD.%26aulast%3DHeimberger%26aufirst%3DA.%2BB.%26atitle%3DMutational%2520burden%252C%2520immune%2520checkpoint%2520expression%252C%2520and%2520mismatch%2520repair%2520in%2520glioma%253A%2520implications%2520for%2520immune%2520checkpoint%2520immunotherapy%26jtitle%3DNeuro-Oncol.%26date%3D2017%26volume%3D19%26spage%3D1047%26epage%3D1057%26doi%3D10.1093%2Fneuonc%2Fnox026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palakurthi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuraguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacharek, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zudaire, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonal, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhaneshwar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePeaux, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowaski, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrante, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">English, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khosla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rytlewski, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquerre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bittinger, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschmeier, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verona, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi, M. V.</span></span> <span> </span><span class="NLM_article-title">The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1457</span>– <span class="NLM_lpage">1471</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-18-0595</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1158%2F2326-6066.CIR-18-0595" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=31331945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFGjsLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=1457-1471&author=S.+Palakurthiauthor=M.+Kuraguchiauthor=S.+J.+Zacharekauthor=E.+Zudaireauthor=W.+Huangauthor=D.+M.+Bonalauthor=J.+Liuauthor=A.+Dhaneshwarauthor=K.+DePeauxauthor=M.+R.+Gowaskiauthor=D.+Baileyauthor=S.+N.+Reganauthor=E.+Ivanovaauthor=C.+Ferranteauthor=J.+M.+Englishauthor=A.+Khoslaauthor=A.+H.+Beckauthor=J.+A.+Rytlewskiauthor=C.+Sanderauthor=S.+Laquerreauthor=M.+A.+Bittingerauthor=P.+T.+Kirschmeierauthor=K.+Packmanauthor=P.+A.+Janneauthor=C.+Moyauthor=K.-K.+Wongauthor=R.+I.+Veronaauthor=M.+V.+Lorenzi&title=The+combined+effect+of+FGFR+inhibition+and+PD-1+blockade+promotes+tumor-intrinsic+induction+of+antitumor+immunity&doi=10.1158%2F2326-6066.CIR-18-0595"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity</span></div><div class="casAuthors">Palakurthi, Sangeetha; Kuraguchi, Mari; Zacharek, Sima J.; Zudaire, Enrique; Huang, Wei; Bonal, Dennis M.; Liu, Jeffrey; Dhaneshwar, Abha; DePeaux, Kristin; Gowaski, Martha R.; Bailey, Dyane; Regan, Samuel N.; Ivanova, Elena; Ferrante, Catherine; English, Jessie M.; Khosla, Aditya; Beck, Andrew H.; Rytlewski, Julie A.; Sanders, Catherine; Laquerre, Sylvie; Bittinger, Mark A.; Kirschmeier, Paul T.; Packman, Kathryn; Janne, Pasi A.; Moy, Christopher; Wong, Kwok-Kin; Verona, Raluca I.; Lorenzi, Matthew V.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1457-1471</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The success of targeted or immune therapies is often hampered by the emergence of resistance and/or clin. benefit in only a subset of patients.  We hypothesized that combining targeted therapy with immune modulation would show enhanced antitumor responses.  Here, we explored the combination potential of erdafitinib, a fibroblast growth factor receptor (FGFR) inhibitor under clin. development, with PD-1 blockade in an autochthonous FGFR2K660N/p53mut lung cancer mouse model.  Erdafitinib monotherapy treatment resulted in substantial tumor control but no significant survival benefit.  Although anti-PD-1 alone was ineffective, the erdafitinib and anti-PD-1 combination induced significant tumor regression and improved survival.  For both erdafitinib monotherapy and combination treatments, tumor control was accompanied by tumor-intrinsic, FGFR pathway inhibition, increased T-cell infiltration, decreased regulatory T cells, and downregulation of PD-L1 expression on tumor cell.  Treatment with erdafitinib decreased T-cell receptor (TCR) clonality, reflecting a broadening of the TCR repertoire induced by tumor cell death, whereas combination with anti-PD-1 led to increased TCR clonality, suggesting a more focused antitumor T-cell response.  Our results showed that the combination of erdafitinib and anti-PD-1 drives expansion of T-cell clones and immunol. changes in the tumor microenvironment to support enhanced antitumor immunity and survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpisqPTNzxu2rVg90H21EOLACvtfcHk0ljwUZKthBxJmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFGjsLzE&md5=3b10f0132050a1951a9c8efb32b6933f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-18-0595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-18-0595%26sid%3Dliteratum%253Aachs%26aulast%3DPalakurthi%26aufirst%3DS.%26aulast%3DKuraguchi%26aufirst%3DM.%26aulast%3DZacharek%26aufirst%3DS.%2BJ.%26aulast%3DZudaire%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DBonal%26aufirst%3DD.%2BM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DDhaneshwar%26aufirst%3DA.%26aulast%3DDePeaux%26aufirst%3DK.%26aulast%3DGowaski%26aufirst%3DM.%2BR.%26aulast%3DBailey%26aufirst%3DD.%26aulast%3DRegan%26aufirst%3DS.%2BN.%26aulast%3DIvanova%26aufirst%3DE.%26aulast%3DFerrante%26aufirst%3DC.%26aulast%3DEnglish%26aufirst%3DJ.%2BM.%26aulast%3DKhosla%26aufirst%3DA.%26aulast%3DBeck%26aufirst%3DA.%2BH.%26aulast%3DRytlewski%26aufirst%3DJ.%2BA.%26aulast%3DSander%26aufirst%3DC.%26aulast%3DLaquerre%26aufirst%3DS.%26aulast%3DBittinger%26aufirst%3DM.%2BA.%26aulast%3DKirschmeier%26aufirst%3DP.%2BT.%26aulast%3DPackman%26aufirst%3DK.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DMoy%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DVerona%26aufirst%3DR.%2BI.%26aulast%3DLorenzi%26aufirst%3DM.%2BV.%26atitle%3DThe%2520combined%2520effect%2520of%2520FGFR%2520inhibition%2520and%2520PD-1%2520blockade%2520promotes%2520tumor-intrinsic%2520induction%2520of%2520antitumor%2520immunity%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2019%26volume%3D7%26spage%3D1457%26epage%3D1471%26doi%3D10.1158%2F2326-6066.CIR-18-0595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tran, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spielbauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Waes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, N. C.</span></span> <span> </span><span class="NLM_article-title">Cisplatin alters antitumor immunity and synergizes with PD-1/PD-L1 inhibition in head and neck squamous cell carcinoma</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1141</span>– <span class="NLM_lpage">1151</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-17-0235</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1158%2F2326-6066.CIR-17-0235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=29097421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWhsbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=1141-1151&author=L.+Tranauthor=C.+T.+Allenauthor=R.+Xiaoauthor=E.+Mooreauthor=R.+Davisauthor=S.-J.+Parkauthor=K.+Spielbauerauthor=C.+Van+Waesauthor=N.+C.+Schmitt&title=Cisplatin+alters+antitumor+immunity+and+synergizes+with+PD-1%2FPD-L1+inhibition+in+head+and+neck+squamous+cell+carcinoma&doi=10.1158%2F2326-6066.CIR-17-0235"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma</span></div><div class="casAuthors">Tran, Linda; Allen, Clint T.; Xiao, Roy; Moore, Ellen; Davis, Ruth; Park, So-Jin; Spielbauer, Katie; Van Waes, Carter; Schmitt, Nicole C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1141-1151</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Head and neck squamous cell carcinoma (HNSCC) has been treated for decades with cisplatin chemotherapy, and anti-PD-1 immunotherapy has recently been approved for the treatment of this disease.  However, preclin. studies of how antitumor immunity in HNSCC is affected by cisplatin alone or in combination with immunotherapies are lacking.  Here, we show that sublethal doses of cisplatin may enhance antigen presentation and T-cell killing in vitro, though cisplatin also upregulates tumor cell expression of PD-L1 and may impair T-cell function at higher doses.  In a syngeneic mouse model of HNSCC, concurrent use of cisplatin and anti-PD-L1/PD-1 delayed tumor growth and enhanced survival without significantly reducing the no. or function of tumor-infiltrating immune cells or increasing cisplatin-induced toxicities.  These results suggest that moderate doses of cisplatin may enhance antitumor immunity by mechanisms other than direct tumor cell killing, which may be further enhanced by anti-PD-L1/PD-1 therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtMQSckrn-BbVg90H21EOLACvtfcHk0ljwUZKthBxJmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWhsbrL&md5=71226b2e8ad3517547145cd286884453</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-17-0235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-17-0235%26sid%3Dliteratum%253Aachs%26aulast%3DTran%26aufirst%3DL.%26aulast%3DAllen%26aufirst%3DC.%2BT.%26aulast%3DXiao%26aufirst%3DR.%26aulast%3DMoore%26aufirst%3DE.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DPark%26aufirst%3DS.-J.%26aulast%3DSpielbauer%26aufirst%3DK.%26aulast%3DVan%2BWaes%26aufirst%3DC.%26aulast%3DSchmitt%26aufirst%3DN.%2BC.%26atitle%3DCisplatin%2520alters%2520antitumor%2520immunity%2520and%2520synergizes%2520with%2520PD-1%252FPD-L1%2520inhibition%2520in%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2017%26volume%3D5%26spage%3D1141%26epage%3D1151%26doi%3D10.1158%2F2326-6066.CIR-17-0235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gunda, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigliotti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashry, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndishabandi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stork, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessandrini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parangi, S.</span></span> <span> </span><span class="NLM_article-title">Anti-PD-1/PD-L1 therapy augments lenvatinib’s efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">2266</span>– <span class="NLM_lpage">2278</span>, <span class="refDoi"> DOI: 10.1002/ijc.32041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1002%2Fijc.32041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=30515783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslCgt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2019&pages=2266-2278&author=V.+Gundaauthor=B.+Gigliottiauthor=T.+Ashryauthor=D.+Ndishabandiauthor=M.+McCarthyauthor=Z.+Zhouauthor=S.+Aminauthor=K.+E.+Leeauthor=T.+Storkauthor=L.+Wirthauthor=G.+J.+Freemanauthor=A.+Alessandriniauthor=S.+Parangi&title=Anti-PD-1%2FPD-L1+therapy+augments+lenvatinib%E2%80%99s+efficacy+by+favorably+altering+the+immune+microenvironment+of+murine+anaplastic+thyroid+cancer&doi=10.1002%2Fijc.32041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-PD-1/PD-L1 therapy augments lenvatinib efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer</span></div><div class="casAuthors">Gunda, Viswanath; Gigliotti, Benjamin; Ashry, Tameem; Ndishabandi, Dorothy; McCarthy, Michael; Zhou, Zhiheng; Amin, Salma; Lee, Kyu Eun; Stork, Tabea; Wirth, Lori; Freeman, Gordon J.; Alessandrini, Alessandro; Parangi, Sareh</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2266-2278</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Patients with anaplastic thyroid cancer (ATC) have an extremely poor prognosis despite multimodal therapy with surgery and chemoradiation.  Lenvatinib, a multi-targeted tyrosine kinase inhibitor, as well as checkpoint inhibitors targeting the programmed cell death pathway, have proven effective in some patients with advanced thyroid cancer.  We utilized our novel immunocompetent murine model of orthotopic ATC to demonstrate that lenvatinib led to significant tumor shrinkage and increased survival, while combination therapy led to dramatic improvements in both.  Lenvatinib monotherapy increased tumor-infiltrating macrophages, CD8+ T-cells, regulatory T-cells, and most notably, polymorphonuclear myeloid derived suppressor cells (PMN-MDSCs).  While both combination therapies led to further increases in CD8+ T-cells, only the lenvatinib and anti-PD-1 combination decreased PMN-MDSCs.  PMN-MDSC expansion was also seen in blood of mice and one patient receiving lenvatinib therapy for ATC.  RNA-Seq of the ATC cell line used in our mouse model demonstrated that lenvatinib has multifaceted effects on angiogenesis, response to hypoxia, the epithelial-to-mesenchymal transition, and on multiple pathways implicated in inflammation and host immunity.  These data suggest that MDSCs play a neg. role in ATC response to lenvatinib and support future study of their role as a potential biomarker and treatment target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquYvkE3flvLbVg90H21EOLACvtfcHk0lipkOmKqL741g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslCgt7Y%253D&md5=c4547c732c5996b7f5106c8c03cbdc1f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fijc.32041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.32041%26sid%3Dliteratum%253Aachs%26aulast%3DGunda%26aufirst%3DV.%26aulast%3DGigliotti%26aufirst%3DB.%26aulast%3DAshry%26aufirst%3DT.%26aulast%3DNdishabandi%26aufirst%3DD.%26aulast%3DMcCarthy%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DAmin%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DK.%2BE.%26aulast%3DStork%26aufirst%3DT.%26aulast%3DWirth%26aufirst%3DL.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DAlessandrini%26aufirst%3DA.%26aulast%3DParangi%26aufirst%3DS.%26atitle%3DAnti-PD-1%252FPD-L1%2520therapy%2520augments%2520lenvatinib%25E2%2580%2599s%2520efficacy%2520by%2520favorably%2520altering%2520the%2520immune%2520microenvironment%2520of%2520murine%2520anaplastic%2520thyroid%2520cancer%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2019%26volume%3D144%26spage%3D2266%26epage%3D2278%26doi%3D10.1002%2Fijc.32041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of [1,2,4]triazolo[4,3-<i>a</i>]pyridines as potent inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 interaction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4703</span>– <span class="NLM_lpage">4715</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00312</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00312" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmvV2qurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4703-4715&author=M.+Qinauthor=Q.+Caoauthor=S.+Zhengauthor=Y.+Tianauthor=H.+Zhangauthor=J.+Xieauthor=H.+Xieauthor=Y.+Liuauthor=Y.+Zhaoauthor=P.+Gong&title=Discovery+of+%5B1%2C2%2C4%5Dtriazolo%5B4%2C3-a%5Dpyridines+as+potent+inhibitors+targeting+the+programmed+cell+death-1%2Fprogrammed+cell+death-ligand+1+interaction&doi=10.1021%2Facs.jmedchem.9b00312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of [1,2,4]Triazolo[4,3-a]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction</span></div><div class="casAuthors">Qin, Mingze; Cao, Qi; Zheng, Shuaishuai; Tian, Ye; Zhang, Haotian; Xie, Jun; Xie, Hongbo; Liu, Yajing; Zhao, Yanfang; Gong, Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4703-4715</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction using small-mol. inhibitors is an emerging immunotherapeutic approach.  A novel series of [1,2,4]triazolo[4,3-a]pyridines were designed and found to be potent inhibitors of the PD-1/PD-L1 interaction.  Among them, compd. I exhibited the most potent activity, as assessed by homogeneous time-resolved fluorescence assay, with an IC50 of 92.3 nM.  Furthermore, I dose-dependent elevated interferon-γ prodn. in a coculture model of Hep3B/OS-8/hPD-L1 and CD3 T cells.  The authors concluded that I is a promising lead compd. for the development of inhibitors of the PD-1/PD-L1 interaction.  In addn., the authors explored the structure-activity relationships of the newly synthesized [1,2,4]triazolo[4,3-a]pyridines and demonstrated that a ring fusion strategy can be employed for designing analogs of the Bristol-Myers Squibb chem. series.  These studies pave the way for future drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCgkEJ5SqGXLVg90H21EOLACvtfcHk0lgbfeKMZkteww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmvV2qurs%253D&md5=44d4ee689be577a86c16cc4da3edec71</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00312%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-a%255Dpyridines%2520as%2520potent%2520inhibitors%2520targeting%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520cell%2520death-ligand%25201%2520interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4703%26epage%3D4715%26doi%3D10.1021%2Facs.jmedchem.9b00312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera-Mularz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kholodovych, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, evaluation, and structural studies of <i>C<sub>2</sub></i>-symmetric small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 protein-protein interaction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7250</span>– <span class="NLM_lpage">7263</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00795</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00795" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOhu7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7250-7263&author=S.+Basuauthor=J.+Yangauthor=B.+Xuauthor=K.+Magiera-Mularzauthor=L.+Skalniakauthor=B.+Musielakauthor=V.+Kholodovychauthor=T.+A.+Holakauthor=L.+Hu&title=Design%2C+synthesis%2C+evaluation%2C+and+structural+studies+of+C2-symmetric+small+molecule+inhibitors+of+programmed+cell+death-1%2Fprogrammed+death-ligand+1+protein-protein+interaction&doi=10.1021%2Facs.jmedchem.9b00795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction</span></div><div class="casAuthors">Basu, Subhadwip; Yang, Jeffrey; Xu, Bin; Magiera-Mularz, Katarzyna; Skalniak, Lukasz; Musielak, Bogdan; Kholodovych, Vladyslav; Holak, Tad A.; Hu, Longqin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7250-7263</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of C2-sym. inhibitors was designed and evaluated for inhibitory activity against the programmed cell death-1/programmed death-ligand 1(PD-1/PD-L1) protein-protein interaction (PPI) in a homogeneous time-resolved fluorescence (HTRF) assay and PD-1 signaling in cell-based coculture assays.  C2-sym. inhibitors 2a (LH1306) and 2b (LH1307) exhibited IC50 values of 25 and 3.0 nM, resp., in the HTRF assay.  While 2a was ∼3.8-fold more potent than previously reported inhibitor 1a, 2b could not be differentiated from 1b due to their high potency and the limit of our HTRF assay conditions.  In one cell-based coculture PD-1 signaling assay, 2a and 2b were 8.2- and 2.8-fold more potent in inhibiting PD-1 signaling than 1a and 1b, resp.  NMR and X-ray cocrystal structural studies provided more structural insights into the interaction between 2b and PD-L1; 2b binds to PD-L1 at the PD-1 binding site and induces the formation of a more sym. arranged PD-L1 homodimer than that previously reported for other inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS9fdh7FbNLLVg90H21EOLACvtfcHk0lgbfeKMZkteww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOhu7zJ&md5=0dae949116a4157a281802aea6d21b6c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00795%26sid%3Dliteratum%253Aachs%26aulast%3DBasu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DMagiera-Mularz%26aufirst%3DK.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DKholodovych%26aufirst%3DV.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26aulast%3DHu%26aufirst%3DL.%26atitle%3DDesign%252C%2520synthesis%252C%2520evaluation%252C%2520and%2520structural%2520studies%2520of%2520C2-symmetric%2520small%2520molecule%2520inhibitors%2520of%2520programmed%2520cell%2520death-1%252Fprogrammed%2520death-ligand%25201%2520protein-protein%2520interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7250%26epage%3D7263%26doi%3D10.1021%2Facs.jmedchem.9b00795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konieczny, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czub, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera-Mularz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myrcha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siedlar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plewka, J.</span></span> <span> </span><span class="NLM_article-title">Di-bromo-based small-molecule inhibitors of the PD-1/PD-L1 immune checkpoint</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">11271</span>– <span class="NLM_lpage">11285</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01260</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01260" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVKhu7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=11271-11285&author=M.+Koniecznyauthor=B.+Musielakauthor=J.+Kocikauthor=L.+Skalniakauthor=D.+Salaauthor=M.+Czubauthor=K.+Magiera-Mularzauthor=I.+Rodriguezauthor=M.+Myrchaauthor=M.+Stecauthor=M.+Siedlarauthor=T.+A.+Holakauthor=J.+Plewka&title=Di-bromo-based+small-molecule+inhibitors+of+the+PD-1%2FPD-L1+immune+checkpoint&doi=10.1021%2Facs.jmedchem.0c01260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint</span></div><div class="casAuthors">Konieczny, Magdalena; Musielak, Bogdan; Kocik, Justyna; Skalniak, Lukasz; Sala, Dominik; Czub, Miroslawa; Magiera-Mularz, Katarzyna; Rodriguez, Ismael; Myrcha, Maja; Stec, Malgorzata; Siedlar, Maciej; Holak, Tad A.; Plewka, Jacek</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">11271-11285</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Immune checkpoint blockade is one of the most promising strategies of cancer immunotherapy.  However, unlike classical targeted therapies, it is currently solely based on expensive monoclonal antibodies, which often inflict immune-related adverse events.  Herein, we propose a novel small-mol. inhibitor targeted at the most clin. relevant immune checkpoint, PD-1/PD-L1.  The compd. is capable of disrupting the PD-1/PD-L1 complex by antagonizing PD-L1 and, therefore, restores activation of T cells similarly to the antibodies, while being cheap in prodn. and possibly nonimmunogenic.  The final compd. is significantly smaller than others reported in the literature while being nontoxic to cells even at high concns.  The scaffold was designed using a structure-activity relationship screening cascade based on a new antagonist-induced dissocn. NMR assay, called the weak-AIDA-NMR.  Weak-AIDA-NMR finds true inhibitors, as opposed to only binders to the target protein, in early steps of lead compd. development, and this process makes it less time and cost consuming.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHW_y-fZej_rVg90H21EOLACvtfcHk0liwDYvKJrXvBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVKhu7%252FL&md5=00b95c22e1bb615c773c1bcc68c0a2ba</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01260%26sid%3Dliteratum%253Aachs%26aulast%3DKonieczny%26aufirst%3DM.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DKocik%26aufirst%3DJ.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DSala%26aufirst%3DD.%26aulast%3DCzub%26aufirst%3DM.%26aulast%3DMagiera-Mularz%26aufirst%3DK.%26aulast%3DRodriguez%26aufirst%3DI.%26aulast%3DMyrcha%26aufirst%3DM.%26aulast%3DStec%26aufirst%3DM.%26aulast%3DSiedlar%26aufirst%3DM.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26aulast%3DPlewka%26aufirst%3DJ.%26atitle%3DDi-bromo-based%2520small-molecule%2520inhibitors%2520of%2520the%2520PD-1%252FPD-L1%2520immune%2520checkpoint%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D11271%26epage%3D11285%26doi%3D10.1021%2Facs.jmedchem.0c01260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: a new choice for immunotherapy?</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">378</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.10.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1016%2Fj.ejmech.2018.10.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=30384043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVyit7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2019&pages=378-398&author=T.+Chenauthor=Q.+Liauthor=Z.+Liuauthor=Y.+Chenauthor=F.+Fengauthor=H.+Sun&title=Peptide-based+and+small+synthetic+molecule+inhibitors+on+PD-1%2FPD-L1+pathway%3A+a+new+choice+for+immunotherapy%3F&doi=10.1016%2Fj.ejmech.2018.10.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?</span></div><div class="casAuthors">Chen, Tingkai; Li, Qi; Liu, Zongliang; Chen, Yao; Feng, Feng; Sun, Haopeng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">378-398</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Blockade the interaction of the programmed cell death protein 1 (PD-1) and its ligand, programmed death-ligand 1 (PD-L1) can prevent immune evasion of tumor cells and significantly prolong the survival of cancer patients.  Currently marketed drugs targeting PD-1/PD-L1 pathway are all monoclonal antibodies (mAbs) that have achieved great success in clin. trials.  With the constantly emerging problems of antibody drugs, small mol. inhibitors have attracted the attention of pharmaceutical chemists due to their controllable pharmacol. and pharmacokinetic properties, which make them potential alternatives or supplements to mAbs to regulate PD-1/PD-L1 pathway.  However, the insufficient target structure information hinders the development of small mol. inhibitors.  Since the publication of human-PD-1/human-PD-L1 (hPD-1/hPD-L1) crystal structure, more and more cocrystal structures of mAbs, cyclopeptides and small mols. with PD-1 and PD-L1 have been resolved.  These complexes provide a valuable starting point for the rational design of peptide-based and small synthetic mol. inhibitors.  Here we reviewed the non-antibody inhibitors that have been published so far and analyzed their structure-activity relationships (SAR).  We also summarized the cocrystal structures with hot spots identified, with the aim to provide ref. for future drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozjhKf91To8LVg90H21EOLACvtfcHk0limOAB0wlk4-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVyit7rI&md5=ecc3b6299bdca40a13af0fc2003b251d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.10.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.10.044%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DPeptide-based%2520and%2520small%2520synthetic%2520molecule%2520inhibitors%2520on%2520PD-1%252FPD-L1%2520pathway%253A%2520a%2520new%2520choice%2520for%2520immunotherapy%253F%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D161%26spage%3D378%26epage%3D398%26doi%3D10.1016%2Fj.ejmech.2018.10.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span> <span> </span><span class="NLM_article-title">Development of inhibitors of the programmed cell death-1/programmed cell death-ligand 1 signaling pathway</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1715</span>– <span class="NLM_lpage">1730</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00990</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00990" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslKqtLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1715-1730&author=T.+Wangauthor=X.+Wuauthor=C.+Guoauthor=K.+Zhangauthor=J.+Xuauthor=Z.+Liauthor=S.+Jiang&title=Development+of+inhibitors+of+the+programmed+cell+death-1%2Fprogrammed+cell+death-ligand+1+signaling+pathway&doi=10.1021%2Facs.jmedchem.8b00990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway</span></div><div class="casAuthors">Wang, Tianyu; Wu, Xiaoxing; Guo, Changying; Zhang, Kuojun; Xu, Jinyi; Li, Zheng; Jiang, Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1715-1730</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The clin. success of inhibitors targeting the PD-1/PD-L1 pathway has made this an active field in cancer immunotherapy.  Currently, most drugs targeting this pathway are monoclonal antibodies.  Small-mol. inhibitors as the alternative to monoclonal antibodies are expected to overcome the disadvantages of mAbs which include prodn. difficulties and their long half-life.  Recently, progress has been reported on anti-PD-1/PD-L1 small-mol. inhibitors.  In this paper, we review the development of inhibitors targeting the PD-1/PD-L1 pathway, focusing mainly on peptide-based and nonpeptidic small-mol. inhibitors.  The structures and the preclin. and clin. studies of several peptide-based small-mol. candidate compds. in clin. trials are discussed.  We also illustrate the design strategies underlying reported nonpeptidic small-mol. inhibitors and provide insight into possible future exploration.  Development of small-mol. drugs for anti-PD-1/PD-L1 activity with specific cancer applications is a promising and challenging prospect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonItidshja8LVg90H21EOLACvtfcHk0limOAB0wlk4-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslKqtLzL&md5=2fc7ee8e9bb8d37c7569913a4529d753</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00990%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DS.%26atitle%3DDevelopment%2520of%2520inhibitors%2520of%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520cell%2520death-ligand%25201%2520signaling%2520pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1715%26epage%3D1730%26doi%3D10.1021%2Facs.jmedchem.8b00990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera-Mularz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czub, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siedlar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plewka, J.</span></span> <span> </span><span class="NLM_article-title">CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2804</span>– <span class="NLM_lpage">2816</span>, <span class="refDoi"> DOI: 10.3390/molecules24152804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.3390%2Fmolecules24152804" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=2804-2816&author=B.+Musielakauthor=J.+Kocikauthor=L.+Skalniakauthor=K.+Magiera-Mularzauthor=D.+Salaauthor=M.+Czubauthor=M.+Stecauthor=M.+Siedlarauthor=T.+A.+Holakauthor=J.+Plewka&title=CA-170+%E2%80%93+A+Potent+Small-Molecule+PD-L1+Inhibitor+or+Not%3F&doi=10.3390%2Fmolecules24152804"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24152804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24152804%26sid%3Dliteratum%253Aachs%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DKocik%26aufirst%3DJ.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DMagiera-Mularz%26aufirst%3DK.%26aulast%3DSala%26aufirst%3DD.%26aulast%3DCzub%26aufirst%3DM.%26aulast%3DStec%26aufirst%3DM.%26aulast%3DSiedlar%26aufirst%3DM.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26aulast%3DPlewka%26aufirst%3DJ.%26atitle%3DCA-170%2520%25E2%2580%2593%2520A%2520Potent%2520Small-Molecule%2520PD-L1%2520Inhibitor%2520or%2520Not%253F%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26spage%3D2804%26epage%3D2816%26doi%3D10.3390%2Fmolecules24152804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chupak, L. S.</span>; <span class="NLM_string-name">Ding, M.</span>; <span class="NLM_string-name">Martin, S. W.</span>; <span class="NLM_string-name">Zheng, X.</span>; <span class="NLM_string-name">Hewawasam, P.</span>; <span class="NLM_string-name">Connolly, T. P.</span>; <span class="NLM_string-name">Xu, N.</span>; <span class="NLM_string-name">Yeung, K-S.</span>; <span class="NLM_string-name">Zhu, J.</span>; <span class="NLM_string-name">Langley, D. R.</span>; <span class="NLM_string-name">Tenney, D. J.</span>; <span class="NLM_string-name">Scola, P. M.</span></span> <span> </span><span class="NLM_article-title">Compounds useful as immunomodulators</span>. <span class="NLM_patent">WO2015160641 A2</span>, Oct 22, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=L.+S.+Chupak&author=M.+Ding&author=S.+W.+Martin&author=X.+Zheng&author=P.+Hewawasam&author=T.+P.+Connolly&author=N.+Xu&author=K-S.+Yeung&author=J.+Zhu&author=D.+R.+Langley&author=D.+J.+Tenney&author=P.+M.+Scola&title=Compounds+useful+as+immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChupak%26aufirst%3DL.%2BS.%26atitle%3DCompounds%2520useful%2520as%2520immunomodulators%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chupak, L. S.</span>; <span class="NLM_string-name">Zheng, X.</span></span> <span> </span><span class="NLM_article-title">Compounds useful as immunomodulators</span>. <span class="NLM_patent">WO2015034820 A1</span>, Mar 12, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=L.+S.+Chupak&author=X.+Zheng&title=Compounds+useful+as+immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChupak%26aufirst%3DL.%2BS.%26atitle%3DCompounds%2520useful%2520as%2520immunomodulators%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guzik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudnik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Törner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors of the programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5857</span>– <span class="NLM_lpage">5867</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00293</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00293" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvFeisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5857-5867&author=K.+Guzikauthor=K.+M.+Zakauthor=P.+Grudnikauthor=K.+Magieraauthor=B.+Musielakauthor=R.+T%C3%B6rnerauthor=L.+Skalniakauthor=A.+Domlingauthor=G.+Dubinauthor=T.+A.+Holak&title=Small-molecule+inhibitors+of+the+programmed+cell+death-1%2Fprogrammed+death-ligand+1+%28PD-1%2FPD-L1%29+interaction+via+transiently+induced+protein+states+and+dimerization+of+PD-L1&doi=10.1021%2Facs.jmedchem.7b00293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1</span></div><div class="casAuthors">Guzik, Katarzyna; Zak, Krzysztof M.; Grudnik, Przemyslaw; Magiera, Katarzyna; Musielak, Bogdan; Torner, Ricarda; Skalniak, Lukasz; Domling, Alexander; Dubin, Grzegorz; Holak, Tad A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5857-5867</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockade of the PD-1/PD-L1 immune checkpoint pathway with monoclonal antibodies has provided significant advances in cancer treatment.  The antibody-based immunotherapies carry a no. of disadvantages such as the high cost of the antibodies, their limited half-life, and immunogenicity.  Development of small-mol. PD-1/PD-L1 inhibitors that could overcome these drawbacks is slow because of the incomplete structural information for this pathway.  The first chem. PD-1/PD-L1 inhibitors have been recently disclosed by Bristol-Myers Squibb.  Here we present NMR and X-ray characterization for the two classes of these inhibitors.  The X-ray structures of the PD-L1/inhibitor complexes reveal one inhibitor mol. located at the center of the PD-L1 homodimer, filling a deep hydrophobic channel-like pocket between two PD-L1 mols.  Derivs. of (2-methyl-3-biphenylyl)methanol exhibit the structures capped on one side of the channel, whereas the compds. based on [3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]methanol induce an enlarged interaction interface that results in the open "face-back" tunnel through the PD-L1 dimer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppmfSesG1M6rVg90H21EOLACvtfcHk0liUrmQ8ecC5Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvFeisLc%253D&md5=c039796cda3b9ef92a0ed3b10b11932b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00293%26sid%3Dliteratum%253Aachs%26aulast%3DGuzik%26aufirst%3DK.%26aulast%3DZak%26aufirst%3DK.%2BM.%26aulast%3DGrudnik%26aufirst%3DP.%26aulast%3DMagiera%26aufirst%3DK.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DT%25C3%25B6rner%26aufirst%3DR.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DDomling%26aufirst%3DA.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520death-ligand%25201%2520%2528PD-1%252FPD-L1%2529%2520interaction%2520via%2520transiently%2520induced%2520protein%2520states%2520and%2520dimerization%2520of%2520PD-L1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5857%26epage%3D5867%26doi%3D10.1021%2Facs.jmedchem.7b00293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachota, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szelazek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudnik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krzanik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyrc, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dömling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">72167</span>– <span class="NLM_lpage">72181</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.20050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.18632%2Foncotarget.20050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=29069777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A280%3ADC%252BC1M7ksVKhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=72167-72181&author=L.+Skalniakauthor=K.+M.+Zakauthor=K.+Guzikauthor=K.+Magieraauthor=B.+Musielakauthor=M.+Pachotaauthor=B.+Szelazekauthor=J.+Kocikauthor=P.+Grudnikauthor=M.+Tomalaauthor=S.+Krzanikauthor=K.+Pyrcauthor=A.+D%C3%B6mlingauthor=G.+Dubinauthor=T.+A.+Holak&title=Small-molecule+inhibitors+of+PD-1%2FPD-L1+immune+checkpoint+alleviate+the+PD-L1-induced+exhaustion+of+T-cells&doi=10.18632%2Foncotarget.20050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells</span></div><div class="casAuthors">Skalniak Lukasz; Guzik Katarzyna; Magiera Katarzyna; Musielak Bogdan; Kocik Justyna; Tomala Marcin; Holak Tad A; Zak Krzysztof M; Pachota Magdalena; Szelazek Bozena; Grudnik Przemyslaw; Krzanik Sylwia; Pyrc Krzysztof; Dubin Grzegorz; Zak Krzysztof M; Pachota Magdalena; Szelazek Bozena; Grudnik Przemyslaw; Krzanik Sylwia; Pyrc Krzysztof; Dubin Grzegorz; Domling Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">72167-72181</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Antibodies targeting the PD-1/PD-L1 immune checkpoint achieved spectacular success in anticancer therapy in the recent years.  In contrast, no small molecules with cellular activity have been reported so far.  Here we provide evidence that small molecules are capable of alleviating the PD-1/PD-L1 immune checkpoint-mediated exhaustion of Jurkat T-lymphocytes.  The two optimized small-molecule inhibitors of the PD-1/PD-L1 interaction, BMS-1001 and BMS-1166, developed by Bristol-Myers Squibb, bind to human PD-L1 and block its interaction with PD-1, when tested on isolated proteins.  The compounds present low toxicity towards tested cell lines and block the interaction of soluble PD-L1 with the cell surface-expressed PD-1.  As a result, BMS-1001 and BMS-1166 alleviate the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes.  Moreover, the compounds were effective in attenuating the inhibitory effect of the cell surface-associated PD-L1.  We also determined the X-ray structures of the complexes of BMS-1001 and BMS-1166 with PD-L1, which revealed features that may be responsible for increased potency of the compounds compared to their predecessors.  Further development may lead to the design of an anticancer therapy based on the orally delivered immune checkpoint inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSnxbjAjsdnFCCEBeYuoi7AfW6udTcc2eZ6LQkqVWZmr7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7ksVKhsw%253D%253D&md5=0b70c6e7aca2f13919bfbb2a47b2e57f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.20050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.20050%26sid%3Dliteratum%253Aachs%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DZak%26aufirst%3DK.%2BM.%26aulast%3DGuzik%26aufirst%3DK.%26aulast%3DMagiera%26aufirst%3DK.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DPachota%26aufirst%3DM.%26aulast%3DSzelazek%26aufirst%3DB.%26aulast%3DKocik%26aufirst%3DJ.%26aulast%3DGrudnik%26aufirst%3DP.%26aulast%3DTomala%26aufirst%3DM.%26aulast%3DKrzanik%26aufirst%3DS.%26aulast%3DPyrc%26aufirst%3DK.%26aulast%3DD%25C3%25B6mling%26aufirst%3DA.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520PD-1%252FPD-L1%2520immune%2520checkpoint%2520alleviate%2520the%2520PD-L1-induced%2520exhaustion%2520of%2520T-cells%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D72167%26epage%3D72181%26doi%3D10.18632%2Foncotarget.20050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel resorcinol dibenzyl ethers targeting the programmed cell death-1/programmed cell death-ligand 1 interaction as potential anticancer agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">8338</span>– <span class="NLM_lpage">8358</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00574</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00574" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtl2rsrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=8338-8358&author=B.+Chengauthor=Y.+Renauthor=X.+Niuauthor=W.+Wangauthor=S.+Wangauthor=Y.+Tuauthor=S.+Liuauthor=J.+Wangauthor=D.+Yangauthor=G.+Liaoauthor=J.+Chen&title=Discovery+of+novel+resorcinol+dibenzyl+ethers+targeting+the+programmed+cell+death-1%2Fprogrammed+cell+death-ligand+1+interaction+as+potential+anticancer+agents&doi=10.1021%2Facs.jmedchem.0c00574"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents</span></div><div class="casAuthors">Cheng, Binbin; Ren, Yichang; Niu, Xiaoge; Wang, Wei; Wang, Shuanghu; Tu, Yingfeng; Liu, Shuwen; Wang, Jin; Yang, Deying; Liao, Guochao; Chen, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">8338-8358</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel small mol. compds. based on various scaffolds including chalcone, flavonoid, and resorcinol dibenzyl ether were designed and tested for their inhibitory activity against the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 (PD-1/PD-L1) pathway.  Among them, compd. NP19(I) inhibited the human PD-1/PD-L1 interaction with IC50 values of 12.5 nM in homogeneous time-resolved fluorescence (HTRF) binding assays.  In addn., NP19 dose-dependently elevated IFN-γ prodn. in a coculture model of Hep3B/OS-8/hPD-L1 and CD3 T cells.  Furthermore, NP19 displayed significant in vivo antitumor efficacy in two different mouse models of cancer (a melanoma B16-F10 tumor model and an H22 hepatoma tumor model).  Moreover, H&E staining and flow cytometry data suggested that NP19 activated the immune microenvironment in the tumor, which may contribute to its antitumor effects.  This work shows NP19 is a promising lead compd. for further development as a new generation of small mol. inhibitors targeting the PD-1/PD-L1 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruD5Zp9HM0jrVg90H21EOLACvtfcHk0lh3DFejg_P6tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtl2rsrfL&md5=a1f6b3b4c440a7152ed8194ad842370f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00574%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DB.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DNiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DLiao%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520novel%2520resorcinol%2520dibenzyl%2520ethers%2520targeting%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520cell%2520death-ligand%25201%2520interaction%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D8338%26epage%3D8358%26doi%3D10.1021%2Facs.jmedchem.0c00574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">111856</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111856</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1016%2Fj.ejmech.2019.111856" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=31734021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFOmu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2020&pages=111856&author=M.+Qinauthor=Q.+Caoauthor=X.+Wuauthor=C.+Liuauthor=S.+Zhengauthor=H.+Xieauthor=Y.+Tianauthor=J.+Xieauthor=Y.+Zhaoauthor=Y.+Houauthor=X.+Zhangauthor=B.+Xuauthor=H.+Zhangauthor=X.+Wang&title=Discovery+of+the+programmed+cell+death-1%2Fprogrammed+cell+death-ligand+1+interaction+inhibitors+bearing+an+indoline+scaffold&doi=10.1016%2Fj.ejmech.2019.111856"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold</span></div><div class="casAuthors">Qin, Mingze; Cao, Qi; Wu, Xia; Liu, Chunyang; Zheng, Shuaishuai; Xie, Hongbo; Tian, Ye; Xie, Jun; Zhao, Yanfang; Hou, Yunlei; Zhang, Xian; Xu, Boxuan; Zhang, Haotian; Wang, Xiaobo</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111856</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy.  Here, a novel series of indoline-contg. compds. were developed, among which, A13 was identified as the most promising PD-1/PD-L1 pathway inhibitor.  At the biochem. level, A13 demonstrated strong inhibition of the PD-1/PD-L1 interaction, with an IC50 of 132.8 nM.  Notably, it exhibited outstanding immunoregulatory activity, and significantly elevated interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, without significant toxic effect.  Therefore, A13 could be employed as a suitable lead compd. for further design of non-peptide inhibitors targeting the PD-1/PD-L1 interaction.  In addn., the preliminary structure-activity relationships of these new indoline compds. were investigated in this study, providing valuable information for future drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7nYUI852jyLVg90H21EOLACvtfcHk0lh3DFejg_P6tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFOmu7zN&md5=b757929dd24437bb5af585e73a884a51</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111856&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111856%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520cell%2520death-ligand%25201%2520interaction%2520inhibitors%2520bearing%2520an%2520indoline%2520scaffold%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D186%26spage%3D111856%26doi%3D10.1016%2Fj.ejmech.2019.111856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RajanBabu, T. V.</span></span> <span> </span><span class="NLM_article-title">Asymmetric hydrovinylation of vinylindoles. A facile route to cyclopenta[<i>g</i>]indole natural products (+)-<i>cis</i>-trikentrin A and (+)-<i>cis</i>-trikentrin B</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">5496</span>– <span class="NLM_lpage">5499</span>, <span class="refDoi"> DOI: 10.1021/ja3004733</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja3004733" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVChtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=5496-5499&author=W.+Liuauthor=H.+J.+Limauthor=T.+V.+RajanBabu&title=Asymmetric+hydrovinylation+of+vinylindoles.+A+facile+route+to+cyclopenta%5Bg%5Dindole+natural+products+%28%2B%29-cis-trikentrin+A+and+%28%2B%29-cis-trikentrin+B&doi=10.1021%2Fja3004733"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric Hydrovinylation of Vinylindoles. A Facile Route to Cyclopenta[g]indole Natural Products (+)-cis-Trikentrin A and (+)-cis-Trikentrin B</span></div><div class="casAuthors">Liu, Wang; Lim, Hwan Jung; RajanBabu, T. V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5496-5499</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Vinylindoles, e.g., I, undergo Ni(II)-catalyzed asym. hydrovinylation under very mild conditions (-78 °C, 1 atm ethylene, 4 mol % catalyst) to give the corresponding 2-but-3-enyl derivs., e.g., II, in excellent yields and enantioselectivities.  Hydroboration of the alkene and oxidn. to an acid, followed by Friedel-Crafts annulation, gives an indole-annulated cyclopentanone that is a suitable precursor for the syntheses of cis-trikentrins and all known herbindoles.  For example, the cyclopentanone III from 4-ethyl-7-vinylindole is converted into (+)-cis-trikentrin A (IV) in four steps (Wittig reaction, alkene isomerization, diastereoselective hydrogenation, and nitrogen deprotection).  The previous synthesis of this mol. from (S)-(-)-malic acid involved more than 20 steps and a preparative HPLC sepn. of diastereomeric intermediates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtmiP9vM7LZrVg90H21EOLACvtfcHk0li4hzfKn9gNuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVChtrY%253D&md5=6cad69602693d02250ee2cd869f657e9</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fja3004733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja3004733%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLim%26aufirst%3DH.%2BJ.%26aulast%3DRajanBabu%26aufirst%3DT.%2BV.%26atitle%3DAsymmetric%2520hydrovinylation%2520of%2520vinylindoles.%2520A%2520facile%2520route%2520to%2520cyclopenta%255Bg%255Dindole%2520natural%2520products%2520%2528%252B%2529-cis-trikentrin%2520A%2520and%2520%2528%252B%2529-cis-trikentrin%2520B%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D5496%26epage%3D5499%26doi%3D10.1021%2Fja3004733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Shen, B.</span>; <span class="NLM_string-name">Li, J.</span>; <span class="NLM_string-name">Li, Z.</span>; <span class="NLM_string-name">Liu, K.</span>; <span class="NLM_string-name">Zhang, F.</span>; <span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic compounds as immunomodulators</span>. <span class="NLM_patent">US20170107216 A1</span>, Apr 20, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=L.+Wu&author=B.+Shen&author=J.+Li&author=Z.+Li&author=K.+Liu&author=F.+Zhang&author=W.+Yao&title=Heterocyclic+compounds+as+immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DL.%26atitle%3DHeterocyclic%2520compounds%2520as%2520immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kadam, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahma, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doshi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemmani, K. V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span> <span> </span><span class="NLM_article-title">Evaluation of thiazole containing biaryl analogs as diacylglycerol acyltransferase 1 (DGAT1) inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">347</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1016%2Fj.ejmech.2013.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=23735282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFeltrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=337-347&author=K.+S.+Kadamauthor=R.+D.+Jadhavauthor=S.+Kandreauthor=T.+Guhaauthor=M.+M.+K.+Reddyauthor=M.+K.+Brahmaauthor=N.+J.+Deshmukhauthor=A.+Dixitauthor=L.+Doshiauthor=S.+Srinivasanauthor=J.+Devleauthor=A.+Damreauthor=K.+V.+S.+Nemmaniauthor=A.+Gupteauthor=R.+Sharma&title=Evaluation+of+thiazole+containing+biaryl+analogs+as+diacylglycerol+acyltransferase+1+%28DGAT1%29+inhibitors&doi=10.1016%2Fj.ejmech.2013.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of thiazole containing biaryl analogs as diacylglycerol acyltransferase 1 (DGAT1) inhibitors</span></div><div class="casAuthors">Kadam, Kishorkumar S.; Jadhav, Ravindra D.; Kandre, Shivaji; Guha, Tandra; Reddy, M. Mahesh Kumar; Brahma, Manoja K.; Deshmukh, Nitin J.; Dixit, Amol; Doshi, Lalit; Srinivasan, Shaila; Devle, Jayendra; Damre, Anagha; Nemmani, Kumar V. S.; Gupte, Amol; Sharma, Rajiv</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">337-347</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Biphenyl carboxylic acids, exemplified by compd. I, are known potent inhibitors of diacylglycerol acyltransferase, DGAT1, an enzyme involved in the final committed step of triglyceride biosynthesis.  We have synthesized and evaluated 2-phenylthiazole, 4-phenylthiazole, and 5-phenylthiazole analogs as DGAT1 inhibitors.  The 5-phenylthiazole series exhibited potent DGAT1 inhibition when evaluated using an in vitro enzymic assay and an in vivo fat tolerance test in mice.  Compd. II (IC50 = 23 nM) exhibiting promising oral pharmacokinetic parameters (AUCinf = 7058 ng*h/mL, T1/2 = 0.83 h) coupled with 87 percent redn. of plasma triglycerides in vivo may serve as a lead for developing newer anti-obesity agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIKdn-LE4fK7Vg90H21EOLACvtfcHk0lj0sLfZxylHZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFeltrvI&md5=f6d90d63f8bfb63f2a171f6c1b125767</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DKadam%26aufirst%3DK.%2BS.%26aulast%3DJadhav%26aufirst%3DR.%2BD.%26aulast%3DKandre%26aufirst%3DS.%26aulast%3DGuha%26aufirst%3DT.%26aulast%3DReddy%26aufirst%3DM.%2BM.%2BK.%26aulast%3DBrahma%26aufirst%3DM.%2BK.%26aulast%3DDeshmukh%26aufirst%3DN.%2BJ.%26aulast%3DDixit%26aufirst%3DA.%26aulast%3DDoshi%26aufirst%3DL.%26aulast%3DSrinivasan%26aufirst%3DS.%26aulast%3DDevle%26aufirst%3DJ.%26aulast%3DDamre%26aufirst%3DA.%26aulast%3DNemmani%26aufirst%3DK.%2BV.%2BS.%26aulast%3DGupte%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DR.%26atitle%3DEvaluation%2520of%2520thiazole%2520containing%2520biaryl%2520analogs%2520as%2520diacylglycerol%2520acyltransferase%25201%2520%2528DGAT1%2529%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D65%26spage%3D337%26epage%3D347%26doi%3D10.1016%2Fj.ejmech.2013.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01958&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative small-molecule inhibitors of the PD-1/PD-L1 interaction.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01958&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compound<b>s A1</b>, <b>A2</b>, <b>A5</b>, and <b>A6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01958&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 5-formylthiophene-2-carboxylic acid or 2-bromothiazole-5-carboxylic acid, HATU, DIPEA, DMF, rt., 3 h, 62–73%; (b) appropriate amine, AcOH, NaBH<sub>3</sub>CN, DCM/MeOH (1/1), rt., 9–16 h, 9–22%; (c) tributyl(vinyl)stannane, Pd(PPh<sub>3</sub>)<sub>4</sub>, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O (3/1), 100 °C, 2 h, 53%; (d) K<sub>2</sub>OsO<sub>4</sub>·2H<sub>2</sub>O, NaIO<sub>4</sub>, 1,4-dioxane/H<sub>2</sub>O (5/1), rt., 2 h, 86%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>A7</b>–<b>15</b> and <b>A34</b>–<b>36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01958&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2-bromomalonaldehyde, DME, rt., 10 h, 51%; (b) ethane-1,2-diol, TsOH·H<sub>2</sub>O, toluene, 110 °C, 5 h, 76%; (c) LiOH, THF/H<sub>2</sub>O (4/1), rt., 2 h, 45%; (d) 4-bromoindoline, HATU, DIPEA, DMF, rt., 3 h, 77%; (e) TsOH·H<sub>2</sub>O, acetone/H<sub>2</sub>O (3/2), 70 °C, 4 h, 81%; (f) 2-aminoethan-1-ol, AcOH, NaBH<sub>3</sub>CN, DCM/MeOH (1/1), rt., 12 h, 35%; (g) aryl borate, PdCl<sub>2</sub>(dppf), Cs<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O (3/1), 70–100 °C, 4–12 h, 5–16%; (h) appropriate amine, AcOH, NaBH<sub>3</sub>CN, DCM/MeOH (1/1), rt., 13–16 h, 6–23%, or <span class="smallcaps smallerCapital">l</span>-proline, NaBH(OAc)<sub>3</sub>, DCM, reflux, 2 h, 16%.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>A3</b>, <b>A4</b>, and <b>A16</b>–<b>33</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01958&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>15</b>, HATU, DIPEA, DMF, rt., 3–4 h, 76–82%; (b) TsOH·H<sub>2</sub>O, acetone/H<sub>2</sub>O (3/2), 70 °C, 3–5 h, 63–79%; (c) appropriate amine, AcOH, NaBH<sub>3</sub>CN, DCM/MeOH (1/1), rt., 8–16 h, 6–23%, or appropriate amine, NaBH(OAc)<sub>3</sub>, DCM, reflux, 2–6 h, 7–26%.</p></p></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Effects of selected compounds on IFN-γ secretion in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3<sup>+</sup> T cells. The data are presented as mean ± SEM, *<i>p</i> < 0.05 and **<i>p</i> < 0.01 vs control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01958&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effects of (A) anti-PD-L1 mAb and (B) <b>A30</b> and <b>1</b> on T-cell proliferation repressed by PD-1 activation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01958&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <i>In vivo</i> antitumor activity of <b>A30</b> in a mouse 4T1 breast carcinoma model. (A) Growth curve of implanted tumors during the treatment period. (B) Changes in the body weight of mice during the treatment period. The data are shown as mean ± SD, **<i>p</i> < 0.01 and ***<i>p</i> < 0.001 vs control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01958&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <i>In vivo</i> antitumor activity of <b>A30</b> in CT26/PD-L1 and CT26/vector models. (A) Growth curve of implanted tumors during the treatment period. (B) Changes in the body weight of mice during the treatment period. The data are shown as mean ± SD, ***<i>p</i> < 0.001 CT26/PD-L1 control group vs CT26/vector control and CT26/PD-L1 <b>A30</b>-treated groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01958&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effects of <b>A30</b> on infiltration and function of TILs in CT26/PD-L1 mice. (A) Proportion of TILs. (B) Proportion of CD8<sup>+</sup> T cells in CD3<sup>+</sup> T cells. (C) Proportion of IFN-γ<sup>+</sup> CD3<sup>+</sup> T cells. (D) Proportion of IL-2<sup>+</sup> CD3<sup>+</sup> T cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01958&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/medium/jm0c01958_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Molecular docking analysis of <b>A30</b> with dimeric PD-L1 protein. (B) Superposition of <b>A30</b> and BMS-200 in the binding site formed by dimeric PD-L1. The crystal structure of the PD-L1 dimer was taken from the RCSB Protein Data Bank (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5N2F">5N2F</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01958/20210506/images/large/jm0c01958_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01958&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i86">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38615" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38615" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 26 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Constantinidou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alifieris, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trafalis, D. T.</span></span> <span> </span><span class="NLM_article-title">Targeting programmed cell death-1 (PD-1) and ligand (PD-L1): a new era in cancer active immunotherapy</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>194</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">106</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2018.09.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1016%2Fj.pharmthera.2018.09.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=30268773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVGisbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2019&pages=84-106&author=A.+Constantinidouauthor=C.+Alifierisauthor=D.+T.+Trafalis&title=Targeting+programmed+cell+death-1+%28PD-1%29+and+ligand+%28PD-L1%29%3A+a+new+era+in+cancer+active+immunotherapy&doi=10.1016%2Fj.pharmthera.2018.09.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy</span></div><div class="casAuthors">Constantinidou, Anastasia; Alifieris, Constantinos; Trafalis, Dimitrios T.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">84-106</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Improved understanding of the immune system and its role in cancer development and progression has led to impressive advances in the field of cancer immunotherapy over the last decade.  While the field is rapidly evolving and the list of drugs receiving regulatory approval for the treatment of various cancers is fast growing, the group of PD1- PDL-1 inhibitors is establishing a leading role amongst immunomodulatory agents.  PD1- PDL-1 inhibitors act against pathways involved in adaptive immune suppression resulting in immune checkpoint blockade.  Within the last four years two PD-1 and three PD-L1 inhibitors have been utilized in clin. practice against a variety of malignancies.  Focus was initially placed on targeting cancers considered immunogenic such as melanoma, renal and lung cancers but subsequently the application expanded to include amongst others Hodgkin Lymphoma, urothelial as well as head and neck cancer.  This article provides a comprehensive review of the early and late phase trials that led to the regulatory approval of all five PD1- PDL-1 inhibitors in the corresponding cancer types.  It presents available data on the combinations of PD1- PDL-1 inhibitors with other therapies (immunotherapy, targeted therapy and chemotherapy), the toxicity profile of the PD1- PDL-1 inhibitors and ongoing trials testing the efficacy of these agents in cancer types beyond those that have been addressed already.  Finally, current and future challenges in the application of PD-1 and PD-L1 inhibitors are discussed with emphasis on the role of predictive biomarkers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNoSdhwOBHPbVg90H21EOLACvtfcHk0lgtuy_lR8q4Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVGisbvL&md5=6f9a8f63f7cc9eb59d9454fb6942ae8d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2018.09.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2018.09.008%26sid%3Dliteratum%253Aachs%26aulast%3DConstantinidou%26aufirst%3DA.%26aulast%3DAlifieris%26aufirst%3DC.%26aulast%3DTrafalis%26aufirst%3DD.%2BT.%26atitle%3DTargeting%2520programmed%2520cell%2520death-1%2520%2528PD-1%2529%2520and%2520ligand%2520%2528PD-L1%2529%253A%2520a%2520new%2520era%2520in%2520cancer%2520active%2520immunotherapy%26jtitle%3DPharmacol.%2520Ther.%26date%3D2019%26volume%3D194%26spage%3D84%26epage%3D106%26doi%3D10.1016%2Fj.pharmthera.2018.09.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourque, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitz, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malenkovich, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouser, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreno, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span> <span> </span><span class="NLM_article-title">Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">1027</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1084/jem.192.7.1027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1084%2Fjem.192.7.1027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=11015443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntFSlt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2000&pages=1027-1034&author=G.+J.+Freemanauthor=A.+J.+Longauthor=Y.+Iwaiauthor=K.+Bourqueauthor=T.+Chernovaauthor=H.+Nishimuraauthor=L.+J.+Fitzauthor=N.+Malenkovichauthor=T.+Okazakiauthor=M.+C.+Byrneauthor=H.+F.+Hortonauthor=L.+Fouserauthor=L.+Carterauthor=V.+Lingauthor=M.+R.+Bowmanauthor=B.+M.+Carrenoauthor=M.+Collinsauthor=C.+R.+Woodauthor=T.+Honjo&title=Engagement+of+the+PD-1+immunoinhibitory+receptor+by+a+novel+B7+family+member+leads+to+negative+regulation+of+lymphocyte+activation&doi=10.1084%2Fjem.192.7.1027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation</span></div><div class="casAuthors">Freeman, Gordon J.; Long, Andrew J.; Iwai, Yoshiko; Bourque, Karen; Chernova, Tatyana; Nishimura, Hiroyuki; Fitz, Lori J.; Malenkovich, Nelly; Okazaki, Taku; Byrne, Michael C.; Horton, Heidi F.; Fouser, Lynette; Carter, Laura; Ling, Vincent; Bowman, Michael R.; Carreno, Beatriz M.; Collins, Mary; Wood, Clive R.; Honjo, Tasuku</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1027-1034</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">PD-1 is an immunoinhibitory receptor expressed by activated T cells, B cells, and myeloid cells.  Mice deficient in PD-1 exhibit a breakdown of peripheral tolerance and demonstrate multiple autoimmune features.  The authors report here that the ligand of PD-1 (PD-L1) is a member of the B7 gene family.  Engagement of PD-1 by PD-L1 leads to the inhibition of T cell receptor-mediated lymphocyte proliferation and cytokine secretion.  In addn., PD-1 signaling can inhibit at least suboptimal levels of CD28-mediated costimulation.  PD-L1 is expressed by antigen-presenting cells, including human peripheral blood monocytes stimulated with interferon γ, and activated human and murine dendritic cells.  In addn., PD-L1 is expressed in nonlymphoid tissues such as heart and lung.  The relative levels of inhibitory PD-L1 and costimulatory B7-1/B7-2 signals on antigen-presenting cells may det. the extent of T cell activation and consequently the threshold between tolerance and autoimmunity.  PD-L1 expression on nonlymphoid tissues and its potential interaction with PD-1 may subsequently det. the extent of immune responses at sites of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZIeEjiecqBbVg90H21EOLACvtfcHk0liSFYAjp-aX_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntFSlt7o%253D&md5=bc1499033282cd9dbfa396a4e2697f6e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1084%2Fjem.192.7.1027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.192.7.1027%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DLong%26aufirst%3DA.%2BJ.%26aulast%3DIwai%26aufirst%3DY.%26aulast%3DBourque%26aufirst%3DK.%26aulast%3DChernova%26aufirst%3DT.%26aulast%3DNishimura%26aufirst%3DH.%26aulast%3DFitz%26aufirst%3DL.%2BJ.%26aulast%3DMalenkovich%26aufirst%3DN.%26aulast%3DOkazaki%26aufirst%3DT.%26aulast%3DByrne%26aufirst%3DM.%2BC.%26aulast%3DHorton%26aufirst%3DH.%2BF.%26aulast%3DFouser%26aufirst%3DL.%26aulast%3DCarter%26aufirst%3DL.%26aulast%3DLing%26aufirst%3DV.%26aulast%3DBowman%26aufirst%3DM.%2BR.%26aulast%3DCarreno%26aufirst%3DB.%2BM.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DC.%2BR.%26aulast%3DHonjo%26aufirst%3DT.%26atitle%3DEngagement%2520of%2520the%2520PD-1%2520immunoinhibitory%2520receptor%2520by%2520a%2520novel%2520B7%2520family%2520member%2520leads%2520to%2520negative%2520regulation%2520of%2520lymphocyte%2520activation%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2000%26volume%3D192%26spage%3D1027%26epage%3D1034%26doi%3D10.1084%2Fjem.192.7.1027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butte, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keir, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phamduy, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span> <span> </span><span class="NLM_article-title">Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2007.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1016%2Fj.immuni.2007.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=17629517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosFeqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=111-122&author=M.+J.+Butteauthor=M.+E.+Keirauthor=T.+B.+Phamduyauthor=A.+H.+Sharpeauthor=G.+J.+Freeman&title=Programmed+death-1+ligand+1+interacts+specifically+with+the+B7-1+costimulatory+molecule+to+inhibit+T+cell+responses&doi=10.1016%2Fj.immuni.2007.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Programmed Death-1 Ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses</span></div><div class="casAuthors">Butte, Manish J.; Keir, Mary E.; Phamduy, Theresa B.; Sharpe, Arlene H.; Freeman, Gordon J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-122</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Pathways in the B7:CD28 family of costimulatory mols. regulate T cell activation and tolerance.  B7-dependent responses in Cd28-/- Ctla4-/- T cells together with reports of stimulatory and inhibitory functions for Programmed Death-1 Ligand 1 or 2 mols. (PD-L1 or PD-L2) have suggested addnl. receptors for these B7 family members.  The authors show that B7-1 and PD-L1 interacted with affinity intermediate to that of B7-1:CD28 and B7-1:CTLA-4.  The PD-L1:B7-1 interface overlapped with the B7-1:CTLA-4 and PD-L1:PD-1 (Programmed Death-1) interfaces.  T cell activation and cytokine prodn. were inhibited by the interaction of B7-1 with PD-L1.  The responses of PD-1-deficient vs. PD-1,B7-1 double-deficient T cells to PD-L1 and of CD28,CTLA-4 double-deficient vs. CD28,CTLA-4,PD-L1 triple-deficient T cells to B7-1 demonstrated that PD-L1 and B7-1 interact specifically to inhibit T cell activation.  The authors' findings point to a substantial bidirectional inhibitory interaction between B7-1 and PD-L1 and add an addnl. dimension to immunoregulatory functions of the B7:CD28 family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMR5dpv_Vr5LVg90H21EOLACvtfcHk0liSFYAjp-aX_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosFeqtrk%253D&md5=8fabef0e1244a1d356378867d92a248e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2007.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2007.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DButte%26aufirst%3DM.%2BJ.%26aulast%3DKeir%26aufirst%3DM.%2BE.%26aulast%3DPhamduy%26aufirst%3DT.%2BB.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26atitle%3DProgrammed%2520death-1%2520ligand%25201%2520interacts%2520specifically%2520with%2520the%2520B7-1%2520costimulatory%2520molecule%2520to%2520inhibit%2520T%2520cell%2520responses%26jtitle%3DImmunity%26date%3D2007%26volume%3D27%26spage%3D111%26epage%3D122%26doi%3D10.1016%2Fj.immuni.2007.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dermani, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samadi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahmani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlan, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najafi, R.</span></span> <span> </span><span class="NLM_article-title">PD-1/PD-L1 immune checkpoint: potential target for cancer therapy</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_fpage">1313</span>– <span class="NLM_lpage">1325</span>, <span class="refDoi"> DOI: 10.1002/jcp.27172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1002%2Fjcp.27172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=30191996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1KjsL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=1313-1325&author=F.+K.+Dermaniauthor=P.+Samadiauthor=G.+Rahmaniauthor=A.+K.+Kohlanauthor=R.+Najafi&title=PD-1%2FPD-L1+immune+checkpoint%3A+potential+target+for+cancer+therapy&doi=10.1002%2Fjcp.27172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy</span></div><div class="casAuthors">Dermani, Fatemeh K.; Samadi, Pouria; Rahmani, Golebagh; Kohlan, Alisa K.; Najafi, Rezvan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1313-1325</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Recent studies show that cancer cells are sometimes able to evade the host immunity in the tumor microenvironment.  Cancer cells can express high levels of immune inhibitory signaling proteins.  One of the most crit. checkpoint pathways in this system is a tumor-induced immune suppression (immune checkpoint) mediated by the programmed cell death protein 1 (PD-1) and its ligand, programmed death ligand 1 (PD-L1).  PD-1 is highly expressed by activated T cells, B cells, dendritic cells, and natural killer cells, whereas PD-L1 is expressed on several types of tumor cells.  Many studies have shown that blocking the interaction between PD-1 and PD-L1 enhances the T-cell response and mediates antitumor activity.  In this review, we highlight a brief overview of the mol. and biochem. events that are regulated by the PD-1 and PD-L1 interaction in various cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBszcahhx8VLVg90H21EOLACvtfcHk0lim8qgeLeEUYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1KjsL7F&md5=b8b9b458baa4e36d8a163ae4cd2845be</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fjcp.27172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.27172%26sid%3Dliteratum%253Aachs%26aulast%3DDermani%26aufirst%3DF.%2BK.%26aulast%3DSamadi%26aufirst%3DP.%26aulast%3DRahmani%26aufirst%3DG.%26aulast%3DKohlan%26aufirst%3DA.%2BK.%26aulast%3DNajafi%26aufirst%3DR.%26atitle%3DPD-1%252FPD-L1%2520immune%2520checkpoint%253A%2520potential%2520target%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2019%26spage%3D1313%26epage%3D1325%26doi%3D10.1002%2Fjcp.27172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span> <span> </span><span class="NLM_article-title">PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: new development and challenges</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>405</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2017.06.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1016%2Fj.canlet.2017.06.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=28688973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFCgsL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=405&publication_year=2017&pages=29-37&author=X.+Mengauthor=Y.+Liuauthor=J.+Zhangauthor=F.+Tengauthor=L.+Xingauthor=J.+Yu&title=PD-1%2FPD-L1+checkpoint+blockades+in+non-small+cell+lung+cancer%3A+new+development+and+challenges&doi=10.1016%2Fj.canlet.2017.06.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges</span></div><div class="casAuthors">Meng, Xiangjiao; Liu, Yanli; Zhang, Jianjun; Teng, Feifei; Xing, Ligang; Yu, Jinming</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">405</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29-37</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">PD-1/PD-L1 checkpoint blockades have dramatically changed the landscape for second-line treatment of non-small cell lung cancer (NSCLC).  Based on the promising results of Keynote-024 presented so far, pembrolizumab has been approved as first-line treatment for advanced PD-L1 pos. NSCLC patients.  However, overall response rate (ORR) is limited to PD-1/PD-L1 checkpoint blockades when used as single agent.  Combining with chemotherapy, anti-CTLA-4 antibodies, targeted therapy, radiotherapy or other treatment options is perceived as an appealing method aimed at achieving higher efficacy.  There are many clin. trials on going or finished assessing the efficacy and safety of the PD-1/PD-L1 blockades alone or combining with other approaches in first-line or second-line treatments.  A lot of challenges need to be overcome before PD-1/PD-L1 checkpoint blockades are widely used in the patients with NSCLC including the identification of optimal combination, treatment-related adverse effects, the high cost and lack of effective predictive markers.  In this review, we focus on outlining current clin. trials and challenges for future research of PD-1/PD-L1 pathway checkpoint blockades in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCJltkyVf6jbVg90H21EOLACvtfcHk0lim8qgeLeEUYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFCgsL7L&md5=a41e659833915b7d6fc6b715cfe84a57</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2017.06.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2017.06.033%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DTeng%26aufirst%3DF.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DJ.%26atitle%3DPD-1%252FPD-L1%2520checkpoint%2520blockades%2520in%2520non-small%2520cell%2520lung%2520cancer%253A%2520new%2520development%2520and%2520challenges%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D405%26spage%3D29%26epage%3D37%26doi%3D10.1016%2Fj.canlet.2017.06.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalbasi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">Tumour-intrinsic resistance to immune checkpoint blockade</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1038/s41577-019-0218-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1038%2Fs41577-019-0218-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=31570880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVOqurfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=25-39&author=A.+Kalbasiauthor=A.+Ribas&title=Tumour-intrinsic+resistance+to+immune+checkpoint+blockade&doi=10.1038%2Fs41577-019-0218-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tumour-intrinsic resistance to immune checkpoint blockade</span></div><div class="casAuthors">Kalbasi, Anusha; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-39</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  'Immune checkpoint blockade' for cancer describes the use of therapeutic antibodies that disrupt neg. immune regulatory checkpoints and unleash pre-existing antitumor immune responses.  Antibodies targeting the checkpoint mols. cytotoxic T lymphocyte antigen 4 (CTLA4), programmed cell death 1 (PD1) and PD1 ligand 1 (PD-L1) have had early success in the clinic, which has led to approval by the US Food and Drug Administration of multiple agents in several cancer types.  Yet, clinicians still have very limited tools to discriminate a priori patients who will and will not respond to treatment.  This has fuelled a wave of research into the mol. mechanisms of tumor-intrinsic resistance to immune checkpoint blockade, leading to the rediscovery of biol. processes crit. to antitumor immunity, namely interferon signalling and antigen presentation.  Other efforts have shed light on the immunol. implications of canonical cancer signalling pathways, such as WNT-β-catenin signalling, cell cycle regulatory signalling, mitogen-activated protein kinase signalling and pathways activated by loss of the tumor suppressor phosphoinositide phosphatase PTEN.  Here we review each of these mol. mechanisms of resistance and explore ongoing approaches to overcome resistance to immune checkpoint blockade and expand the spectrum of patients who can benefit from immune checkpoint blockade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0rmwAAmvFGbVg90H21EOLACvtfcHk0lim8qgeLeEUYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVOqurfM&md5=9ba5285a05c554b90760620c367547ef</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fs41577-019-0218-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41577-019-0218-4%26sid%3Dliteratum%253Aachs%26aulast%3DKalbasi%26aufirst%3DA.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DTumour-intrinsic%2520resistance%2520to%2520immune%2520checkpoint%2520blockade%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2020%26volume%3D20%26spage%3D25%26epage%3D39%26doi%3D10.1038%2Fs41577-019-0218-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazhenova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frampton, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzrock, R.</span></span> <span> </span><span class="NLM_article-title">Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2598</span>– <span class="NLM_lpage">2608</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-0386</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1158%2F1535-7163.MCT-17-0386" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=28835386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGisrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=2598-2608&author=A.+M.+Goodmanauthor=S.+Katoauthor=L.+Bazhenovaauthor=S.+P.+Patelauthor=G.+M.+Framptonauthor=V.+Millerauthor=P.+J.+Stephensauthor=G.+A.+Danielsauthor=R.+Kurzrock&title=Tumor+mutational+burden+as+an+independent+predictor+of+response+to+immunotherapy+in+diverse+cancers&doi=10.1158%2F1535-7163.MCT-17-0386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers</span></div><div class="casAuthors">Goodman, Aaron M.; Kato, Shumei; Bazhenova, Lyudmila; Patel, Sandip P.; Frampton, Garrett M.; Miller, Vincent; Stephens, Philip J.; Daniels, Gregory A.; Kurzrock, Razelle</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2598-2608</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Immunotherapy induces durable responses in a subset of patients with cancer.  High tumor mutational burden (TMB) may be a response biomarker for PD-1/PD-L1 blockade in tumors such as melanoma and non-small cell lung cancer (NSCLC).  Our aim was to examine the relationship between TMB and outcome in diverse cancers treated with various immunotherapies.  We reviewed data on 1,638 patients who had undergone comprehensive genomic profiling and had TMB assessment.  Immunotherapy-treated patients (N = 151) were analyzed for response rate (RR), progression-free survival (PFS), and overall survival (OS).  Higher TMB was independently assocd. with better outcome parameters (multivariable anal.).  The RR for patients with high (≥20 mutations/mb) vs. low to intermediate TMB was 22/38 (58%) vs. 23/113 (20%; P = 0.0001); median PFS, 12.8 mo vs. 3.3 mo (P ≤ 0.0001); median OS, not reached vs. 16.3 mo (P = 0.0036).  Results were similar when anti-PD-1/PD-L1 monotherapy was analyzed (N = 102 patients), with a linear correlation between higher TMB and favorable outcome parameters; the median TMB for responders vs. nonresponders treated with anti-PD-1/PD-L1 monotherapy was 18.0 vs. 5.0 mutations/mb (P < 0.0001).  Interestingly, anti-CTLA4/anti-PD-1/PD-L1 combinations vs. anti-PD-1/PD-L1 monotherapy was selected as a factor independent of TMB for predicting better RR (77% vs. 21%; P = 0.004) and PFS (P = 0.024).  Higher TMB predicts favorable outcome to PD-1/PD-L1 blockade across diverse tumors.  Benefit from dual checkpoint blockade did not show a similarly strong dependence on TMB.  Mol Cancer Ther; 16(11); 2598-608. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUwjFKpJPbjrVg90H21EOLACvtfcHk0lglgiDy56ioSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGisrvL&md5=47c40d69a862cc0077452e32fbc5ef53</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0386%26sid%3Dliteratum%253Aachs%26aulast%3DGoodman%26aufirst%3DA.%2BM.%26aulast%3DKato%26aufirst%3DS.%26aulast%3DBazhenova%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DS.%2BP.%26aulast%3DFrampton%26aufirst%3DG.%2BM.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DDaniels%26aufirst%3DG.%2BA.%26aulast%3DKurzrock%26aufirst%3DR.%26atitle%3DTumor%2520mutational%2520burden%2520as%2520an%2520independent%2520predictor%2520of%2520response%2520to%2520immunotherapy%2520in%2520diverse%2520cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D2598%26epage%3D2608%26doi%3D10.1158%2F1535-7163.MCT-17-0386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hodges, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatalica, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huse, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Groot, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overwijk, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spetzler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimberger, A. B.</span></span> <span> </span><span class="NLM_article-title">Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy</span>. <i>Neuro-Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1047</span>– <span class="NLM_lpage">1057</span>, <span class="refDoi"> DOI: 10.1093/neuonc/nox026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1093%2Fneuonc%2Fnox026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=28371827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFOmt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=1047-1057&author=T.+R.+Hodgesauthor=M.+Ottauthor=J.+Xiuauthor=Z.+Gatalicaauthor=J.+Swensenauthor=S.+Zhouauthor=J.+T.+Huseauthor=J.+De+Grootauthor=S.+Liauthor=W.+W.+Overwijkauthor=D.+Spetzlerauthor=A.+B.+Heimberger&title=Mutational+burden%2C+immune+checkpoint+expression%2C+and+mismatch+repair+in+glioma%3A+implications+for+immune+checkpoint+immunotherapy&doi=10.1093%2Fneuonc%2Fnox026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy</span></div><div class="casAuthors">Hodges, Tiffany R.; Ott, Martina; Xiu, Joanne; Gatalica, Zoran; Swensen, Jeff; Zhou, Shouhao; Huse, Jason T.; de Groot, John; Li, Shulin; Overwijk, Willem W.; Spetzler, David; Heimberger, Amy B.</div><div class="citationInfo"><span class="NLM_cas:title">Neuro-Oncology (Cary, NC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1047-1057</span>CODEN:
                <span class="NLM_cas:coden">NEURJR</span>;
        ISSN:<span class="NLM_cas:issn">1523-5866</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background.  Despite a multiplicity of clin. trials testing immune checkpoint inhibitors, the frequency of expression of potential predictive biomarkers is unknown in glioma.  Methods.  In this study, we profiled the frequency of shared biomarker phenotypes.  To clarify the relationships among tumor mutational load (TML), mismatch repair (MMR), and immune checkpoint expression, we profiled patients with glioma (n = 327), including glioblastoma (GBM) (n = 198), whose samples had been submitted for anal. from 2009 to 2016.  The calcn. algorithm for TML included nonsynonymous mutation counts per tumor, with germline mutations filtered out.  Immunohistochem. anal. and next-generation sequencing were used to det. tumor-infiltrating lymphocyte expression pos. for programmed cell death protein 1 (PD-1), PD ligand 1 (PD-L1) expression on tumor cells, MMR (MLH1, MSH2, MSH6, and PMS2) protein expression and mutations, and DNA polymerase epsilon (POLE) mutations.  Results.  High TML was only found in 3.5% of GBM patients (7 of 198) and was assocd. with the absence of protein expression of mutL homolog 1 (MLH1) (P = .0345), mutS homolog 2 (MSH2) (P = .0099), MSH6 (P = .0022), and postmeiotic segregation increased 2 (PMS2) (P = .0345) and the presence of DNA MMR mutations.  High and moderate TML GBMs did not have an enriched influx of CD8 + T cells, PD-1 + T cells, or tumor-expressed PD-L1.  IDH1 mutant gliomas were not enriched for high TML, PD-1 + T cells, or PD-L1 expression.  Conclusions.  To clarify the relationships among TML, MMR, and immune checkpoint expression, we profiled the frequency of shared biomarker phenotypes.  On the basis of a variety of potential biomarkers of response to immune checkpoints, only small subsets of glioma patients are likely to benefit from monotherapy immune checkpoint inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptvDAw21Yh-rVg90H21EOLACvtfcHk0lglgiDy56ioSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFOmt7zI&md5=abcfbec32be314e5404ffd76cd0b305f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnox026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnox026%26sid%3Dliteratum%253Aachs%26aulast%3DHodges%26aufirst%3DT.%2BR.%26aulast%3DOtt%26aufirst%3DM.%26aulast%3DXiu%26aufirst%3DJ.%26aulast%3DGatalica%26aufirst%3DZ.%26aulast%3DSwensen%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DHuse%26aufirst%3DJ.%2BT.%26aulast%3DDe%2BGroot%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DOverwijk%26aufirst%3DW.%2BW.%26aulast%3DSpetzler%26aufirst%3DD.%26aulast%3DHeimberger%26aufirst%3DA.%2BB.%26atitle%3DMutational%2520burden%252C%2520immune%2520checkpoint%2520expression%252C%2520and%2520mismatch%2520repair%2520in%2520glioma%253A%2520implications%2520for%2520immune%2520checkpoint%2520immunotherapy%26jtitle%3DNeuro-Oncol.%26date%3D2017%26volume%3D19%26spage%3D1047%26epage%3D1057%26doi%3D10.1093%2Fneuonc%2Fnox026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palakurthi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuraguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacharek, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zudaire, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonal, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhaneshwar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePeaux, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowaski, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrante, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">English, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khosla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rytlewski, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquerre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bittinger, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschmeier, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verona, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi, M. V.</span></span> <span> </span><span class="NLM_article-title">The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1457</span>– <span class="NLM_lpage">1471</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-18-0595</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1158%2F2326-6066.CIR-18-0595" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=31331945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFGjsLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=1457-1471&author=S.+Palakurthiauthor=M.+Kuraguchiauthor=S.+J.+Zacharekauthor=E.+Zudaireauthor=W.+Huangauthor=D.+M.+Bonalauthor=J.+Liuauthor=A.+Dhaneshwarauthor=K.+DePeauxauthor=M.+R.+Gowaskiauthor=D.+Baileyauthor=S.+N.+Reganauthor=E.+Ivanovaauthor=C.+Ferranteauthor=J.+M.+Englishauthor=A.+Khoslaauthor=A.+H.+Beckauthor=J.+A.+Rytlewskiauthor=C.+Sanderauthor=S.+Laquerreauthor=M.+A.+Bittingerauthor=P.+T.+Kirschmeierauthor=K.+Packmanauthor=P.+A.+Janneauthor=C.+Moyauthor=K.-K.+Wongauthor=R.+I.+Veronaauthor=M.+V.+Lorenzi&title=The+combined+effect+of+FGFR+inhibition+and+PD-1+blockade+promotes+tumor-intrinsic+induction+of+antitumor+immunity&doi=10.1158%2F2326-6066.CIR-18-0595"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity</span></div><div class="casAuthors">Palakurthi, Sangeetha; Kuraguchi, Mari; Zacharek, Sima J.; Zudaire, Enrique; Huang, Wei; Bonal, Dennis M.; Liu, Jeffrey; Dhaneshwar, Abha; DePeaux, Kristin; Gowaski, Martha R.; Bailey, Dyane; Regan, Samuel N.; Ivanova, Elena; Ferrante, Catherine; English, Jessie M.; Khosla, Aditya; Beck, Andrew H.; Rytlewski, Julie A.; Sanders, Catherine; Laquerre, Sylvie; Bittinger, Mark A.; Kirschmeier, Paul T.; Packman, Kathryn; Janne, Pasi A.; Moy, Christopher; Wong, Kwok-Kin; Verona, Raluca I.; Lorenzi, Matthew V.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1457-1471</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The success of targeted or immune therapies is often hampered by the emergence of resistance and/or clin. benefit in only a subset of patients.  We hypothesized that combining targeted therapy with immune modulation would show enhanced antitumor responses.  Here, we explored the combination potential of erdafitinib, a fibroblast growth factor receptor (FGFR) inhibitor under clin. development, with PD-1 blockade in an autochthonous FGFR2K660N/p53mut lung cancer mouse model.  Erdafitinib monotherapy treatment resulted in substantial tumor control but no significant survival benefit.  Although anti-PD-1 alone was ineffective, the erdafitinib and anti-PD-1 combination induced significant tumor regression and improved survival.  For both erdafitinib monotherapy and combination treatments, tumor control was accompanied by tumor-intrinsic, FGFR pathway inhibition, increased T-cell infiltration, decreased regulatory T cells, and downregulation of PD-L1 expression on tumor cell.  Treatment with erdafitinib decreased T-cell receptor (TCR) clonality, reflecting a broadening of the TCR repertoire induced by tumor cell death, whereas combination with anti-PD-1 led to increased TCR clonality, suggesting a more focused antitumor T-cell response.  Our results showed that the combination of erdafitinib and anti-PD-1 drives expansion of T-cell clones and immunol. changes in the tumor microenvironment to support enhanced antitumor immunity and survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpisqPTNzxu2rVg90H21EOLACvtfcHk0lglgiDy56ioSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFGjsLzE&md5=3b10f0132050a1951a9c8efb32b6933f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-18-0595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-18-0595%26sid%3Dliteratum%253Aachs%26aulast%3DPalakurthi%26aufirst%3DS.%26aulast%3DKuraguchi%26aufirst%3DM.%26aulast%3DZacharek%26aufirst%3DS.%2BJ.%26aulast%3DZudaire%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DBonal%26aufirst%3DD.%2BM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DDhaneshwar%26aufirst%3DA.%26aulast%3DDePeaux%26aufirst%3DK.%26aulast%3DGowaski%26aufirst%3DM.%2BR.%26aulast%3DBailey%26aufirst%3DD.%26aulast%3DRegan%26aufirst%3DS.%2BN.%26aulast%3DIvanova%26aufirst%3DE.%26aulast%3DFerrante%26aufirst%3DC.%26aulast%3DEnglish%26aufirst%3DJ.%2BM.%26aulast%3DKhosla%26aufirst%3DA.%26aulast%3DBeck%26aufirst%3DA.%2BH.%26aulast%3DRytlewski%26aufirst%3DJ.%2BA.%26aulast%3DSander%26aufirst%3DC.%26aulast%3DLaquerre%26aufirst%3DS.%26aulast%3DBittinger%26aufirst%3DM.%2BA.%26aulast%3DKirschmeier%26aufirst%3DP.%2BT.%26aulast%3DPackman%26aufirst%3DK.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DMoy%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DVerona%26aufirst%3DR.%2BI.%26aulast%3DLorenzi%26aufirst%3DM.%2BV.%26atitle%3DThe%2520combined%2520effect%2520of%2520FGFR%2520inhibition%2520and%2520PD-1%2520blockade%2520promotes%2520tumor-intrinsic%2520induction%2520of%2520antitumor%2520immunity%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2019%26volume%3D7%26spage%3D1457%26epage%3D1471%26doi%3D10.1158%2F2326-6066.CIR-18-0595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tran, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spielbauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Waes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, N. C.</span></span> <span> </span><span class="NLM_article-title">Cisplatin alters antitumor immunity and synergizes with PD-1/PD-L1 inhibition in head and neck squamous cell carcinoma</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1141</span>– <span class="NLM_lpage">1151</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-17-0235</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1158%2F2326-6066.CIR-17-0235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=29097421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWhsbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=1141-1151&author=L.+Tranauthor=C.+T.+Allenauthor=R.+Xiaoauthor=E.+Mooreauthor=R.+Davisauthor=S.-J.+Parkauthor=K.+Spielbauerauthor=C.+Van+Waesauthor=N.+C.+Schmitt&title=Cisplatin+alters+antitumor+immunity+and+synergizes+with+PD-1%2FPD-L1+inhibition+in+head+and+neck+squamous+cell+carcinoma&doi=10.1158%2F2326-6066.CIR-17-0235"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma</span></div><div class="casAuthors">Tran, Linda; Allen, Clint T.; Xiao, Roy; Moore, Ellen; Davis, Ruth; Park, So-Jin; Spielbauer, Katie; Van Waes, Carter; Schmitt, Nicole C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1141-1151</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Head and neck squamous cell carcinoma (HNSCC) has been treated for decades with cisplatin chemotherapy, and anti-PD-1 immunotherapy has recently been approved for the treatment of this disease.  However, preclin. studies of how antitumor immunity in HNSCC is affected by cisplatin alone or in combination with immunotherapies are lacking.  Here, we show that sublethal doses of cisplatin may enhance antigen presentation and T-cell killing in vitro, though cisplatin also upregulates tumor cell expression of PD-L1 and may impair T-cell function at higher doses.  In a syngeneic mouse model of HNSCC, concurrent use of cisplatin and anti-PD-L1/PD-1 delayed tumor growth and enhanced survival without significantly reducing the no. or function of tumor-infiltrating immune cells or increasing cisplatin-induced toxicities.  These results suggest that moderate doses of cisplatin may enhance antitumor immunity by mechanisms other than direct tumor cell killing, which may be further enhanced by anti-PD-L1/PD-1 therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtMQSckrn-BbVg90H21EOLACvtfcHk0lhLWPecNoxPTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWhsbrL&md5=71226b2e8ad3517547145cd286884453</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-17-0235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-17-0235%26sid%3Dliteratum%253Aachs%26aulast%3DTran%26aufirst%3DL.%26aulast%3DAllen%26aufirst%3DC.%2BT.%26aulast%3DXiao%26aufirst%3DR.%26aulast%3DMoore%26aufirst%3DE.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DPark%26aufirst%3DS.-J.%26aulast%3DSpielbauer%26aufirst%3DK.%26aulast%3DVan%2BWaes%26aufirst%3DC.%26aulast%3DSchmitt%26aufirst%3DN.%2BC.%26atitle%3DCisplatin%2520alters%2520antitumor%2520immunity%2520and%2520synergizes%2520with%2520PD-1%252FPD-L1%2520inhibition%2520in%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2017%26volume%3D5%26spage%3D1141%26epage%3D1151%26doi%3D10.1158%2F2326-6066.CIR-17-0235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gunda, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigliotti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashry, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndishabandi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stork, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessandrini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parangi, S.</span></span> <span> </span><span class="NLM_article-title">Anti-PD-1/PD-L1 therapy augments lenvatinib’s efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">2266</span>– <span class="NLM_lpage">2278</span>, <span class="refDoi"> DOI: 10.1002/ijc.32041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1002%2Fijc.32041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=30515783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslCgt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2019&pages=2266-2278&author=V.+Gundaauthor=B.+Gigliottiauthor=T.+Ashryauthor=D.+Ndishabandiauthor=M.+McCarthyauthor=Z.+Zhouauthor=S.+Aminauthor=K.+E.+Leeauthor=T.+Storkauthor=L.+Wirthauthor=G.+J.+Freemanauthor=A.+Alessandriniauthor=S.+Parangi&title=Anti-PD-1%2FPD-L1+therapy+augments+lenvatinib%E2%80%99s+efficacy+by+favorably+altering+the+immune+microenvironment+of+murine+anaplastic+thyroid+cancer&doi=10.1002%2Fijc.32041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-PD-1/PD-L1 therapy augments lenvatinib efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer</span></div><div class="casAuthors">Gunda, Viswanath; Gigliotti, Benjamin; Ashry, Tameem; Ndishabandi, Dorothy; McCarthy, Michael; Zhou, Zhiheng; Amin, Salma; Lee, Kyu Eun; Stork, Tabea; Wirth, Lori; Freeman, Gordon J.; Alessandrini, Alessandro; Parangi, Sareh</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2266-2278</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Patients with anaplastic thyroid cancer (ATC) have an extremely poor prognosis despite multimodal therapy with surgery and chemoradiation.  Lenvatinib, a multi-targeted tyrosine kinase inhibitor, as well as checkpoint inhibitors targeting the programmed cell death pathway, have proven effective in some patients with advanced thyroid cancer.  We utilized our novel immunocompetent murine model of orthotopic ATC to demonstrate that lenvatinib led to significant tumor shrinkage and increased survival, while combination therapy led to dramatic improvements in both.  Lenvatinib monotherapy increased tumor-infiltrating macrophages, CD8+ T-cells, regulatory T-cells, and most notably, polymorphonuclear myeloid derived suppressor cells (PMN-MDSCs).  While both combination therapies led to further increases in CD8+ T-cells, only the lenvatinib and anti-PD-1 combination decreased PMN-MDSCs.  PMN-MDSC expansion was also seen in blood of mice and one patient receiving lenvatinib therapy for ATC.  RNA-Seq of the ATC cell line used in our mouse model demonstrated that lenvatinib has multifaceted effects on angiogenesis, response to hypoxia, the epithelial-to-mesenchymal transition, and on multiple pathways implicated in inflammation and host immunity.  These data suggest that MDSCs play a neg. role in ATC response to lenvatinib and support future study of their role as a potential biomarker and treatment target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquYvkE3flvLbVg90H21EOLACvtfcHk0lhLWPecNoxPTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslCgt7Y%253D&md5=c4547c732c5996b7f5106c8c03cbdc1f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fijc.32041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.32041%26sid%3Dliteratum%253Aachs%26aulast%3DGunda%26aufirst%3DV.%26aulast%3DGigliotti%26aufirst%3DB.%26aulast%3DAshry%26aufirst%3DT.%26aulast%3DNdishabandi%26aufirst%3DD.%26aulast%3DMcCarthy%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DAmin%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DK.%2BE.%26aulast%3DStork%26aufirst%3DT.%26aulast%3DWirth%26aufirst%3DL.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DAlessandrini%26aufirst%3DA.%26aulast%3DParangi%26aufirst%3DS.%26atitle%3DAnti-PD-1%252FPD-L1%2520therapy%2520augments%2520lenvatinib%25E2%2580%2599s%2520efficacy%2520by%2520favorably%2520altering%2520the%2520immune%2520microenvironment%2520of%2520murine%2520anaplastic%2520thyroid%2520cancer%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2019%26volume%3D144%26spage%3D2266%26epage%3D2278%26doi%3D10.1002%2Fijc.32041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of [1,2,4]triazolo[4,3-<i>a</i>]pyridines as potent inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 interaction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4703</span>– <span class="NLM_lpage">4715</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00312</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00312" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmvV2qurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4703-4715&author=M.+Qinauthor=Q.+Caoauthor=S.+Zhengauthor=Y.+Tianauthor=H.+Zhangauthor=J.+Xieauthor=H.+Xieauthor=Y.+Liuauthor=Y.+Zhaoauthor=P.+Gong&title=Discovery+of+%5B1%2C2%2C4%5Dtriazolo%5B4%2C3-a%5Dpyridines+as+potent+inhibitors+targeting+the+programmed+cell+death-1%2Fprogrammed+cell+death-ligand+1+interaction&doi=10.1021%2Facs.jmedchem.9b00312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of [1,2,4]Triazolo[4,3-a]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction</span></div><div class="casAuthors">Qin, Mingze; Cao, Qi; Zheng, Shuaishuai; Tian, Ye; Zhang, Haotian; Xie, Jun; Xie, Hongbo; Liu, Yajing; Zhao, Yanfang; Gong, Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4703-4715</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction using small-mol. inhibitors is an emerging immunotherapeutic approach.  A novel series of [1,2,4]triazolo[4,3-a]pyridines were designed and found to be potent inhibitors of the PD-1/PD-L1 interaction.  Among them, compd. I exhibited the most potent activity, as assessed by homogeneous time-resolved fluorescence assay, with an IC50 of 92.3 nM.  Furthermore, I dose-dependent elevated interferon-γ prodn. in a coculture model of Hep3B/OS-8/hPD-L1 and CD3 T cells.  The authors concluded that I is a promising lead compd. for the development of inhibitors of the PD-1/PD-L1 interaction.  In addn., the authors explored the structure-activity relationships of the newly synthesized [1,2,4]triazolo[4,3-a]pyridines and demonstrated that a ring fusion strategy can be employed for designing analogs of the Bristol-Myers Squibb chem. series.  These studies pave the way for future drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCgkEJ5SqGXLVg90H21EOLACvtfcHk0lgRPL3qn_tufw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmvV2qurs%253D&md5=44d4ee689be577a86c16cc4da3edec71</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00312%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-a%255Dpyridines%2520as%2520potent%2520inhibitors%2520targeting%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520cell%2520death-ligand%25201%2520interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4703%26epage%3D4715%26doi%3D10.1021%2Facs.jmedchem.9b00312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera-Mularz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kholodovych, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, evaluation, and structural studies of <i>C<sub>2</sub></i>-symmetric small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 protein-protein interaction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7250</span>– <span class="NLM_lpage">7263</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00795</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00795" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOhu7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7250-7263&author=S.+Basuauthor=J.+Yangauthor=B.+Xuauthor=K.+Magiera-Mularzauthor=L.+Skalniakauthor=B.+Musielakauthor=V.+Kholodovychauthor=T.+A.+Holakauthor=L.+Hu&title=Design%2C+synthesis%2C+evaluation%2C+and+structural+studies+of+C2-symmetric+small+molecule+inhibitors+of+programmed+cell+death-1%2Fprogrammed+death-ligand+1+protein-protein+interaction&doi=10.1021%2Facs.jmedchem.9b00795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction</span></div><div class="casAuthors">Basu, Subhadwip; Yang, Jeffrey; Xu, Bin; Magiera-Mularz, Katarzyna; Skalniak, Lukasz; Musielak, Bogdan; Kholodovych, Vladyslav; Holak, Tad A.; Hu, Longqin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7250-7263</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of C2-sym. inhibitors was designed and evaluated for inhibitory activity against the programmed cell death-1/programmed death-ligand 1(PD-1/PD-L1) protein-protein interaction (PPI) in a homogeneous time-resolved fluorescence (HTRF) assay and PD-1 signaling in cell-based coculture assays.  C2-sym. inhibitors 2a (LH1306) and 2b (LH1307) exhibited IC50 values of 25 and 3.0 nM, resp., in the HTRF assay.  While 2a was ∼3.8-fold more potent than previously reported inhibitor 1a, 2b could not be differentiated from 1b due to their high potency and the limit of our HTRF assay conditions.  In one cell-based coculture PD-1 signaling assay, 2a and 2b were 8.2- and 2.8-fold more potent in inhibiting PD-1 signaling than 1a and 1b, resp.  NMR and X-ray cocrystal structural studies provided more structural insights into the interaction between 2b and PD-L1; 2b binds to PD-L1 at the PD-1 binding site and induces the formation of a more sym. arranged PD-L1 homodimer than that previously reported for other inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS9fdh7FbNLLVg90H21EOLACvtfcHk0lgRPL3qn_tufw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOhu7zJ&md5=0dae949116a4157a281802aea6d21b6c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00795%26sid%3Dliteratum%253Aachs%26aulast%3DBasu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DMagiera-Mularz%26aufirst%3DK.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DKholodovych%26aufirst%3DV.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26aulast%3DHu%26aufirst%3DL.%26atitle%3DDesign%252C%2520synthesis%252C%2520evaluation%252C%2520and%2520structural%2520studies%2520of%2520C2-symmetric%2520small%2520molecule%2520inhibitors%2520of%2520programmed%2520cell%2520death-1%252Fprogrammed%2520death-ligand%25201%2520protein-protein%2520interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7250%26epage%3D7263%26doi%3D10.1021%2Facs.jmedchem.9b00795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konieczny, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czub, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera-Mularz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myrcha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siedlar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plewka, J.</span></span> <span> </span><span class="NLM_article-title">Di-bromo-based small-molecule inhibitors of the PD-1/PD-L1 immune checkpoint</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">11271</span>– <span class="NLM_lpage">11285</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01260</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01260" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVKhu7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=11271-11285&author=M.+Koniecznyauthor=B.+Musielakauthor=J.+Kocikauthor=L.+Skalniakauthor=D.+Salaauthor=M.+Czubauthor=K.+Magiera-Mularzauthor=I.+Rodriguezauthor=M.+Myrchaauthor=M.+Stecauthor=M.+Siedlarauthor=T.+A.+Holakauthor=J.+Plewka&title=Di-bromo-based+small-molecule+inhibitors+of+the+PD-1%2FPD-L1+immune+checkpoint&doi=10.1021%2Facs.jmedchem.0c01260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint</span></div><div class="casAuthors">Konieczny, Magdalena; Musielak, Bogdan; Kocik, Justyna; Skalniak, Lukasz; Sala, Dominik; Czub, Miroslawa; Magiera-Mularz, Katarzyna; Rodriguez, Ismael; Myrcha, Maja; Stec, Malgorzata; Siedlar, Maciej; Holak, Tad A.; Plewka, Jacek</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">11271-11285</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Immune checkpoint blockade is one of the most promising strategies of cancer immunotherapy.  However, unlike classical targeted therapies, it is currently solely based on expensive monoclonal antibodies, which often inflict immune-related adverse events.  Herein, we propose a novel small-mol. inhibitor targeted at the most clin. relevant immune checkpoint, PD-1/PD-L1.  The compd. is capable of disrupting the PD-1/PD-L1 complex by antagonizing PD-L1 and, therefore, restores activation of T cells similarly to the antibodies, while being cheap in prodn. and possibly nonimmunogenic.  The final compd. is significantly smaller than others reported in the literature while being nontoxic to cells even at high concns.  The scaffold was designed using a structure-activity relationship screening cascade based on a new antagonist-induced dissocn. NMR assay, called the weak-AIDA-NMR.  Weak-AIDA-NMR finds true inhibitors, as opposed to only binders to the target protein, in early steps of lead compd. development, and this process makes it less time and cost consuming.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHW_y-fZej_rVg90H21EOLACvtfcHk0lgRPL3qn_tufw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVKhu7%252FL&md5=00b95c22e1bb615c773c1bcc68c0a2ba</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01260%26sid%3Dliteratum%253Aachs%26aulast%3DKonieczny%26aufirst%3DM.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DKocik%26aufirst%3DJ.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DSala%26aufirst%3DD.%26aulast%3DCzub%26aufirst%3DM.%26aulast%3DMagiera-Mularz%26aufirst%3DK.%26aulast%3DRodriguez%26aufirst%3DI.%26aulast%3DMyrcha%26aufirst%3DM.%26aulast%3DStec%26aufirst%3DM.%26aulast%3DSiedlar%26aufirst%3DM.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26aulast%3DPlewka%26aufirst%3DJ.%26atitle%3DDi-bromo-based%2520small-molecule%2520inhibitors%2520of%2520the%2520PD-1%252FPD-L1%2520immune%2520checkpoint%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D11271%26epage%3D11285%26doi%3D10.1021%2Facs.jmedchem.0c01260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: a new choice for immunotherapy?</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">378</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.10.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1016%2Fj.ejmech.2018.10.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=30384043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVyit7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2019&pages=378-398&author=T.+Chenauthor=Q.+Liauthor=Z.+Liuauthor=Y.+Chenauthor=F.+Fengauthor=H.+Sun&title=Peptide-based+and+small+synthetic+molecule+inhibitors+on+PD-1%2FPD-L1+pathway%3A+a+new+choice+for+immunotherapy%3F&doi=10.1016%2Fj.ejmech.2018.10.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?</span></div><div class="casAuthors">Chen, Tingkai; Li, Qi; Liu, Zongliang; Chen, Yao; Feng, Feng; Sun, Haopeng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">378-398</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Blockade the interaction of the programmed cell death protein 1 (PD-1) and its ligand, programmed death-ligand 1 (PD-L1) can prevent immune evasion of tumor cells and significantly prolong the survival of cancer patients.  Currently marketed drugs targeting PD-1/PD-L1 pathway are all monoclonal antibodies (mAbs) that have achieved great success in clin. trials.  With the constantly emerging problems of antibody drugs, small mol. inhibitors have attracted the attention of pharmaceutical chemists due to their controllable pharmacol. and pharmacokinetic properties, which make them potential alternatives or supplements to mAbs to regulate PD-1/PD-L1 pathway.  However, the insufficient target structure information hinders the development of small mol. inhibitors.  Since the publication of human-PD-1/human-PD-L1 (hPD-1/hPD-L1) crystal structure, more and more cocrystal structures of mAbs, cyclopeptides and small mols. with PD-1 and PD-L1 have been resolved.  These complexes provide a valuable starting point for the rational design of peptide-based and small synthetic mol. inhibitors.  Here we reviewed the non-antibody inhibitors that have been published so far and analyzed their structure-activity relationships (SAR).  We also summarized the cocrystal structures with hot spots identified, with the aim to provide ref. for future drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozjhKf91To8LVg90H21EOLACvtfcHk0lihynNgl9z4Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVyit7rI&md5=ecc3b6299bdca40a13af0fc2003b251d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.10.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.10.044%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DPeptide-based%2520and%2520small%2520synthetic%2520molecule%2520inhibitors%2520on%2520PD-1%252FPD-L1%2520pathway%253A%2520a%2520new%2520choice%2520for%2520immunotherapy%253F%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D161%26spage%3D378%26epage%3D398%26doi%3D10.1016%2Fj.ejmech.2018.10.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span> <span> </span><span class="NLM_article-title">Development of inhibitors of the programmed cell death-1/programmed cell death-ligand 1 signaling pathway</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1715</span>– <span class="NLM_lpage">1730</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00990</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00990" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslKqtLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1715-1730&author=T.+Wangauthor=X.+Wuauthor=C.+Guoauthor=K.+Zhangauthor=J.+Xuauthor=Z.+Liauthor=S.+Jiang&title=Development+of+inhibitors+of+the+programmed+cell+death-1%2Fprogrammed+cell+death-ligand+1+signaling+pathway&doi=10.1021%2Facs.jmedchem.8b00990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway</span></div><div class="casAuthors">Wang, Tianyu; Wu, Xiaoxing; Guo, Changying; Zhang, Kuojun; Xu, Jinyi; Li, Zheng; Jiang, Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1715-1730</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The clin. success of inhibitors targeting the PD-1/PD-L1 pathway has made this an active field in cancer immunotherapy.  Currently, most drugs targeting this pathway are monoclonal antibodies.  Small-mol. inhibitors as the alternative to monoclonal antibodies are expected to overcome the disadvantages of mAbs which include prodn. difficulties and their long half-life.  Recently, progress has been reported on anti-PD-1/PD-L1 small-mol. inhibitors.  In this paper, we review the development of inhibitors targeting the PD-1/PD-L1 pathway, focusing mainly on peptide-based and nonpeptidic small-mol. inhibitors.  The structures and the preclin. and clin. studies of several peptide-based small-mol. candidate compds. in clin. trials are discussed.  We also illustrate the design strategies underlying reported nonpeptidic small-mol. inhibitors and provide insight into possible future exploration.  Development of small-mol. drugs for anti-PD-1/PD-L1 activity with specific cancer applications is a promising and challenging prospect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonItidshja8LVg90H21EOLACvtfcHk0lihynNgl9z4Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslKqtLzL&md5=2fc7ee8e9bb8d37c7569913a4529d753</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00990%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DS.%26atitle%3DDevelopment%2520of%2520inhibitors%2520of%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520cell%2520death-ligand%25201%2520signaling%2520pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1715%26epage%3D1730%26doi%3D10.1021%2Facs.jmedchem.8b00990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera-Mularz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czub, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siedlar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plewka, J.</span></span> <span> </span><span class="NLM_article-title">CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2804</span>– <span class="NLM_lpage">2816</span>, <span class="refDoi"> DOI: 10.3390/molecules24152804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.3390%2Fmolecules24152804" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=2804-2816&author=B.+Musielakauthor=J.+Kocikauthor=L.+Skalniakauthor=K.+Magiera-Mularzauthor=D.+Salaauthor=M.+Czubauthor=M.+Stecauthor=M.+Siedlarauthor=T.+A.+Holakauthor=J.+Plewka&title=CA-170+%E2%80%93+A+Potent+Small-Molecule+PD-L1+Inhibitor+or+Not%3F&doi=10.3390%2Fmolecules24152804"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24152804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24152804%26sid%3Dliteratum%253Aachs%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DKocik%26aufirst%3DJ.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DMagiera-Mularz%26aufirst%3DK.%26aulast%3DSala%26aufirst%3DD.%26aulast%3DCzub%26aufirst%3DM.%26aulast%3DStec%26aufirst%3DM.%26aulast%3DSiedlar%26aufirst%3DM.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26aulast%3DPlewka%26aufirst%3DJ.%26atitle%3DCA-170%2520%25E2%2580%2593%2520A%2520Potent%2520Small-Molecule%2520PD-L1%2520Inhibitor%2520or%2520Not%253F%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26spage%3D2804%26epage%3D2816%26doi%3D10.3390%2Fmolecules24152804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chupak, L. S.</span>; <span class="NLM_string-name">Ding, M.</span>; <span class="NLM_string-name">Martin, S. W.</span>; <span class="NLM_string-name">Zheng, X.</span>; <span class="NLM_string-name">Hewawasam, P.</span>; <span class="NLM_string-name">Connolly, T. P.</span>; <span class="NLM_string-name">Xu, N.</span>; <span class="NLM_string-name">Yeung, K-S.</span>; <span class="NLM_string-name">Zhu, J.</span>; <span class="NLM_string-name">Langley, D. R.</span>; <span class="NLM_string-name">Tenney, D. J.</span>; <span class="NLM_string-name">Scola, P. M.</span></span> <span> </span><span class="NLM_article-title">Compounds useful as immunomodulators</span>. <span class="NLM_patent">WO2015160641 A2</span>, Oct 22, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=L.+S.+Chupak&author=M.+Ding&author=S.+W.+Martin&author=X.+Zheng&author=P.+Hewawasam&author=T.+P.+Connolly&author=N.+Xu&author=K-S.+Yeung&author=J.+Zhu&author=D.+R.+Langley&author=D.+J.+Tenney&author=P.+M.+Scola&title=Compounds+useful+as+immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChupak%26aufirst%3DL.%2BS.%26atitle%3DCompounds%2520useful%2520as%2520immunomodulators%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chupak, L. S.</span>; <span class="NLM_string-name">Zheng, X.</span></span> <span> </span><span class="NLM_article-title">Compounds useful as immunomodulators</span>. <span class="NLM_patent">WO2015034820 A1</span>, Mar 12, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=L.+S.+Chupak&author=X.+Zheng&title=Compounds+useful+as+immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChupak%26aufirst%3DL.%2BS.%26atitle%3DCompounds%2520useful%2520as%2520immunomodulators%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guzik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudnik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Törner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors of the programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5857</span>– <span class="NLM_lpage">5867</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00293</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00293" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvFeisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5857-5867&author=K.+Guzikauthor=K.+M.+Zakauthor=P.+Grudnikauthor=K.+Magieraauthor=B.+Musielakauthor=R.+T%C3%B6rnerauthor=L.+Skalniakauthor=A.+Domlingauthor=G.+Dubinauthor=T.+A.+Holak&title=Small-molecule+inhibitors+of+the+programmed+cell+death-1%2Fprogrammed+death-ligand+1+%28PD-1%2FPD-L1%29+interaction+via+transiently+induced+protein+states+and+dimerization+of+PD-L1&doi=10.1021%2Facs.jmedchem.7b00293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1</span></div><div class="casAuthors">Guzik, Katarzyna; Zak, Krzysztof M.; Grudnik, Przemyslaw; Magiera, Katarzyna; Musielak, Bogdan; Torner, Ricarda; Skalniak, Lukasz; Domling, Alexander; Dubin, Grzegorz; Holak, Tad A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5857-5867</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockade of the PD-1/PD-L1 immune checkpoint pathway with monoclonal antibodies has provided significant advances in cancer treatment.  The antibody-based immunotherapies carry a no. of disadvantages such as the high cost of the antibodies, their limited half-life, and immunogenicity.  Development of small-mol. PD-1/PD-L1 inhibitors that could overcome these drawbacks is slow because of the incomplete structural information for this pathway.  The first chem. PD-1/PD-L1 inhibitors have been recently disclosed by Bristol-Myers Squibb.  Here we present NMR and X-ray characterization for the two classes of these inhibitors.  The X-ray structures of the PD-L1/inhibitor complexes reveal one inhibitor mol. located at the center of the PD-L1 homodimer, filling a deep hydrophobic channel-like pocket between two PD-L1 mols.  Derivs. of (2-methyl-3-biphenylyl)methanol exhibit the structures capped on one side of the channel, whereas the compds. based on [3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]methanol induce an enlarged interaction interface that results in the open "face-back" tunnel through the PD-L1 dimer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppmfSesG1M6rVg90H21EOLACvtfcHk0li1PDCw9IEZ4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvFeisLc%253D&md5=c039796cda3b9ef92a0ed3b10b11932b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00293%26sid%3Dliteratum%253Aachs%26aulast%3DGuzik%26aufirst%3DK.%26aulast%3DZak%26aufirst%3DK.%2BM.%26aulast%3DGrudnik%26aufirst%3DP.%26aulast%3DMagiera%26aufirst%3DK.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DT%25C3%25B6rner%26aufirst%3DR.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DDomling%26aufirst%3DA.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520death-ligand%25201%2520%2528PD-1%252FPD-L1%2529%2520interaction%2520via%2520transiently%2520induced%2520protein%2520states%2520and%2520dimerization%2520of%2520PD-L1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5857%26epage%3D5867%26doi%3D10.1021%2Facs.jmedchem.7b00293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachota, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szelazek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudnik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krzanik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyrc, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dömling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">72167</span>– <span class="NLM_lpage">72181</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.20050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.18632%2Foncotarget.20050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=29069777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A280%3ADC%252BC1M7ksVKhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=72167-72181&author=L.+Skalniakauthor=K.+M.+Zakauthor=K.+Guzikauthor=K.+Magieraauthor=B.+Musielakauthor=M.+Pachotaauthor=B.+Szelazekauthor=J.+Kocikauthor=P.+Grudnikauthor=M.+Tomalaauthor=S.+Krzanikauthor=K.+Pyrcauthor=A.+D%C3%B6mlingauthor=G.+Dubinauthor=T.+A.+Holak&title=Small-molecule+inhibitors+of+PD-1%2FPD-L1+immune+checkpoint+alleviate+the+PD-L1-induced+exhaustion+of+T-cells&doi=10.18632%2Foncotarget.20050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells</span></div><div class="casAuthors">Skalniak Lukasz; Guzik Katarzyna; Magiera Katarzyna; Musielak Bogdan; Kocik Justyna; Tomala Marcin; Holak Tad A; Zak Krzysztof M; Pachota Magdalena; Szelazek Bozena; Grudnik Przemyslaw; Krzanik Sylwia; Pyrc Krzysztof; Dubin Grzegorz; Zak Krzysztof M; Pachota Magdalena; Szelazek Bozena; Grudnik Przemyslaw; Krzanik Sylwia; Pyrc Krzysztof; Dubin Grzegorz; Domling Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">72167-72181</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Antibodies targeting the PD-1/PD-L1 immune checkpoint achieved spectacular success in anticancer therapy in the recent years.  In contrast, no small molecules with cellular activity have been reported so far.  Here we provide evidence that small molecules are capable of alleviating the PD-1/PD-L1 immune checkpoint-mediated exhaustion of Jurkat T-lymphocytes.  The two optimized small-molecule inhibitors of the PD-1/PD-L1 interaction, BMS-1001 and BMS-1166, developed by Bristol-Myers Squibb, bind to human PD-L1 and block its interaction with PD-1, when tested on isolated proteins.  The compounds present low toxicity towards tested cell lines and block the interaction of soluble PD-L1 with the cell surface-expressed PD-1.  As a result, BMS-1001 and BMS-1166 alleviate the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes.  Moreover, the compounds were effective in attenuating the inhibitory effect of the cell surface-associated PD-L1.  We also determined the X-ray structures of the complexes of BMS-1001 and BMS-1166 with PD-L1, which revealed features that may be responsible for increased potency of the compounds compared to their predecessors.  Further development may lead to the design of an anticancer therapy based on the orally delivered immune checkpoint inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSnxbjAjsdnFCCEBeYuoi7AfW6udTcc2ebc2dQXUZlFErntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7ksVKhsw%253D%253D&md5=0b70c6e7aca2f13919bfbb2a47b2e57f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.20050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.20050%26sid%3Dliteratum%253Aachs%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DZak%26aufirst%3DK.%2BM.%26aulast%3DGuzik%26aufirst%3DK.%26aulast%3DMagiera%26aufirst%3DK.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DPachota%26aufirst%3DM.%26aulast%3DSzelazek%26aufirst%3DB.%26aulast%3DKocik%26aufirst%3DJ.%26aulast%3DGrudnik%26aufirst%3DP.%26aulast%3DTomala%26aufirst%3DM.%26aulast%3DKrzanik%26aufirst%3DS.%26aulast%3DPyrc%26aufirst%3DK.%26aulast%3DD%25C3%25B6mling%26aufirst%3DA.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520PD-1%252FPD-L1%2520immune%2520checkpoint%2520alleviate%2520the%2520PD-L1-induced%2520exhaustion%2520of%2520T-cells%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D72167%26epage%3D72181%26doi%3D10.18632%2Foncotarget.20050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel resorcinol dibenzyl ethers targeting the programmed cell death-1/programmed cell death-ligand 1 interaction as potential anticancer agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">8338</span>– <span class="NLM_lpage">8358</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00574</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00574" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtl2rsrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=8338-8358&author=B.+Chengauthor=Y.+Renauthor=X.+Niuauthor=W.+Wangauthor=S.+Wangauthor=Y.+Tuauthor=S.+Liuauthor=J.+Wangauthor=D.+Yangauthor=G.+Liaoauthor=J.+Chen&title=Discovery+of+novel+resorcinol+dibenzyl+ethers+targeting+the+programmed+cell+death-1%2Fprogrammed+cell+death-ligand+1+interaction+as+potential+anticancer+agents&doi=10.1021%2Facs.jmedchem.0c00574"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents</span></div><div class="casAuthors">Cheng, Binbin; Ren, Yichang; Niu, Xiaoge; Wang, Wei; Wang, Shuanghu; Tu, Yingfeng; Liu, Shuwen; Wang, Jin; Yang, Deying; Liao, Guochao; Chen, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">8338-8358</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel small mol. compds. based on various scaffolds including chalcone, flavonoid, and resorcinol dibenzyl ether were designed and tested for their inhibitory activity against the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 (PD-1/PD-L1) pathway.  Among them, compd. NP19(I) inhibited the human PD-1/PD-L1 interaction with IC50 values of 12.5 nM in homogeneous time-resolved fluorescence (HTRF) binding assays.  In addn., NP19 dose-dependently elevated IFN-γ prodn. in a coculture model of Hep3B/OS-8/hPD-L1 and CD3 T cells.  Furthermore, NP19 displayed significant in vivo antitumor efficacy in two different mouse models of cancer (a melanoma B16-F10 tumor model and an H22 hepatoma tumor model).  Moreover, H&E staining and flow cytometry data suggested that NP19 activated the immune microenvironment in the tumor, which may contribute to its antitumor effects.  This work shows NP19 is a promising lead compd. for further development as a new generation of small mol. inhibitors targeting the PD-1/PD-L1 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruD5Zp9HM0jrVg90H21EOLACvtfcHk0li1PDCw9IEZ4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtl2rsrfL&md5=a1f6b3b4c440a7152ed8194ad842370f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00574%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DB.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DNiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DLiao%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520novel%2520resorcinol%2520dibenzyl%2520ethers%2520targeting%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520cell%2520death-ligand%25201%2520interaction%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D8338%26epage%3D8358%26doi%3D10.1021%2Facs.jmedchem.0c00574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">111856</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111856</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1016%2Fj.ejmech.2019.111856" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=31734021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFOmu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2020&pages=111856&author=M.+Qinauthor=Q.+Caoauthor=X.+Wuauthor=C.+Liuauthor=S.+Zhengauthor=H.+Xieauthor=Y.+Tianauthor=J.+Xieauthor=Y.+Zhaoauthor=Y.+Houauthor=X.+Zhangauthor=B.+Xuauthor=H.+Zhangauthor=X.+Wang&title=Discovery+of+the+programmed+cell+death-1%2Fprogrammed+cell+death-ligand+1+interaction+inhibitors+bearing+an+indoline+scaffold&doi=10.1016%2Fj.ejmech.2019.111856"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold</span></div><div class="casAuthors">Qin, Mingze; Cao, Qi; Wu, Xia; Liu, Chunyang; Zheng, Shuaishuai; Xie, Hongbo; Tian, Ye; Xie, Jun; Zhao, Yanfang; Hou, Yunlei; Zhang, Xian; Xu, Boxuan; Zhang, Haotian; Wang, Xiaobo</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111856</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy.  Here, a novel series of indoline-contg. compds. were developed, among which, A13 was identified as the most promising PD-1/PD-L1 pathway inhibitor.  At the biochem. level, A13 demonstrated strong inhibition of the PD-1/PD-L1 interaction, with an IC50 of 132.8 nM.  Notably, it exhibited outstanding immunoregulatory activity, and significantly elevated interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, without significant toxic effect.  Therefore, A13 could be employed as a suitable lead compd. for further design of non-peptide inhibitors targeting the PD-1/PD-L1 interaction.  In addn., the preliminary structure-activity relationships of these new indoline compds. were investigated in this study, providing valuable information for future drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7nYUI852jyLVg90H21EOLACvtfcHk0li9XCUMtqkFdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFOmu7zN&md5=b757929dd24437bb5af585e73a884a51</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111856&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111856%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520cell%2520death-ligand%25201%2520interaction%2520inhibitors%2520bearing%2520an%2520indoline%2520scaffold%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D186%26spage%3D111856%26doi%3D10.1016%2Fj.ejmech.2019.111856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RajanBabu, T. V.</span></span> <span> </span><span class="NLM_article-title">Asymmetric hydrovinylation of vinylindoles. A facile route to cyclopenta[<i>g</i>]indole natural products (+)-<i>cis</i>-trikentrin A and (+)-<i>cis</i>-trikentrin B</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">5496</span>– <span class="NLM_lpage">5499</span>, <span class="refDoi"> DOI: 10.1021/ja3004733</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja3004733" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVChtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=5496-5499&author=W.+Liuauthor=H.+J.+Limauthor=T.+V.+RajanBabu&title=Asymmetric+hydrovinylation+of+vinylindoles.+A+facile+route+to+cyclopenta%5Bg%5Dindole+natural+products+%28%2B%29-cis-trikentrin+A+and+%28%2B%29-cis-trikentrin+B&doi=10.1021%2Fja3004733"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric Hydrovinylation of Vinylindoles. A Facile Route to Cyclopenta[g]indole Natural Products (+)-cis-Trikentrin A and (+)-cis-Trikentrin B</span></div><div class="casAuthors">Liu, Wang; Lim, Hwan Jung; RajanBabu, T. V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5496-5499</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Vinylindoles, e.g., I, undergo Ni(II)-catalyzed asym. hydrovinylation under very mild conditions (-78 °C, 1 atm ethylene, 4 mol % catalyst) to give the corresponding 2-but-3-enyl derivs., e.g., II, in excellent yields and enantioselectivities.  Hydroboration of the alkene and oxidn. to an acid, followed by Friedel-Crafts annulation, gives an indole-annulated cyclopentanone that is a suitable precursor for the syntheses of cis-trikentrins and all known herbindoles.  For example, the cyclopentanone III from 4-ethyl-7-vinylindole is converted into (+)-cis-trikentrin A (IV) in four steps (Wittig reaction, alkene isomerization, diastereoselective hydrogenation, and nitrogen deprotection).  The previous synthesis of this mol. from (S)-(-)-malic acid involved more than 20 steps and a preparative HPLC sepn. of diastereomeric intermediates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtmiP9vM7LZrVg90H21EOLACvtfcHk0li9XCUMtqkFdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVChtrY%253D&md5=6cad69602693d02250ee2cd869f657e9</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fja3004733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja3004733%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLim%26aufirst%3DH.%2BJ.%26aulast%3DRajanBabu%26aufirst%3DT.%2BV.%26atitle%3DAsymmetric%2520hydrovinylation%2520of%2520vinylindoles.%2520A%2520facile%2520route%2520to%2520cyclopenta%255Bg%255Dindole%2520natural%2520products%2520%2528%252B%2529-cis-trikentrin%2520A%2520and%2520%2528%252B%2529-cis-trikentrin%2520B%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D5496%26epage%3D5499%26doi%3D10.1021%2Fja3004733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Shen, B.</span>; <span class="NLM_string-name">Li, J.</span>; <span class="NLM_string-name">Li, Z.</span>; <span class="NLM_string-name">Liu, K.</span>; <span class="NLM_string-name">Zhang, F.</span>; <span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic compounds as immunomodulators</span>. <span class="NLM_patent">US20170107216 A1</span>, Apr 20, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=L.+Wu&author=B.+Shen&author=J.+Li&author=Z.+Li&author=K.+Liu&author=F.+Zhang&author=W.+Yao&title=Heterocyclic+compounds+as+immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DL.%26atitle%3DHeterocyclic%2520compounds%2520as%2520immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kadam, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahma, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doshi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemmani, K. V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span> <span> </span><span class="NLM_article-title">Evaluation of thiazole containing biaryl analogs as diacylglycerol acyltransferase 1 (DGAT1) inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">347</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=10.1016%2Fj.ejmech.2013.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=23735282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFeltrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=337-347&author=K.+S.+Kadamauthor=R.+D.+Jadhavauthor=S.+Kandreauthor=T.+Guhaauthor=M.+M.+K.+Reddyauthor=M.+K.+Brahmaauthor=N.+J.+Deshmukhauthor=A.+Dixitauthor=L.+Doshiauthor=S.+Srinivasanauthor=J.+Devleauthor=A.+Damreauthor=K.+V.+S.+Nemmaniauthor=A.+Gupteauthor=R.+Sharma&title=Evaluation+of+thiazole+containing+biaryl+analogs+as+diacylglycerol+acyltransferase+1+%28DGAT1%29+inhibitors&doi=10.1016%2Fj.ejmech.2013.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of thiazole containing biaryl analogs as diacylglycerol acyltransferase 1 (DGAT1) inhibitors</span></div><div class="casAuthors">Kadam, Kishorkumar S.; Jadhav, Ravindra D.; Kandre, Shivaji; Guha, Tandra; Reddy, M. Mahesh Kumar; Brahma, Manoja K.; Deshmukh, Nitin J.; Dixit, Amol; Doshi, Lalit; Srinivasan, Shaila; Devle, Jayendra; Damre, Anagha; Nemmani, Kumar V. S.; Gupte, Amol; Sharma, Rajiv</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">337-347</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Biphenyl carboxylic acids, exemplified by compd. I, are known potent inhibitors of diacylglycerol acyltransferase, DGAT1, an enzyme involved in the final committed step of triglyceride biosynthesis.  We have synthesized and evaluated 2-phenylthiazole, 4-phenylthiazole, and 5-phenylthiazole analogs as DGAT1 inhibitors.  The 5-phenylthiazole series exhibited potent DGAT1 inhibition when evaluated using an in vitro enzymic assay and an in vivo fat tolerance test in mice.  Compd. II (IC50 = 23 nM) exhibiting promising oral pharmacokinetic parameters (AUCinf = 7058 ng*h/mL, T1/2 = 0.83 h) coupled with 87 percent redn. of plasma triglycerides in vivo may serve as a lead for developing newer anti-obesity agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIKdn-LE4fK7Vg90H21EOLACvtfcHk0li9XCUMtqkFdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFeltrvI&md5=f6d90d63f8bfb63f2a171f6c1b125767</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DKadam%26aufirst%3DK.%2BS.%26aulast%3DJadhav%26aufirst%3DR.%2BD.%26aulast%3DKandre%26aufirst%3DS.%26aulast%3DGuha%26aufirst%3DT.%26aulast%3DReddy%26aufirst%3DM.%2BM.%2BK.%26aulast%3DBrahma%26aufirst%3DM.%2BK.%26aulast%3DDeshmukh%26aufirst%3DN.%2BJ.%26aulast%3DDixit%26aufirst%3DA.%26aulast%3DDoshi%26aufirst%3DL.%26aulast%3DSrinivasan%26aufirst%3DS.%26aulast%3DDevle%26aufirst%3DJ.%26aulast%3DDamre%26aufirst%3DA.%26aulast%3DNemmani%26aufirst%3DK.%2BV.%2BS.%26aulast%3DGupte%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DR.%26atitle%3DEvaluation%2520of%2520thiazole%2520containing%2520biaryl%2520analogs%2520as%2520diacylglycerol%2520acyltransferase%25201%2520%2528DGAT1%2529%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D65%26spage%3D337%26epage%3D347%26doi%3D10.1016%2Fj.ejmech.2013.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5N2F" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5N2F','PDB','5N2F'); return false;">PDB: 5N2F</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i83"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01958">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_47251"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01958?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01958</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">5N2F-<b>A30</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01958/suppl_file/jm0c01958_si_001.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01958/suppl_file/jm0c01958_si_001.pdb">CSV</a>)</p></li><li><p class="inline">Figures generated from <i>in vitro</i> studies of <b>A30</b> for effects on CT26 cell viability and <i>in vivo</i> activity in mouse 4T1 and CT26 tumor models; flow cytometry analysis of spleen lymphocytes after <b>A30</b> treatment; and <sup>1</sup>H NMR, <sup>13</sup>C NMR, and HPLC spectra and HRMS of the final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01958/suppl_file/jm0c01958_si_001.pdb">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01958/suppl_file/jm0c01958_si_001.pdb">jm0c01958_si_001.pdb (162.21 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01958/suppl_file/jm0c01958_si_002.csv">jm0c01958_si_002.csv (3.2 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01958/suppl_file/jm0c01958_si_003.pdf">jm0c01958_si_003.pdf (4.78 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01958&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-9%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01958%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01958" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"667981f8a9e0d942","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
